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ABSTRACT 
 
Carcinomas begin with a single transformed cell in an otherwise normal epithelial 
monolayer. To study the nature of interactions between a transformed cell and its 
neighbours at this initial stage of tumourigenesis a tetracycline-inducible system 
driving expression of a constitutively active form of oncogenic Ras (RasV12) was 
established in MDCK epithelial cells by the Fujita laboratory. Upon interaction 
with normal cells, RasV12 cells most commonly undergo apical extrusion from an 
epithelial monolayer. 
In order to identify proteins and pathways involved in interactions between 
normal and transformed cells, I have performed several biochemical screens 
described in this thesis. Firstly, I have shown that Hsp90β, identified previously in 
a 2D gel screen, is increased in RasV12 cells surrounded by normal neighbours in a 
non-cell-autonomous fashion. By using inhibitors and a dominant negative form 
of Hsp90, I have shown that upregulation of this chaperone is most likely a part 
of a stress response delaying extrusion of transformed cells. 
Secondly, I have performed a screen for tyrosine phosphorylated proteins and 
identified myosin IE and plectin as modified in mixed cultures of normal and 
transformed cells.  
Finally, I have undertaken quantitative mass spectrometry of phosphorylated 
peptides using SILAC labelling to assess changes in RasV12 cells upon their 
interaction with normal cells. In this screen I have found that an actin anti-
capping protein, VASP, is phosphorylated on serine 239 in RasV12 cells interacting 
with normal cells. This modification is known to inhibits its related to actin 
function. I have shown that depletion of VASP in RasV12 cells results in their 
enhanced extrusion from normal monolayers, most likely due to their 
compromised attachment. The phosphorylation on serine 239 may be an early 
step in extrusion, contributing to disassembly of focal adhesions and stress fibres 
in transformed cells. I have also studied the role of another protein identified in 
the SILAC screen, MRCKβ, and shown that its depletion results in enhanced 
extrusion of RasV12 cells from normal monolayers. 
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CHAPTER 1: INTRODUCTION 
1.1 INTRODUCTION – THE IDEA BEHIND THE STUDY 
 
 Cancer is an ever-growing threat for everyone. Most cancers can only be 
detected at later stages of the disease, when they have accumulated a lot of 
mutations and start to form tumours. However we cannot underestimate the 
importance of early detection of the developing disease, as it correlates with 
much better prognosis for patients. In order to be able to detect cancer at earlier 
stages, we need to understand how it originates. Despite the general agreement 
in the field that carcinomas start off from a single mutated cell within a normal 
epithelial monolayer, not many studies have been carried out to clarify what 
exactly happens at the very beginning. Is a single transformed cell recognised by 
its neighbours and how do normal cells react to a sudden change in their 
environment? 
Some of these questions have been addressed by the Fujita laboratory 
where, in a mammalian tissue culture system, cells transformed either by 
overexpression of an oncogene (H-RasV12 or v-Src) or depletion of a tumour 
suppressor (Scribble) were mixed with normal cells. These studies revealed that 
transformed cells are recognised by their normal neighbours and either killed, as 
in the Scribble system (Norman et al., 2012), or extruded from the monolayer, as in 
the RasV12 (Hogan et al., 2009) and v-Src (Kajita et al., 2010) systems (since the 
extruded cells remain alive the significance of these events is still unknown). This 
elimination phenomenon resembles cell competition in Drosophila (described in 
section 1.3) where less fit mutant cells are removed from imaginal discs of a 
developing embryo in order to maintain the integrity of the whole organ. A 
similar mechanism may function in mammalian epithelial monolayers leading to 
the removal of randomly appearing transformed cells. 
Although some of the questions about extrusion in the RasV12 system have 
already been addressed (described in section 1.5.4), unclear remains which 
signalling pathways are involved, how the recognition occurs and what the actual 
mechanism of extrusion is. The aim of my thesis is to identify novel proteins that 
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are important at early stages of extrusion using different biochemical screens and 
to understand their role. 
 
1.2 RAS IN NON-TRANSFOMED CELLS AND AS AN ONCOGENE 
1.2.1 DISCOVERY OF RAS PROTEINS 
 
Ras genes were first identified in the late seventies in retroviruses (in this 
case, oncoviruses) that, as it was later clarified, hijacked them from non-
transformed cells. The ras genes were subsequently mutated during viral 
replication and served as oncogenes upon reinfection and transformation of 
vertebrate cells. The Harvey sarcoma virus-associated oncogene was named H-ras, 
the Kirsten sarcoma virus-associated oncogene – K-ras (reviewed in (Karnoub and 
Weinberg, 2008)). Shortly after, mutated H-Ras and K-Ras genes were discovered in 
mouse and human cancer cell lines as well as in actual carcinoma samples. 
Another prominent member of the Ras family, N-RAS, was cloned from 
neuroblastoma and leukaemia cell lines. 
Studies on human carcinomas revealed an association of particular 
mutations with different types of cancers: K-RAS was most commonly found 
mutated in pancreatic and colonic carcinomas, H-RAS in bladder carcinomas, and 
N-RAS in lymphomas and melanomas (reviewed in (Karnoub and Weinberg, 2008)) 
(more information in section 1.2.5). 
1.2.2 RAS SUPERFAMILY AS SMALL GTPASES 
 
In order to understand why mutations in Ras genes are crucial for some 
types of cancers, it is important to understand the function of Ras proteins in 
non-transformed cells.  
The extended Ras superfamily, known up to date, comprises of more than 
150 different proteins, playing vital roles in cell cycle progression (Ras and Rho), 
cell survival (Ras and Rho), actin cytoskeleton reorganisation (Rho), cell polarity 
and movement (Rho), vesicular (Rab, Arf) and nuclear (Ran) transport (reviewed in 
(Wennerberg et al., 2005)). 
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Ras proteins are small GTPases (20-25 kDa, 188-189 amino acids) that act as 
GTP-GDP regulated cellular switches. In contrast to heterotrimeric G proteins, 
another family of cellular GTPases, Ras consists of only one subunit, which is in 
fact similar to the α subunit of G proteins. The core G domain involved in GTP 
hydrolysis constitutes nearly 90% of the whole Ras protein (5-166 amino acids) 
and is conserved among all family members (Figure 1). Within this domain, five 
small G motives are responsible for binding of nucleotides (residues: 10-17, 35, 57-
60, 116-119, 145-147). Upon GDP/GTP exchange, switches I and II (residues 32-38 
and 59-67, respectively) undergo a conformational change that results in higher 
affinity of Ras proteins towards their effectors which can now bind to the core 
effector domain (32-40). The last segment of Ras proteins (residues 167-188,189) is 
highly variable and contains membrane targeting sequences that will be 
discussed later (section 1.2.3) (reviewed in (Cox and Der, 2010; Ellis and Clark, 2000; 
Wennerberg et al., 2005)). 
 
Figure 1. Structure of Ras proteins. 
 
 
Since the intrinsic GTP binding and hydrolysis activities are weak, Ras 
proteins are regulated by guanine nucleotide exchange factors (GEFs) as 
activators stimulating GDP/GTP exchange, and GTPase-activating proteins (GAPs) 
as inactivators catalysing GTP hydrolysis (Rho and Rab proteins are also assisted 
by guanine nucleotide dissociation inhibitors) (reviewed in (Vigil et al., 2010)) 
(Figure 2). 
All Ras GEFs contain a common catalytic domain called CDC25 homology 
domain (about 250 amino acids long) and a shorter Ras-exchange motif (REM). 
Additional sequences within different GEFs provide specificity for upstream 
regulators and activation mechanisms as well as further catalytic functions. Two 
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family members of the Ras GEFs, Sos (Son of Sevenless) and RasGRFs (guanine 
nucleotide-releasing factors), contain Dbl homology (DH) and pleckstrin 
homology (PH) domains, which allow them to catalyse guanine nucleotide 
exchange also on Rho family members, in particular Rac1. Proteins that belong to 
the third family of Ras GEFs, RasGRPs (guanyl nucleotide-releasing proteins), 
contain calcium-binding EF motives and a C1 domain with affinity for 
diacylglycerol (DAG) and phorbol easter (PE). These structures enable regulation 
by both DAG and PE of the catalytic activity of RasGRPs (reviewed in (Mitin et al., 
2005)). 
Ras GAPs are a more heterogeneous group compared to the GEFs. They 
contain only one common domain, RasGAP that stimulates GTP hydrolysis (±250 
amino acids long), but share no other universal features. Although non-functional 
Ras GAPs can contribute to overactivation of Ras proteins and lead to cancer, they 
have been considerably less studied than the GEFs. The discovery of p120 RasGAP, 
provided an explanation why only particular residues within Ras proteins often 
undergo missense mutations in cancer (section 1.2.5). Mutations of the residues 
G12 (glycine in position 12) and Q61 (glutamine in position 61), which all main 
isoforms of Ras have in common, result in insensitivity of the protein to the GAP. 
As a consequence, Ras becomes permanently bound to GTP and is constitutively 
active (reviewed in (Mitin et al., 2005; Vigil et al., 2010)). 
 
Figure 2. Regulation of Ras GTPases by their GAPs and GEFs. Ras proteins require 
the assistance of GEFs and GAPs to function as GTP-GDP regulated molecular 
switches. Known Ras GAPs – in red, Ras GEFs – in green. 
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1.2.3 POST-TRANSLATIONAL MODIFICATIONS AND SUBCELLULAR LOCALIZATION OF RAS 
IS CRUCIAL FOR PARTICULAR FUNCTIONS 
 
 Apart from GAPs and GEFs, the function of Ras proteins is regulated by 
enzymes facilitating their post-translational modifications (PTMs). Directly after 
translation, Ras proteins exist in the cytoplasm as globular hydrophilic molecules. 
As their signalling function is primarily dependent on their association with 
cellular membranes, they require post-translational processing that results in 
converting their C-terminus into a hydrophobic tail that mediates their 
membrane insertion. Complex PTMs of Ras proteins control their localization to 
different cellular compartments, which in turn affects their transforming abilities 
(e.g. signalling downstream of Ras differs depending on its localization to the 
Golgi membranes and to the plasma membrane) (reviewed in (Ahearn et al., 2012)). 
 The first signal for a constitutive modification of the C-terminal end of Ras 
proteins is the CAAX motif (where C is cysteine, A – aliphatic, X – any amino acid) 
that is recognised by farnesyltransferase (FTase). FTase catalysis the addition of a 
farnesyl isoprenoid to the cysteine residue in a newly translated Ras protein. This 
modification directs the protein to the endoplasmic reticulum (ER), where the 
CAAX motif is processed by two other enzymes: endoprotease RAS-converting 
enzyme 1 (RCE1) and isoprenylcysteine carboxylmethyltransferase (ICMT). Firstly, 
RCE1 removes the AAX part of the motif, leaving farnesylcysteine at the C-
terminus, then ICMT catalyses the methyl esterification of the α-carboxyl group of 
farnesylcysteine. The end product of all three modifications is a membrane-
associated Ras protein with a hydrophobic C-terminus. However, at this stage Ras 
is still not hydrophobic enough to facilitate translocation to the plasma 
membrane (PM) (reviewed in (Ahearn et al., 2012)). 
 In order to become a PM component, Ras proteins require a second signal 
within the amino acid sequence that undergoes modifications, another cysteine 
residue (in case of H-RAS, N-RAS and one isoform of K-RAS – K-RAS4A) or a lysine-
rich region (in case of KRAS4B). The cysteine residue can be palmitoylated in a 
reversible manner by palmitoyl acyltransferase DHHC9–GPC16 that resides in the 
Golgi Apparatus (GA) (Swarthout et al., 2005). This modification increases the 
affinity of Ras proteins for membranes over 100-fold comparing to only 
 21 
farnesylated Ras. In case of KRAS4B, the lysine-rich region itself stabilizes 
association of this protein with the PM. Moreover, it can be further modified by 
PKC, which phosphorylates serine 181 within the lysine-rich region. This 
modification is known as farnesyl-electrostatic switch: once phosphorylated, 
KRAS4B looses the affinity for membranes, dephosphorylation brings it back 
(Silvius et al., 2006). 
 Among other known Ras modifications are acylation/deacylation (linked to 
RAS trafficking to and from the GA), peptidyl-prolyl isomerization, ubiquitylation 
(regulates trafficking of HRAS to and from endosomes) and S-nitrosylation 
(reviewed in (Ahearn et al., 2012)). 
1.2.4 MOLECULAR AND CELLULAR EFFECTS OF RAS ACTIVATION 
 
 In non-transformed cells, in which Ras proteins are not constitutively 
active, upstream signalling of Ras starts at the PM. Firstly, growth factors, such as 
EGF, FGF, PDGF, bind appropriate receptor tyrosine kinases, stimulating receptor 
dimerization, autophosphorylation and activation. This event leads to the 
recruitment of a cytoplasmic complex of a RasGEF with an adaptor protein 
containing an SH2 domain, which binds phospho-tyrosine on the active receptor 
(e.g. SOS RasGEF and Grb2 adaptor). The now membrane-associated RasGEF 
complex is positioned in close proximity to membrane-bound Ras and can 
facilitate GDP/GTP exchange and activation of this small GTPase (reviewed in 
(Mitin et al., 2005)). 
Ras activation triggers many distinct cellular pathways (summarised in 
Figure 3). Most of the downstream effectors share a Ras-binding domain (RBD) or 
a Ras-association domain (RA) that enables them to be recruited to the membrane 
by GTP-bound Ras (reviewed in (Cox and Der, 2010)).  
The first identified Ras effector is Raf-1, the top kinase in the mitogen-
activated protein kinases (MAPK) cascade, a major mechanism by which mitogens 
stimulate cell proliferation. Raf proteins (A-Raf, B-Raf, Raf-1 also known as c-Raf) 
are Ser/Thr kinases that upon activation act as MAPK kinase kinases (MAP3K) by 
phosphorylating MAPK kinases (here MEKs), which in turn activate the MAPK 
extracellular-signal-regulated kinases (here ERKs). After translocation to the 
nucleus, ERK proteins activate various transcription factors, among them the well-
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described Elk-1 protein. Active Elk-1 forms a ternary complex with serum response 
factor (SRF) on promoters of genes containing serum response elements (SRE), e.g. 
the growth-related cFos and JunB genes (reviewed in (Sharrocks, 2001)). 
The second best characterised downstream effector of Ras is 
phosphoinositide 3 kinase (PI3K), which is important for numerous cellular 
processes, such as cell cycle progression, growth, survival, migration, and 
intracellular vesicular transport. PI3K phosphorylates the 3-hydroxyl group of the 
inositol ring of phosphatidylinositol lipids (PtdIns, PI). Depending on the 
phosphorylation state of other hydroxyl groups in the inositol ring, 3-
phosphorylated PtdIns molecules can subsequently bind effector proteins 
containing various lipid binding domains: PH domains, phox homology domains 
(PX) and FYVE domains (reviewed in (Vanhaesebroeck et al., 2010)). Binding of 3-
phosphoinositides coordinates the localization and function of effector proteins, 
among them are Akt family Ser/Thr kinases, PI3K-dependent kinase-1 (PKD1), as 
well as some GEFs for Rho and Ras (reviewed in (Kyriakis, 2009)). 
The Ral guanine nucleotide dissociation stimulators (RalGDS) family of Ras 
effectors consists of four members: RalGDS, RGL, RGL2/Rlf and RGL3. All of them 
share high sequence homology as well as three conserved domains: a CDC25 
homology domain, an upstream Ras exchange motif (REM), and a C-terminal 
Ras/Rap binding domain (RBD). The CDC25 domain allows RasGDS to act as GEFs 
for Ral proteins (members of the Ras family), while the RBD part mediates their 
interaction with Rap and Ras themselves. Due to the presence of both sequences, 
RalGDS are a unique link between different small GTPases allowing them to 
regulate each other. Activated Ral proteins bind and regulate Sec5, filamin, RalBP1, 
and ZONAB, thereby, play a role in the regulation of endocytosis, exocytosis, actin 
organization, and changes in gene expression (reviewed in (Ferro and Trabalzini, 
2010)). 
 Another Ras effector with a GEF activity is T-lymphoma and metastasis 
gene 1 (TIAM1), which stimulates Rac1 activation. Through Rac1, TIAM1 contributes 
to actin cytoskeleton rearrangements, activation of p21-activated kinases (PAKs) 
and JUN N-terminal kinase (JNK) (reviewed in (Minard et al., 2004)). 
A particularly powerful Ras effector is phosphoinositide-specific 
phospholipase C epsilon (PLCε), which directly generates inositol 1,4,5-
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triphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-
bisphosphate (PIP2). Production of these secondary messengers stimulates two 
cellular events: release of calcium from the ER into the cytosol as well as activation 
of PKC signalling cascades. Consequently, this results in the modulation of 
important cellular processes, such as cell division and differentiation. On a 
physiological level, these second messengers are important for correct heart and 
kidney function. Similarly to RalGDS and TIAM1, PLCε has a CDC25 domain, which 
enables it to act as a GEF for Rap1 and Ras, creating a positive regulation loop 
that results in prolonged activation of PLCε (reviewed in (Smrcka et al., 2012)). 
The Rin family is another group of Ras effectors with GEF activity, this time 
towards Rab proteins, in particular, they have an ability to stimulate Rab5-
dependent endocytosis (Kajiho et al., 2011; Kimura et al., 2006; Tall et al., 2001). Rin1 
has also been implicated in activation of ABL tyrosine kinase and as a 
consequence actin remodelling (Hu et al., 2005). 
Ras association domain family members (RASSF) are a recently discovered 
group of Ras effectors that were implicated in activation of cell death, but also 
stabilization of microtubules and regulation of the cell cycle. RASSF are a unique 
group of effectors without any catalytic activity, instead serving as adaptor 
proteins for various signalling molecules. The two best studied members of the 
family, RASSF5A as well as RASSF1A, have been shown to promote apoptosis 
through interactions via their SARAH domain with the kinases MST1 and MST2. 
This association leads to activation of the kinases and their translocation to the 
nucleus, where they contribute to the DNA damage response (reviewed in 
(Gordon and Baksh, 2011; Pfeifer et al., 2010)). 
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Figure 3. Ras effectors. Main pathways triggered by Ras activation downstream of 
a growth factor (GF) binding to a receptor tyrosine kinase (RTK). Further 
explanation in the text (1.2.4). 
 
 
1.2.5 RAS ONCOGENES IN CANCER 
CANCER AS A MULTISTEP PROCESS 
 
Early studies on Ras function in cancer revealed that oncogenic Ras was 
unable to transform primary cells, e.g. freshly isolated rodent embryos, on its own 
(Land et al., 1983). However introduction of H-RasV12 (a mutant with a glycine to 
valine substitution on residue 12) led to transformation of cells already 
immortalised (Newbold and Overell, 1983) or those that had undergone other 
predisposing modifications (Land et al., 1983). The finding supported the idea of 
carcinogenesis as a graduate, multistep process. 
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After decades of research, there is an agreement in the field that 
development of cancer requires a set of basic cellular processes to be altered. In 
their review, Hanahan and Weinberg enumerate the hallmarks of cancer: cells 
have to become independent of growth signals, but still be able to proliferate, 
they need to develop insensitivity to growth inhibition and cell death, as well as 
change their metabolism. At later stages, tumours require sustained angiogenesis, 
and eventually gain invasive and metastatic properties (Hanahan and Weinberg, 
2000; Hanahan and Weinberg, 2011). Interestingly, most of these features can be 
reached via mutations in Ras genes themselves, their regulators and effectors. 
Therefore Bar-Sagi calls the Ras pathway a “tumourigenic web” that captures 
numerous changes required for cancer to arise and progress (Pylayeva-Gupta et 
al., 2011). 
 
MUTATIONS IN RAS GENES 
 
RAS proteins are mutated in 33% of human cancers (from COSMIC 
database, June 2012). Most common mutations are missense substitutions (over 
98% of all sequenced RAS mutations) that usually occur in three particular 
positions of RAS proteins: glycine 12 (G12), glycine 13 (G13) and glutamine 61 
(Q61) (Figure 4). These changes impair the ability of RAS to hydrolyse GTP through 
either interfering with GAP binding (G12, G13) or preventing water molecules to 
access GTP, an event that is essential for GTP hydrolysis. As a result these 
oncoproteins become permanently bound to GTP and constitutively activate their 
downstream effectors (reviewed in (Pylayeva-Gupta et al., 2011)). 
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Figure 4. Frequency of particular mutations in different RAS genes found in human 
cancers. [COSMIC database, June 2012] 
 
 
 In human cancers, K-RAS is mutated most commonly in malignancies of 
lungs, intestines and pancreas. Changes in H-RAS are found in cancers arising 
from skin, head and reproductive organs, while N-RAS – in diseases of 
haematopoietic tissues and skin (Table 1). It is unclear why certain type of cancer 
would benefit from mutations in particular RAS isoforms. According to some 
available data, tissue specific expression levels of different Ras proteins matter 
most, and if the promoters are replaced, the isoforms can be functionally 
redundant (Potenza et al., 2005). Conversely, other studies suggest that RAS 
proteins have separate cellular functions (Haigis et al., 2008). Further research is 
necessarily to clarify the differences between K-RAS, H-RAS and N-RAS in normal 
as well as pathological conditions. 
 
Table 1. Frequency of mutations in RAS genes found in different types of human 
cancers. NA – not available. Shaded fields – found in over 5% of samples. * - Data 
from the COSMIC database from 5/6/2012. Numbers in brackets indicate total 
number of unique samples sequenced. ** - Data from the US National Cancer 
Institute SEER Cancer Statistics Review. The rates are shown as per 100,000 people 
per year within a period 2005-2009. 
 H-RAS K-RAS N-RAS 
Primary Tissue  % 
Mutated* 
% 
Mutated* 
% 
Mutated* 
Incidence 
Rate** 
Mortality 
Rate** 
Adrenal gland 1%  (136) 0  (211) 5  (171) NA NA 
Autonomic ganglia 0%  (63) 3  (63) 6  (102) NA NA 
Biliary tract 0%  (153) 28 (1766) 2  (287) NA NA 
Bone 2%  (199) 1  (252) 0  (207) 0.9 0.4 
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Breast 1%  (759) 3  (974) 2  (548) 124.3 23.0 
Central nervous 
system 
0%  (964) 1  (1184) 1  (1074) 6.5 4.3 
Cervix 9%  (264) 7  (637) 2  (132) 8.1 2.4 
Endometrium 1%  (314) 14 (2312) 1  (337) 23.9 4.1 
Eye 0%  (33) 4  (108) 2  (127) 0.8 0.1 
Haematopoietic 
and lymphoid 
tissue 
0%  (3171) 5  (6265) 10 (9155) 40.8 17.5 
Kidney 0%  (273) 1  (706) 0  (435) 15.1 4.0 
Large intestine 0%  (757) 35 (39774) 3  (2197) 46.3 16.7 
Liver 0%  (271) 6  (537) 3  (310) 6.9 4.2 
Lung 0%  (2118) 17 (19130) 1  (3637) 62.6 50.6 
Meninges 0%  (62) 0  (62) 0  (62) NA NA 
Oesophgus 1%  (161) 3  (375) 0  (161) 4.5 4.3 
Ovary 0%  (152) 14 (3193) 3  (191) 12.7 8.2 
Pancreas 0%  (279) 58 (5838) 2  (306) 12.1 10.8 
Parathyroid 0%  (100) 0  (100) 0  (100) NA NA 
Penis 7%  (28) 4  (28) 0  (28) 0.8 0.2 
Peritoneum 0%  (3) 7  (87) - 0.7 0.3 
Pituitary 3%  (300) 0  (300) 0  (300) NA NA 
Prostate 5%  (558) 8  (1009) 1  (558) 154.8 23.6 
Salivary gland 15% (164) 3  (173) 0  (48) 1.3 0.2 
Skin 6%  (2466) 2  (1829) 16 (5939) 23.0 3.6 
Small intestine 0%  (5) 17 (380) 0  (6) 2.0 0.4 
Soft tissue 5%  (745) 6  (1145) 5  (514) 3.3 1.3 
Stomach 4%  (384) 7  (2822) 2  (216) 7.6 3.6 
Testis 4%  (130) 4  (432) 3  (283) 5.4 0.2 
Thymus 2%  (46) 2  (186) 0  (46) 0.7 0.3 
Thyroid 4%  (4327) 2  (5446) 7  (4943) 11.6 0.5 
Upper 
aerodigestive track 
9%  (1202) 3  (1734) 3  (860) 10.8 2.5 
Urinary track 9 % (1765) 4  (1099) 1  (873) 21.1 4.5 
TOTAL 3%  
(22379) 
23% 
(100428) 
7%  
(34554) 
465.2  
(All sites) 
178.7 
(All sites) 
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MUTATIONS IN OTHER COMPONENTS OF THE RAS PATHWAY 
 
Apart from RAS itself, many of its regulators as well as effectors have been 
implicated in tumourigenesis. This includes the oncogenes EGFR, BRAF, PI3KCA 
(catalytic domain) and RALGDS that are mutated in 20%, 20%, 12% and 1% of 
human cancers, respectively (from COSMIC database, June 2012). Another two 
important RAS effectors, PLCε and TIAM1, are not recognised as proto-oncogenes; 
however, they have been shown to contribute to tumour progression in mice 
(TIAM1 was shown to be essential for Ras-dependent transformation) (Bai et al., 
2004; Malliri et al., 2002). Importantly, among RAS effectors we can also find 
tumour suppressors, namely RIN1 and RASSF. RIN1 blocks Ras signalling by 
stimulating endocytosis of EGFR (Tall et al., 2001), while RASSF can trigger 
apoptosis (Khokhlatchev et al., 2002). Both have been found silenced through 
methylation in cancer cell lines (reviewed in (Milstein et al., 2007; Richter et al., 
2009)) and in case of RASSF also in primary tumours (Meng et al., 2012). 
Upstream of Ras, GEFs could theoretically be overactivated in cancer. This 
type of mutations however is found very rarely in malignant tissues for any of 
the traditional GEFs (excluding PLCε, which functions as both Ras effector and 
activator) (Swanson et al., 2008). Another possibility leading to Ras activation 
would be eliminating its GAPs. In case of Neurofibromin 1 (NF1) RasGAP, this event 
indeed occurs in many glioblastomas. Moreover, patients suffering from 
neurofibromatosis type 1, an inherited condition in which expression of NF1 is 
lost, have increased risk of developing tumours (McClatchey, 2007). 
IN SEARCH OF A CURE 
 
 Studies on Ras genes and their effectors encouraged researches to look for 
inhibitors of these signalling pathways that could be used for treatments. The 
search started off from GTP antagonists, that were suggested in hope to repeat 
the success of molecules mimicking ATP used for inhibition of kinases. The idea 
fell quite quickly upon realisation that GTP has much higher affinity to Ras than 
ATP to kinases. Attempts to restore GAP activity towards Ras mutants failed as 
well, leading to diversion of the search towards more indirect ways of inhibition 
(reviewed in (Baines et al., 2011)). 
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Given that membrane recruitment is crucial for Ras to function, researches 
looked for inhibitors of enzymes facilitating its association with the PM. FTase 
inhibitors, though efficient for H-Ras, did not have an effect on K-Ras, due to 
differences in processing of these two proteins as well as additional mechanisms 
within the cells replacing the missing activity. The multitude of other farnesylated 
proteins that were inhibited together with Ras, including some tumour 
suppressors, eventually forced scientists to look for a cure elsewhere (reviewed in 
(Rowinsky, 2006)). Other modifications of Ras proteins leading to their PM 
localization have been considered; however, no major progress has been reported 
thus far. Preventing insertion of Ras proteins into cellular membranes may also be 
achieved through modification of relevant signals within this oncoprotein. 
Inhibition of prenyl insertion sites using salirasib, proved efficient for dislodging 
Ras from the PM. The drug is now undergoing clinical trials (reviewed in (Baines et 
al., 2011)). 
Since mutations in RAS effectors are often associated with cancer, various 
studies considered targeting signalling downstream of RAS for treatment. Two 
pathways in particular were the main object of interest: Raf-MEK-ERK and PI3K-
AKT-mTOR.  
Sorafenib was considered a promising candidate against RAF and was 
indeed approved for treatment of some types of cancers. It appears, however, that 
the mechanism behind the success of this compound is most likely blocking 
angiogenesis, as opposed to targeting tumour cells directly, and seems to involve 
inhibition of other than RAF kinases, including vascular endothelial growth factor 
receptors (VEGFR) (reviewed in (Baines et al., 2011)). A more successful attempt to 
inhibit RAF is based on vemurafenib, a selective inhibitor of B-RAF kinase activity. 
Vemurafenib proved to rapidly reduce melanomas with mutated B-RAF; however, 
patients developed resistance to the drug relatively quickly (Flaherty et al., 2010). 
Another potential complication is that the inhibitor can lead to activation of ERK, 
instead of inhibition, in cancer cell lines with mutated RAS (Heidorn et al., 2010; 
Rajakulendran et al., 2009). Vemurafenib, together with many other inhibitors 
against RAF and MEK, is still undergoing clinical trials (details on 
http://www.clinicaltrials.gov). 
From the PI3K-AKT-mTOR pathway, all three types of proteins have been 
targeted and inhibitors against them are undergoing clinical trials. Most 
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successful so far are temsirolimus and everolimus, compounds compromising 
mTOR activity, which have already been approved for treatment of advanced 
renal cell cancer (reviewed in (Fasolo and Sessa, 2012)). 
In view of the recent discovery that Ral GTPases are essential for some RAS-
dependent tumours, inhibition of this group of proteins has been investigated as 
well with some success, leading to current clinical trials (reviewed in (Baines et al., 
2011)). 
As tumours consist of heterogeneous groups of cells, a reasonable and 
most effective approach to treatment is using several different methods, so called 
combination therapy. It can rely on two different inhibitors, but most commonly 
includes chemotherapy (compounds interfering with DNA replication or cell 
division, such as doxorubicin or taxol) or radiotherapy combined with inhibitors 
(reviewed in (Baines et al., 2011)). 
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1.3 CELL COMPETITION IN DROSOPHILA 
1.3.1 MINUTE MUTANTS 
 
 The idea of cell competition appeared in cell biology for the first time in 
1975, when Genes Morata and Pedro Ripoll published their study on Minute 
mutant fly cells, later identified as carrying a mutation in ribosomal proteins 
(Kongsuwan et al., 1985). Slower proliferating Minute cells were eliminated from 
imaginal discs of mosaic Drosophila embryos comprising of normal and Minute 
heterozygous mutant cells, while embryos consisting of Minute mutant cells alone 
were viable and could develop into healthy flies (Morata and Ripoll, 1975). The 
new phenomenon was shown to depend on cell growth and proliferation: 
starved cells did not compete as effectively and competition did not occur after 
the completion of growth (Simpson, 1979). Since it did not cross developmental 
boundaries (Simpson and Morata, 1981), cell competition was proposed to be a 
mechanism that regulates robustness of the organ size control in flies. 
1.3.2 DMYC DRIVEN CELL COMPETITION 
 
 The next step in understanding cell competition was identifying proto-
oncogene dMyc (Drosophila Myc) as a super-competitor. Myc is a transcription 
factor controlling expression of genes which products are involved in 
proliferation, apoptosis, energy metabolism and protein biosynthesis (reviewed in 
(Luscher and Vervoorts, 2012)). Cells carrying diminutive, a hypomorphic version of 
dmyc, are eliminated from imaginal discs of developing Drosophila embryos by 
their wild-type neighbours through induction of apoptosis dependent on the 
pro-death factor Hid (de la Cova et al., 2004; Moreno and Basler, 2004). More 
interestingly, when a mosaic contains cells overexpressing dMyc in addition to 
normal cells, the roles reverse and former wild-type “winners” become “losers”.  
These studies indicate that the relative levels of dMyc appear to be a source of 
cell competition in Drosophila; for that reason dMyc was labelled a super-
competitor (de la Cova et al., 2004; Moreno and Basler, 2004). 
 More recently, another set of genes involved in cell competition was 
identified: the tumour suppressor components of the Hippo-Salvador–Warts 
 32 
(HSW) pathway, which is involved in the regulation of cell proliferation and 
apoptosis (Tyler et al., 2007). When mutated, HSW genes (expanded, fat, salvador, 
hippo, warts) are known to transform fly cells into super-competitors. The same 
was observed upon overexpression of the downstream effector of the HSW 
pathway, Yorkie (Yki) (Neto-Silva et al., 2012), (Ziosi et al., 2012). Yki is a 
transcription co-factor negatively regulated by the HSW pathway. Experiments 
have revealed that active Yki supports cell growth, most likely by directly 
promoting dmyc expression (Neto-Silva et al., 2012). A definite proof that cell 
competition driven by HSW pathway occurs via dMyc was demonstration that in 
the absence of dMyc, cells overexpressing Yki were no longer super-competitors 
(Neto-Silva et al., 2012). Moreover, diminutive heterozygotes overexpressing Yki 
remained outcompeted when confronted with wild-type cells (Ziosi et al., 2012). 
 Although ribosomal genes and dmyc are involved in cell growth, it was 
shown that not all growth related genes initiate cell competition. Overexpression 
of neither phosphatidylinositol 3-kinase (PI3K) nor cyclin D together with cyclin-
dependent kinase 4 (Cdk4) resulted in triggering competitive interactions in 
Drosophila (de la Cova et al., 2004). These observations suggest that differences in 
growth rates between neighbouring cells are not sufficient to drive cell 
competition. 
1.3.3 WNT PATHWAY-DEPENDENT COMPETITIVE BEHAVIOUR – AWAY FROM DMYC 
 
 The next breakthrough in the field of cell competition was the 
demonstration that not all competitive behaviour is related to dMyc. 
Unexpectedly, help arrived from one of the vital and conserved pathways, the 
Wnt signalling pathway, a known regulator of cell survival and growth often over 
activated in tumours. When Wingless (Wg), the ligand of the Wnt pathway, or its 
receptor Frizzled are mutated in some cells of a developing wing disc, they 
frequently die. However when the whole compartment is lacking Wnt signalling, 
cells survive. On the other hand, when Wnt signalling is overactivated due to the 
mutation of its negative suppressors APC and axin, cells become super-
competitiors and induce apoptosis in their neighbours (Vincent et al., 2011). Cell 
competition triggered by this conserved pathway was shown to be completely 
independent of dMyc; in fact, high levels of Wnt activation repress dmyc 
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expression in both APC and axin mutants. In the same study another novel 
concept was introduced to the field of cell competition: Notum, a secreted 
inhibitor of Wnt signalling, was found to be produced by super-competitors in 
order to compromise the Wnt response in their neighbours and lead to their 
apoptotic death (Vincent et al., 2011). 
1.3.4 POLARITY PROTEINS IN CELL COMPETITION 
 
Oncogenic alterations in cells do not necessarily provide a competitive 
advantage. Potentially tumourigenic cells with mutations in their apical-basal 
polarity genes discs large (dlg), scribble (scrib) or lethal-giant larvae (lgl), which on 
their own overproliferate and lose their epithelial integrity, are out-competed 
from mosaic imaginal discs of developing fly embryos (Brumby and Richardson, 
2003; Grzeschik et al., 2007). Further studies on scribble and lgl mutants revealed 
that normal cells produce and secrete Eiger (a fly TNF), which induces pro-
apoptotic JNK activity in the mutant cells (Igaki et al., 2009). Growth of scribble 
mutants is also inhibited upon signalling downstream of Eiger: JNK itself was 
found to promote HSW activity and consequently inhibit Yki and prevent dmyc 
expression (Chen et al., 2012). In line with these results are previous findings that 
lgl and scribble mutant cells can be rescued from elimination in a mosaic wing disc 
by overexpression of dMyc (Chen et al., 2012; Froldi et al., 2010). It has been 
suggested that fitness of the cells surrounding these polarity markers mutants 
determines whether they will be eliminated from the fly imaginal discs or not. 
Related to polarity complexes is another protein triggering cell 
competition in Drosophila, an Lgl binding protein Mahjong (Mahj). Flies carrying a 
homozygous mutation in mahj develop more slowly than wild-type animals and 
die at a late pupal stage. Mutant larvae however are not exhibiting any visible 
morphological defects. In contrast, when found in a mosaic environment in a 
Drosophila wing disc, mahj mutant cells become apoptotic through activation of 
the JNK pathway. Moreover, overexpression of Mahj prevents JNK 
phosphorylation in lgl mutants and rescues them from being outcompeted 
(Tamori et al., 2010). Up to date, the role of Mahj in polarity formation and its 
relation to Lgl remains unknown. 
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1.3.5 UNDERSTANDING THE MECHANISM OF CELL COMPETITION 
 
 Several mechanisms of cell competition have been proposed. Early studies 
on Minute and dmyc mutants pointed towards ribosomal proteins and the 
efficiency of protein synthesis as an outcome that could be compared between 
the neighbours and result in competitive behaviour. 
Later on, Moreno and colleagues suggested another possible explanation 
of how ribosomal and dmyc mutations could trigger cell competition. They have 
shown that “loser” cells upregulate repressor Brinker (Brk), what in turn leads to 
JNK activation and apoptosis. In “winner” cells Brk is downregulated due to high 
activity of the decapentaplegic (Dpp) pathway. Dpp is a secreted morphogen, a 
member of the TGFβ family, produced in a part of the fly wing disc and taken up 
via receptor-mediated endocytosis. Moreno and colleagues suggested that cells in 
Drosophila imaginal discs compete for survival factors and that those with a 
slower endocytic uptake, for example due to impaired ribosomal activity, may not 
activate Dpp signalling as efficiently as the wild type cells (Moreno et al., 2002). 
This hypothesis cannot explain all the types of cell competition, however, since 
some of them have been proven to be independent of Dpp signalling (de la Cova 
et al., 2004). 
The possibility that cell competition is mediated by different from Dpp 
secreted soluble factors was proposed by de la Cova and colleagues after they 
noticed that close proximity, but not direct contact was required to induce cell 
death of normal cells by dMyc super-competitors (de la Cova et al., 2004). This 
hypothesis was further investigated in an in vitro system with Drosophila S2 cells 
overexpressing dmyc (Senoo-Matsuda and Johnston, 2007). The authors used a 
cell culture system in which they co-cultured S2 normal cells with S2 cells 
overexpressing dmyc so that they could not have direct physical contact by 
separating them with a membrane filter. Although not in contact with each other, 
cells were still competing, leading to increased death rates of normal cells. 
Consequently, conditioned media from mixed competing cocultures had the 
ability to induce cell death in naive normal cells grown alone. It is not known 
whether soluble factors also play a role in vivo, and, if yes, what their nature is or 
whether they are important for other types of cell competition. 
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 One of the biggest questions in understanding cell competition is how do 
cells recognise each other and decide which of them will end up as a “loser” and 
which as a “winner”. Gene arrays comparing expression patterns of competing 
cells revealed that a calcium channel Flower (Fwe) is expressed in three different 
isoforms, two of which, FweLose-A and FweLose-B, are specific for “loser” cells while the 
third one, FweUbi, always marks a “winner” (Rhiner et al., 2010). The pattern was 
confirmed in dMyc super-competitors as well as Minute mutants. Importantly, 
overexpression of one of the “loser” isoforms of Fwe in an otherwise normal wing 
disc in a mosaic fashion was sufficient to induce their elimination. Even reducing 
expression levels of FweUbi itself in some of the cells within the fly epithelium led 
to their apoptosis. Rhiner et al. proposed that Fwe labelling is a downstream 
event of a mechanism aiming to compare fitness of the cells and marking them 
for death or survival. What the upstream mechanism is and how exactly cell death 
is executed remains to be elucidated. 
 In the same screen in which Fwe was implicated in cell competition, 
another gene with altered expression was identified: dSparc, a secreted acidic 
protein rich in cysteine. dSparc is also known as osteonectin and was recently 
suggested to be a molecular chaperone for collagen IV (Martinek et al., 2007). 
dSparc was found upregulated and secreted to the basement membrane by 
“loser” cells in cell competition triggered by altered expression or mutations in 
ribosomal proteins, dMyc, and the polarity genes scribble, lgl, dlg (Portela et al., 
2010). dSparc is enriched at an early stage of the cell competition and its 
expression transiently protects “loser” cells from activation of caspases and delays 
their apoptosis (Portela et al., 2010). Since dSparc is also expressed upon serum 
depravation in non-competitive conditions (Portela et al., 2010) or in hemocytes 
invading tissues (Martinek et al., 2002), it has been proposed a part of a general 
stress response rather than a specific competition marker.  
In human cancers SPARC has been studied with conflicting results: in some 
tumours it was found upregulated, in others downregulated (Lapointe et al., 2004; 
Mantoni et al., 2008). It is however generally believed to promote metastatic 
growth and cancer progression (reviewed in (Podhajcer et al., 2008)). Most recently, 
Moreno and colleagues have found SPARC to be upregulated at the boundaries 
of several types of tumours and normal tissues consistent with the idea that cell 
competition may play a role in cancer (Petrova et al., 2011). 
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1.4 ACTIVATION OF RAS AND SRC IN DROSOPHILA 
 
Cancer has been extensively studied in Drosophila and not only in the 
context of cell competition. This model organism is very well characterised with 
multiple tools for genetic manipulation available to researchers. Despite genetic 
and structural differences between these invertebrates and humans, for example, 
the lack of blood vessels, many basic processes as well as most of the major 
signalling pathways involved in mammalian cancerogenesis, can be modelled in 
flies (reviewed in (Rudrapatna et al., 2012; Stefanatos and Vidal, 2011)). 
 The most relevant for this thesis studies relate to oncogenic activation of 
Src and Ras proteins. Direct activation of Src in flies through overexpression of 
either wild-type or constitutively active forms of this protein leads to increased 
proliferation as well as apoptosis (Pedraza et al., 2004). In contrast, activation of Src 
achieved through a knockdown of an inhibitor of Src family kinases, C-terminal 
Src kinase (dCsk), results in blocking of apoptosis accompanied by decreased 
adhesion and overproliferation (Vidal et al., 2006). Interestingly, the latter occurs 
only when the loss of dCsk is widespread. Discrete, local deficits of this regulator 
have a non-cell-autonomous effect within the fly epithelium and lead to basal 
exclusion and apoptotic death of cells with overactivated Src. This phenomenon 
is mediated by dE-cadherin, p120-catenin, Rho1, JNK and MMP2 (Vidal et al., 2006). 
The mystery of the opposite outcomes of two different ways of activation of Src 
can be explained by the nature of Src signalling itself. Low levels of Src activity, 
similar to these achieved through depleting dCsk, trigger antiapoptotic pathways, 
whereas high levels promote cell death. In tumours, however, higher Src 
activation is often coupled with mutations in other oncogenes or tumour 
suppressors abolishing the apoptotic response and ultimately resulting in 
overgrowth and metastasis of the transformed tissues (Vidal et al., 2007). 
 Abnormal activation of Ras obtained by overexpressing its constitutively 
active form dRasV12 in Drosophila results in overgrowth of the affected tissue and 
formation of benign ‘tumours’. These highly proliferative cellular masses acquire 
metastatic-like behaviour upon gaining additional oncogenic mutations, for 
example, as mentioned earlier, loss of the polarity marker Scribble (Brumby and 
Richardson, 2003; Pagliarini and Xu, 2003). Strikingly, cooperation between the two 
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mutants was observed even when the mutations occurred in separate 
neighbouring cells. Studies have shown that downstream of Scribble, active JNK is 
sufficient to cooperate with Ras, drive extracellular matrix remodelling and enable 
invasion through MMP1 (Uhlirova and Bohmann, 2006). Further exploration of 
oncogene cooperation revealed the importance of the tumour microenvironment 
in invasion of dRasV12, scrib-/- cells. A cytokine called tumour necrosis factor (TNF), in 
Drosophila known as Eiger, is also required for JNK activation and promotion of 
invasive growth (Cordero et al., 2010). Remarkably, both JNK and Eiger have been 
found to play contradictory roles in cancer progression depending on the genetic 
context. Promotion of cancer progression by these two proteins is evident in 
double mutants of Ras and scribble, which invade surrounding tissues in a JNK- 
and Eiger-dependent fashion. Conversely, in scrib-/- cells exposed to cell 
competition within a normal fly epithelium, JNK and Eiger act as tumour 
suppressors and drive apoptotic cell death of these cells (reviewed in (Rudrapatna 
et al., 2012; Vidal, 2010)). 
 Apart from scrib-/- other mutations were found to cooperate with RasV12 in 
driving tumour progression. High levels of active Src itself promote malignant 
growth and metastasis in concert with Ras, which does not come as a surprise, 
since the JNK pathway contributes to dCsk-mediated phenotypes (Vidal et al., 
2007). 
 From the studies of cancer and competition in Drosophila, a picture 
emerges that depicts a fine balance between elimination of transformed cells 
from a normal epithelium and their escape followed by hijacking of the whole 
organism. It appears that one mutation in one cell is often not enough to drive 
tumourigenesis. With greater numbers or more mutations, transformed cells gain 
an advantage over the normal cells. The artificial divisions introduced by 
researchers between cancer and competition studies are bound to be shattered in 
the future. 
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1.5 CELL COMPETITION AND RELATED PHENOMENA MAMMALIAN CELLS 
1.5.1 COMPETITION IN NON-TRANSFORMED CELLS 
 
 In two recent reports, cell competition was identified in mammalian non-
transformed cells (Bondar and Medzhitov, 2010; Marusyk et al., 2010). The authors 
used lethally irradiated mice to study mechanisms of repopulation of 
haematopoietic stem cells (HSC). When two non-irradiated populations of HSC are 
mixed, they reconstitute the haematopoietic lineages according to their starting 
ratios. However, if one of the groups is treated with a low dose of ionizing 
irradiation causing mild DNA damage (at the level that still allows them to 
reconstitute haematopoietic lineage when they are introduced on their own), 
they become outcompeted by the non-irradiated group. This type of competition 
was shown to be dependent on p53 levels in the two populations. Low levels of 
p53 are sufficient for HSC to outcompete cells with higher p53 levels, which 
normally correlates with DNA damage, even without previous irradiation. In the 
process, outcompeted cells do not undergo apoptosis, but express growth arrest 
and senescence-related genes, such as p16 (Bondar and Medzhitov, 2010).  
 Since downregulation of p53 often occurs in cancer, there is a risk that 
p53-mutants could overtake the HSC niche. Hence, an additional protective 
mechanism was assumed, but not characterised so far, helping with elimination 
of the transformed cells with a competitive advantage (reviewed in (Green, 2010)). 
1.5.2 EARLY STUDIES ON COCULTURES OF NORMAL AND TRANSFORMED CELLS 
 
Interactions between normal and transformed mammalian cells have been 
studied for over fifty years. In the early reports, fibroblasts transformed with 
either viruses (Stoker, 1964), carcinogens (Borek and Sachs, 1966) or oncogenes 
(Alexander et al., 2004) were cocultured with normal fibroblasts. As a result of the 
mixing, growth of the transformed cells was inhibited. GAP junctions were 
implicated in (Bignami et al., 1988) and out of (Alexander et al., 2004) the role in 
transmission of the inhibitory signal from normal to transformed cells. Not clear 
remains what sort of signals would be transduced. The relevance of these studies 
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to cancer can also be questioned, since most of cancers originate from epithelial 
tissues, not fibroblasts. 
1.5.3 POLARITY PROTEINS-RELATED CELL COMPETITION 
 
 The first tumour suppressor that when depleted has been shown to cause 
cell competition in mammalian cells was scribble (Norman et al., 2012). In a 
mammalian cell culture system based on Martin-Darby Canine Kidney (MDCK) 
cells, downregulation of Scribble results in the elimination of these cells from 
monolayers of normal cells. Similarly to the events in the Drosophila imaginal 
discs, Scribble-knockdown cells (hereafter referred as Scribble cells) undergo 
apoptosis upon interaction with normal cells. Active Caspase-3, Bak and Bax can 
be detected in extruded Scribble cells, suggesting that their cell death occurs as a 
result of mitochondrial apoptosis. It has been shown that apoptotic death of 
Scribble cells is independent of their extrusion: treatment with myosin II inhibitor 
blebbistatin inhibits extrusion but does not prevent activation of caspases. While 
active JNK has been implicated in the competitive elimination of Scribble cells in 
Drosophila, it does not seem to play a role in the mammalian system. Instead 
activation of p38 mitogen activated protein kinase (p38 MAPK) is required for 
apoptotic elimination of Scribble cells (Norman et al., 2012). 
 Another polarity related protein studied in Drosophila has also been shown 
to induce cell competition in mammalian cells. MDCK cells with depleted Mahj, a 
Lgl binding partner that is conserved among species, are capable of not only 
forming monolayers but also cysts with well defined lumen and correctly 
localized polarity markers. In contrast, plating Mahj-knockdown cells within a 
monolayer of normal cells results in their apoptotic death followed by apical 
extrusion, which, analogically to the Drosophila system, occurs via activation of the 
JNK pathway (Tamori et al., 2010). 
Although the pathways triggering apoptosis in mammalian cells 
downregulating Scribble differ from their Drosophila counterparts, both described 
above phenomena can be classified as mammalian cell competition. After all, the 
ultimate result of the interaction between two otherwise viable populations is 
elimination of one of them via cell death. 
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1.5.4 INTERACTIONS OF NORMAL AND RASV12-TRANSFORMED CELLS 
 
 In 2009, the first study on interactions between H-RasV12-transformed and 
normal MDCK cells was published (Hogan et al., 2009). The system was created to 
imitate early stages of cancerogenesis during which a single mutation transforms 
a single cell within an otherwise normal monolayer. H-RasV12 was expressed in 
MDCK cells (hereafter referred as RasV12 cells) in an inducible manner under a 
tetracycline-controlled promoter. Upon mixing of RasV12 cells with normal cells at 
a ratio 1 to 100 on a collagen gel, two phenomena occurred: apical extrusion of 
transformed cells from the normal monolayer (the most common event) or 
formation of basal protrusions by RasV12 cells under their normal neighbours. 
Apical extrusion was also confirmed in an in vivo system based on Drosophila 
imaginal discs in which some of the cells expressed RasV12. In the tissue culture 
system, extruded RasV12 cells remained alive and proliferated on top of the normal 
monolayer. In contrast to the competition known from Drosophila, extrusion of 
transformed cells was independent of apoptosis and, for that reason, it is difficult 
to classify it as cell competition without knowing the fate of extruded cells in a 
living organism. 
 Two aspects of apical extrusion of RasV12 cells have been studied so far: 
signalling downstream of Ras that leads to the extrusion events and some of the 
cytoskeletal rearrangements that occur during the process. The MAPK pathway 
was shown to be required for apical extrusion, while PI3K was not involved (both 
of these pathways were important for formation of basal protrusions). At the top 
of the MAPK pathway, Raf (serine/threonine protein kinase, also known as MAP 
kinase kinase kinase) was required, but not sufficient, in its active form for apical 
extrusion to take place. 
 During apical extrusion various cytoskeletal rearrangements occur. Prior to 
extrusion RasV12 cells increase their height, accumulate RasV12, actin and E-cadherin 
at the junctions between each other. These changes happen in a non-cell-
autonomous manner. Hogan and colleagues have studied in details the role of 
myosin and actin in this process. They have shown that inhibition of myosin 
activity or actin polymerization both supress apical extrusion. Phosphorylated 
myosin (Thr-18, Ser-19) was upregulated in RasV12 cells surrounded by normal cells 
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24 hours after induction of RasV12 expression. Upstream of myosin, Rho-associated 
protein kinase (ROCK) and the Rho GTP-ase cell division control protein 42 (Cdc42), 
but not the Rho GTP-ase Rac, were shown to take part in extrusion. The dominant 
negative mutants of both of ROCK and Cdc42 proteins inhibited extrusion. Cdc42 
was also shown to be active in RasV12 cells prior to extrusion using recombinant 
protein for the Cdc42-binding domain (CRIB) of WASP. The molecular mechanism 
that links Cdc42 signalling to ROCK activation is not known. 
 Further studies are required to clarify whether what happens in this 
system is related to cell competition known from the Scribble and Mahjong 
downregulation systems, if similar pathways are involved, and what the role of 
this process is in a living organism. 
1.5.5 INTERFACE BETWEEN NORMAL AND V-SRC-TRANSFORMED CELLS 
 
 Another oncogene study quickly followed the RasV12 paper and confirmed 
that extrusion of transformed cells from mammalian epithelia is a phenomenon 
occurring in vivo in vertebrates, in particular in a Zebra fish embryo (Kajita et al., 
2010). The object of this analysis was the Rous sarcoma virus src gene (v-src), the 
first oncogene ever identified (Hunter, 1980). Src is a non-receptor tyrosine kinase 
that regulates various cellular process, including remodelling of the actin 
cytoskeleton, cell adhesion and proliferation (reviewed in (Yeatman, 2004)). In 
order to study interactions between v-Src-transformed and normal epithelial cells, 
Kajita and colleagues used a temperature sensitive mutant of v-Src in MDCK cells 
(hereafter referred as Src cells): Src becomes active after moving the cells from 
40.5oC to 35oC. Upon mixing Src cells with normal cells at a ratio 1 to 100 followed 
by Src activation, transformed cells become extruded from a normal monolayer in 
the same way as RasV12 cells. However, they were never observed to form basal 
protrusions. Similarly to RasV12 cells, extrusion of Src-transformed cells was 
independent of apoptosis and extruded cells remained alive, loosely attached to 
a normal monolayer. 
 Since the events in the Src system closely resembled what happened to 
RasV12 cells, Kajita and colleagues decided to investigate whether there were any 
common pathways activated upon interactions with normal cells. Firstly, they 
noticed that before extrusion Src cells undergo shape changes similar to RasV12 
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cells. They became taller than their normal neighbours or Src cells grown on their 
own; their shape also changed into more rounded. Myosin II was shown to be 
involved in extrusion: blebbistatin along with the inhibitors of myosin light chain 
kinase (MLCK) and ROCK prevented the process. What differed from the RasV12 
extrusion was the site of accumulation of phosphorylated myosin, as increased 
phospho-myosin staining was found at the plasma membrane.  
 Secondly, the authors discovered that Ras itself played a role in the 
extrusion of Src cells by using a dominant negative form of this protein. 
Downstream of Ras, the MAPK pathway, but not PI3K, was required for extrusion 
of Src cells. In contrast to RasV12 cells, however, Src cells when surrounded by their 
normal neighbours accumulated active MAPK along the cell cortex. 
 Downsteam of Src, active focal adhesion kinase (phospho-FAK) was shown 
to be necessary for extrusion to occur and, strikingly, also accumulated along the 
membranes. Further experiments revealed that although FAK and myosin II were 
activated independently of each other, they both contributed to MAPK activation. 
Interestingly, E-cadherin and β-catenin were mislocalized in Src cells prior to 
extrusion from the apical to the basal part of cell-cell adhesions, a change that 
was not reported in the RasV12 system. 
Taking into consideration the early reports about communication between 
normal and transformed cells through the GAP junctions, the authors examined 
and subsequently excluded their involvement in the phenomenon.  
 Although a lot of similarities were reported between RasV12- and v-Src- 
driven extrusion of transformed cells from the normal monolayers, there is also 
evidence that different pathways are regulated upon interactions with normal 
neighbours in each of the cell types. It is possible that the recognition and 
signalling from normal cells might be common and conserved in mammalian 
cells. We can speculate that in a living organism after extrusion transformed cells 
are exposed to harsh conditions (as flow of urine or stool) and removed from the 
organism. When the transformation happens in other niches (for example, breast 
epithelium), extruded cells could become a target for the immunological 
clearance mechanisms. 
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1.5.6 INTERACTIONS OF NORMAL AND ONCOGENE-TRANSFORMED CELLS IN 
ORGANOTYPIC CULTURES 
 
 An alternative possibility to cell removal via extrusion was suggested in a 
recent study on interactions between normal and transformed cells in three-
dimensional (3D) organotypic cultures of MCF10A, a non-transformed human 
mammary epithelial cell line (Leung and Brugge, 2012). The authors propose that 
the clonal outgrowth of oncogene-transformed single cells from the growth-
arrested acinar structures, that they observe, might be an early step in tumour 
progression. 
 In this study, oncogenes were classified into two groups: those that when 
activated were sufficient to drive clonal expansion of the transformed cells on 
their own, as erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and 
those that upon activation were not capable of releasing the cells from the 
growth inhibition within the acni, as c-MYC or AKT (also known as protein kinase 
b). The latter group could be divided further if the attachment of the transformed 
cells was modified, e.g., by overexpressing matrix metalloproteinases (MMP). In 
this situation, cells with active AKT that had translocated to the lumen could 
proliferate, whereas cells overexpressing c-MYC could not. 
 Interestingly, clonal outgrowth of ERBB2 overexpressing cells was 
dependent on the same pathways as extrusion of RasV12 and Src cells from normal 
epithelial monolayers of MDCK cells. Activation of the MAPK kinase pathway was 
required for this phenomenon to occur, while PI3K inhibition did not affect the 
process. 
 In this study, the authors separate extrusion from subsequent proliferation 
or apoptosis. It is a notable distinction which may tell us about the fate and 
ultimately the role of this process in mammals. In the future, research looking at 
extrusion in living adult organisms with developed immune systems will clarify 
the fate of extruded cells, whether the outcome of extrusion depends on the 
environment and if some primary tumours are already metastatic. 
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1.6 THE AIM OF THIS THESIS 
 
The general goal of my thesis is gaining a better understanding of the 
process of extrusion of transformed cells from a normal epithelial monolayer. In 
particular, in this project I aimed to identify and clarify the role of novel proteins 
important for interactions between normal and RasV12-transformed cells at an 
early stage of extrusion using an unbiased approach of biochemical screening. In 
the first result chapter, I present validation of a 2D gel screen performed 
previously, in which Hsp90β was identified as a molecule altered in cocultures of 
normal and transformed cells. In the following chapters, I describe two other 
biochemical screens I performed in the course of my studies. The aim of both of 
these screens was to pinpoint novel signalling pathways regulated by 
phosphorylation in cocultures of normal and transformed cells. Firstly, a 
traditional approach of immunoprecipitation of tyrosine-phosphorylated 
proteins from cocultures of normal and transformed cells was used. This method 
was then perfected in the last screen, through utilisation of a SILAC labelling 
technique, which allowed for quantitative analysis of changes in phosphorylation 
levels of proteins in just one of the cell types from cocultures (here, in 
transformed cells). In this thesis, I present results of both screens as well as 
preliminary validation data supporting the involvement of two identified 
molecules in the process of extrusion. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 MOLECULAR BIOLOGY AND BIOCHEMISTRY 
2.1.1 TRANSFORMATION OF COMPETENT CELLS 
Escherichia coli DH5α chemically competent cells (Invitrogen) were thawed on ice. 
To 50 µl of the cell suspension ± 1 µg of plasmid DNA was added for a further 30-
minute-incubation on ice. Cells were then heat-shocked at 42oC for 45 seconds 
and returned to ice for 3 minutes. 1 ml of fresh LB medium was added to the cells 
followed by a 1 hour incubation at 37oC. 100 µl of the cell suspension were then 
plated on LB agarose plates supplemented with 100 µg/ml ampicillin and 
incubated overnight at 37oC. 
2.1.2 PREPARATION OF PLASMID DNA 
Colonies obtained after plating transfected bacteria were picked, inoculated into 
200 ml LB media supplemented with 100 µg/ml ampicillin and incubated 
overnight at 37oC. Plasmid DNA for transfection was isolated from bacterial cells 
using Plasmid Maxi Kit (Qiagen) using the manufacturer’s instructions. 
2.1.3 SDS SAMPLE PREPARATION 
Confluent cells were washed with ice-cold PBS and lysed in the well with an 
appropriate amount of lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 1% 
Triton X-100) supplemented with protease inhibitors (details in chapter 2.1.8), e.g. 
300 µl or 80 µl of the lysis buffer per well in a 6-well or 48-well culture dish, 
respectively. Lysates were collected in 1.5 ml tubes and SDS buffer was added 
(one third of final volume). Samples were boiled at 99oC for 10 minutes. 
2.1.4 SDS POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
SDS polyacrylamide gels were prepared using the ingredients listed in table 2 
(proportions for a most commonly used 10% gel are shown). 
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Table 2. Composition of SDS-PAGE gels used throughout the thesis. 
 
Resolving gel 10% Stacking gel  
Mini Maxi Mini Maxi 
Water 3 ml 12 ml 3.2 ml 9.5 ml 
1.5 M Tris/Cl (pH 8.8) 2.5 ml 10 ml x x 
0.5 M Tris/Cl (pH 6.8) x x 1.25 ml 3.75 ml 
50% glycerol 2 ml 8 ml x x 
40% acrylamide 
/bisarylamide solution 
2.5 ml 10 ml 500 µl 1.5 ml 
10% SDS 100 µl 400 µl 50 µl 150 µl 
TEMED 15 µl 50 µl 5 µl 15 µl 
10% APS 30 µl 120 µl 50 µl 150 µl 
Total Volume 10 ml 40 ml 5 ml 15 ml 
 
Large gels were run overnight at 18 mA (per two gels) in a PROTEAN II xi gel 
electrophoresis tank (Bio-Rad). Small gels were run for 1-2 hours at 40 mA (per two 
gels) in a Mini-PROTEAN II gel electrophoresis tank (Bio-Rad). Protein size was 
assessed by comparison with PageRulerTM Prestained Protein Ladder (Fermentas). 
2.1.5 IMMUNOBLOTTING 
Proteins resolved in SDS-PAGE were subsequently transferred onto 
polyvinylidene fluoride membrane (PVDF, Millipore) in Bio-Rad Trans-Blot cells at 
70 V for 2 hours or at 220 mA overnight at 4oC. Before transfer, membranes were 
soaked for at least 5 minutes in methanol and briefly washed in transfer buffer 
(100 mM glycine, 10 mM Trizma base, 10% methanol). A transfer sandwich was 
prepared as follows: the PVDF membrane and the polyacrylamide gel, which had 
been washed in transfer buffer, were placed in between four sheets of soaked in 
transfer buffer Whattman blotting paper and two sponges. After removing air 
bubbles, the whole cassette was placed in a tank filled with transfer buffer. 
Membranes were then stained with 0.1% amido black (MERCK Millipore) for 30 
seconds, briefly washed with ultrapure water and agitated with a destaining 
buffer (20% methanol, 7.5% acetic acid) for 30 minutes at room temperature. 
Membranes were blocked with 3% skimmed milk (Marvel) in PBST (0.05% Tween20 
in PBS from Fisher Bioreagents) for 2 – 3 hours. Primary antibodies were diluted in 
3% milk/PBST and incubated with membranes overnight at 4oC or for at least 3 
hours at room temperature. Next, membranes were washed three times for 10 
minutes in PBST and incubated with secondary antibodies for a further 1 to 4 
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hours. Horseradish peroxidase-conjugated (HRP) secondary antibodies were also 
diluted in 3% milk/PBST. Goat anti-mouse and goat anti-rat antibodies (Jackson 
Immunoresearch) were used at a dilution 1:2000, goat anti-rabbit (Jackson 
Immunoresearch) was used at 1:5000 and mouse anti-goat (Sigma) was used at 
1:1000. Membranes were washed three time with PBST and bands were visualised 
using ECL detection reagents (solution I: 2.5 mM luminol, 0.45 mM p-coumaric 
acid, 0.1 M Tris/Cl pH 8.5; solution II: 0.02% hydrogen peroxide, 0.1 M Tris/Cl pH 8.5) 
combined in a 1 to 1 ratio applied onto membranes. High performance 
chemiluminescence film (Hyperfilm, Kodak) was used to capture the images. 
2.1.6 ANTIBODIES 
Table 3. List of primary antibodies used throughout the thesis for 
immunofluorescence, immunoblotting and immunoprecipitation. 
Antigen Catalog 
number 
Company Species Concentration 
used 
Hsp90α SPA-840 Stressgen Rat IF – 1:100 
Hsp90β ab2927 Abcam Rabbit IF – 1:50 
WB – 1:1000 
Raf-1 ab32025 Abcam Rabbit WB – 1:1000 
Erbb2 610161 BD Biosciences Mouse WB – 1:500 
GAPDH MAB374 Millipore Mouse WB – 1:5000 
pERK M9692 
 
Sigma-Aldrich Mouse WB – 1:1000 
ERK2 34680 Qiagen Mouse WB – 1:1000 
Plectin sc-33649 Santa Cruz 
Biotechnology 
Mouse IF – 1:100 
VASP 3132 Cell Signaling Rabbit IF – 1:200 
pVASP 
Ser239 
3114 Cell Signaling Rabbit IF – 1:100 
pVASP 
Ser239 
sc-101439 Santa Cruz 
Biotechnology 
Mouse IF – 1:100 
Vinculin V9131 Santa Cruz 
Biotechnology 
Mouse IF – 1:200 
MRCKβ sc48834 Santa Cruz 
Biotechnology 
Rabbit IB – 1:1000 
Myosin IIA M8064 SIGMA Rabbit IF – 1:200 
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pMLC 3675 Cell Signaling Mouse IF – 1:100 
ppMLC 3674 Cell Signaling Rabbit IF – 1:50 
p-Tyrosine 
4G10 
16-638 Millipore Mouse IP – Agarose-
conjugated beads 
p-Tyrosine 9419 Cell Signaling Mouse IP – Sepharose 
Bead Conjugate 
 
2.1.7 GEL STAINING WITH SYPRO® RUBY 
After SDS-PAGE large gels were transferred into a clean box, washed briefly with 
ultrapure water and fixed in 200 ml of fixing solution (50% methanol, 7% acetic 
acid) twice for 1 hour at room temperature. The gels were then stained in SYPRO® 
Ruby dye (Invitrogen) overnight at 4oC. The following day, the gels were distained 
with 200 ml of wash solution (10% methanol and 7% acetic acid) for 1 hour and 
stored in ultrapure water. Images were taken using default settings for SYPRO® 
Ruby stained gels on a Molecular Imager FX (BioRad). 
2.1.8 IMMUNOPRECIPITATION 
Cells were plated under three conditions: normal MDCK cells alone, RasV12 cells 
alone and a 1 to 1 mixed population. 1.2 x 107 cells were plated in a 15-cm plate 
and two plates were used for analysis for each condition. After 6-8 hours of 
plating, tetracycline (2 µg ml-1) was added to induce GFP-RasV12 expression. After 
14 hours, the cells were washed with ice-cold PBS, scraped and lysed in 1 ml Triton 
X-100 lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 1% Triton X-100) 
containing leupeptin (5 µg ml-1), phenylmethylsulfonylfluoride (50 mM), aprotinin 
(7.2 trypsin inhibitor units), as well as phosphatases inhibitors: sodium 
orthovanadate (1 mM), ammonium molybdate (0.1 mM) and sodium fluoride (10 
mM) (all inhibitors were from Sigma). The cells were then lysed for 20 minutes at 
4oC. After centrifugation at 14,000 x g for 10 minutes at 4oC, the supernatants were 
incubated with prewashed sepharose beads for 30 minutes at 4oC for preclearing. 
This step was repeated 3 times. 50 µl of the precleared supernatants were taken as 
‘total cell lysate’ fraction. The rest of the supernatants was subjected to 
immunoprecipitation for 4 hours with 50 µl of prewashed beads with conjugated 
anti-phospho-tyrosine antibodies (Millipore and Cell Signalling, mixed in a ratio 
1:1).  
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The beads were subsequently washed twice with the lysis buffer, and bound 
proteins were eluted with 200 µl of SDS sample buffer for 10 minutes at 95oC. 
Eluted fractions were analysed by perfoming sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), followed by SYPRO® Ruby protein 
gel staining (Invitrogen)  or Western blotting with anti-phospho-tyrosine-
antibody. 
2.2 CELL BIOLOGY 
2.2.1 CELL CULTURE 
MDCK cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) 
supplemented with 10% fetal calf serum (FCS; Sigma), 1% GlutamaxTM (Gibco) and 
penicillin/streptomycin (PAA Laboratories) at 37°C and ambient air supplemented 
with 5% CO2. MDCK cells stably expressing GFP-RasV12 in a tetracycline inducible 
manner were made by Catherine Hogan (Hogan et al., 2009). These cells were 
maintained in selective medium containing 10% FCS (tetracycline-free; PAA 
Laboratories, Pasching, Austria), 5 μg ml-1 of blasticidin (PAA Laboratories) and 400 
μg ml-1 of zeocin (Invitrogen). To induce GFP-RasV12 expression, 2 μg ml-1 
tetracycline was added to the culture medium. 
2.2.2 CELL STORAGE 
For storage, cells (in their second generation since thawing) were trypsinised, 
spun down at 1000 rpm for 5 minutes, resuspended in fresh medium 
supplemented with 10% DMSO to a concentration (1-2) x 106 cells/ml and 
transferred to cryovials. Initial freezing took place in a isopropanol bath at -80oC 
overnight. Cells were subsequently transferred to liquid nitrogen for long term 
storage (-150oC). 
2.2.3 PREPARATION OF COLLAGEN COATED PLATES AND COVERSLIPS 
Type‑I collagen solution was obtained from Nitta Gelatin (Nitta Cellmatrix type 
1‑A), and was neutralized on ice to a final concentration of 2 mg ml–1 according 
to the manufacturer’s instructions. Glass coverslips in 6‑well culture dishes were 
coated with 1 ml of neutralized collagen and allowed to solidify for 30 minutes at 
37oC. Alternatively, for time-lapse experiments 6-well glass-bottom dishes were 
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coated with 400 µl of neutralized collagen. For each assay, between 0.8 x 106 and 2 
x 106 cells were plated per well onto the collagen gel. RasV12 cells were combined 
with MDCK cells at a ratio of 1:100 or 1:50. After incubation for 6–16 hours at 37oC, 
tetracycline was added to induce RasV12 expression. Cells were incubated for the 
indicated times. 
2.2.4 TRANSFECTION METHODS 
LIPOFECTAMINE 2000 
Lipofectamine 2000 (Invitrogen) was used for creating stable cell lines (described 
below) as well as extrusion studies with the following constructs: pcDNA3-HA-
Hsp90β, pcDNA3-HA-DNHsp90β (both purchased from Addgene), pcDNA/T0/GFP 
(Dupre-Crochet et al., 2007), pcDNA/T0/GFP-RasV12 (Hogan et al., 2009). MDCK cells 
were split into collagen coated 6-well plates at 0.5 x 106 per well and allowed to 
recover overnight. The following day, the medium was replaced with fresh DMEM 
without antibiotics. Transfection mixtures were prepared as follows: 2 µg of DNA 
were resuspended in 250 µl of Opti-MEM (Invitrogen), while 5 µl of Lipofectamine 
2000 was added to another 250 µl of Opti-MEM. After 5 minutes both mixtures 
were combined and allowed to form transfection complexes for 20 minutes at 
room temperature. The mixture was then added to the cells. After 4-6 hours, the 
medium was replaced with fresh DMEM, and the cells were fixed with 4% PFA 
after a further 18-20 hours. 
CALCIUM PHOSPHATE 
HEK293 cells were used for confirming expression of Hsp90β and DNHsp90 from 
purchased constructs. Cells were split into 10-cm culture dishes at 2.0 x 106 cells 
per plate. The following day a transfection mixture was prepared as follows: to 
450 µl sterile water 50 µl of 2.5 M CaCl2 solution was added together with 5 µg of 
plasmid DNA. DNA was then precipitated by adding dropwise 500 µl 2x HEPES 
buffer (280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4, pH 7.05) while vortexing. After 5 
minutes, the mixture was applied onto the cells. After 4-6 hours, the medium was 
replaced with fresh DMEM, and the cells were lysed and used for Western blot 
analysis after 18-20 hours. 
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INTERFERIN 
Interferin (Polyplus-transfection) was used for transfection of siRNAs into MDCK, 
RasV12 or GFP cells. Cells were plated in 48-well plates at 0.5-1 x 104 cells per well. 
After 16-18 hours (for next-day-transfections) or immediately afterwards (for 
trypsin-transfection), the transfection procedure was carried out. 0.5 µl of 20 µM 
siRNA (Table 4) was added to 50 µl of Opti-MEM. Next, 1 µl of Interferin was added 
to the mixture, which was then incubated at room temperature for 25 minutes. 
Complete medium was added to the transfection mixture, which was afterwards 
applied onto the cells up to the final transfection volume of 250 µl. After 2 days, 
cells were split and combined with normal cells in 6-well plates (one knockdown 
well with 1 x 106 MDCK cells) on collagen coated coverslips or collagen coated 
time-lapse dishes. After overnight incubation, tetracycline (2 μg ml-1) was added to 
induce GFP-RasV12 expression and cells were either fixed at 8 hours or 24 hours 
from GFP-RasV12 induction or followed using time-lapse microscopy. 
 
Table 4. Sequences of siRNA molecules used in this thesis. All siRNA reagents were 
ordered from Thermo Scientific, resuspended to a final concentration of 20 µM in 
1X siRNA buffer (20 mM KCl, 0.2 mM MgCl2, 6 mM HEPES, pH 7.5) and stored at -
80oC. 
siRNA name siRNA sequence 
Control_si_RNA MISSION siRNA Universal Negative Control  1 and 2 mixed in a 1 to 1 ratio (Sigma) 
VASP_dog_oligo_1 GGAAATAAGATGAGGGAGA 
VASP_dog_oligo_2 CCACAGGGCTCCAGAAGAT 
VASP_dog_oligo_3 CCAGAATGGTCCCGCCTCA 
MRCK_pan _dog_oligo_1 AGAGAAGACTTTGAGATAT 
MRCK_alpha _dog_oligo_2 AAGATATGGCTCGATTTTA 
MRCK_beta _dog_oligo_3 AAAGAATTCTGAAACGATG 
 
2.2.5 GENERATION OF STABLE CELLS LINES 
MDCK-GFP-RasV12 cells stably expressing HA-Hsp90β were produced as follows. 
MDCK-GFP-RasV12 cells were transfected with pcDNA3-HA-Hsp90β (Addgene) using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions, 
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followed by selection in medium containing 800 μg ml-1 of G418 (Calbiochem), 5 
μg ml-1 of blasticidin and 400 μg ml-1 of zeocin. Overexpression of Hsp90β-HA was 
analysed by immunofluorescence and immunoblotting. 
2.2.6 FLUORESCENT LABELLING OF CELLS 
For some experiments cells were labelled with CellTracker Red CMTPX dye 
(Molecular Probes). Supplied powder was reconstituted in DMSO up to 0.67 
mg/ml. 25 µl of the dye was then added to a 80% confluent 6 cm dish of MDCK 
cells in FCS free medium. After 25-30 minutes cells were washed with PBS and 
recovered in normal medium for a further 30 minutes before being trypsinised 
and used for experiments. 
2.2.7 INHIBITORS 
All the inhibitors were added to mixed cultures or RasV12 cells alone together with 
tetracycline, which due to the 2 hour incubation time for GFP-RasV12 expression 
accounted for pre-incubation. Two Hsp90 inhibitors (both from Sigma-Aldrich) 
were used in this thesis: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) used 
for most experiments at 100 nM and celastrol used for most experiments at 1 µM 
(unless indicated otherwise). Myosin II inhibitor, blebbistatin, was used at 60 µM 
(Toronto Research Chemicals). 
2.2.8 HGF ASSAY 
In the HGF assay, 1 x105 MDCK cells were plated and in 35 mm wells and cultured 
for 24 hours in the presence of 100 nM HGF (Chmicon) and with Hsp90 inhibitor 
17-AAG (50, 75, 100 nM). 
2.2.9 TIME-LAPSE MICROSCOPY 
MDCK cells stably expressing GFP–RasV12 with or without indicated siRNA 
knockdown were trypsinized and combined with wild type MDCK cells at a ratio 
of 1 : 50. Cells were plated at a density of 1 x 106 cells per well or 2 x 106 cells per 
well in 35 mm glass-bottom culture dishes (MatTek Corporation) for all 
experiments. Mixed cells were incubated for 16 hours or 4 hours, respectively, at 
37oC before being transferred to a tetracycline-containing medium. 4 hours after 
tetracycline addition, the cells were filmed for up to 48 hours with pictures taken 
every 10 minutes. Only groups smaller than four cells at the beginning of the 
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movie were chosen. To assess cell viability ethdium homodimer-1 (EthD-1, 
Molecular Probes) was added to the medium while imaging at 400 nM.  
To obtain time-lapse images, a Zeiss Axiovert 200 M microscope was used with a 
Ludl Electronic Products Biopoint Controller and a Hamamatsu C4742‑95 Orca 
camera (Hamamatsu). Images were captured and analysed using Volocity software 
(Improvision). 
2.2.10 FIXATION METHODS 
PFA 
PFA fixation was performed after 8, 18 and 24 hours from tetracycline addition. 
Confluent monolayers were washed with PBS before 4% PFA in PBS was applied 
for 5 to 15 minutes at room temperature (depending on cell density, matrix and 
primary antibody used afterwards). Cells were then washed 3 times with PBS and 
either permeabilised straight away or left at 4oC for no longer than for 3 days 
until staining. 
METHANOL 
Cells plated on glass were in some cases fixed with methanol (for certain 
antibodies). Fixation was performed after 8, 18 and 24 hours from tetracycline 
addition. Confluent monolayers were washed with PBS before pure methanol  
(-20oC) was applied for 5 to 8 minutes at -20oC. Cells were then rehydrated for 10 
minutes with PBS, and either permeabilised immediately afterwards or left at 4oC 
for no longer than for 3 days until staining. 
COMBINED PFA AND METHANOL METHOD 
Cells plated on collagen used for stainings with antibodies typically working only 
in methanol fixed cells were first washed with PBS, then treated for 5 to 10 
minutes with 4% PFA/PBS at room temperature, washed 3 times with PBS, and 
finally fixed for further 3 to 5 minutes in pure methanol (-20oC) for 3 to 5 minutes. 
Rehydration and further immunostaining steps followed. 
2.2.11 IMMUNOFLUORESCENCE 
Primary antibodies used for stainings are listed in table 3.  
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ON GLASS 
After fixation, cells on glass were permeabilized in 0.5% Triton X-100/0.3% 
BSA/PBS for 10 minutes. If fixed with PFA, the cells were then washed once in 
quenching solution (20 mM glycine, 0.5% BSA in PBS) and left in the same 
solution for 30 minutes. Next, the cells were incubated with blocking buffer (0.5% 
BSA, 0.2% Triton X-100 in PBS) for over 3 hours. Primary antibodies diluted in 
blocking buffer were applied overnight. The following day, coverslips were 
washed three times for 10 minutes each with blocking buffer, and incubated with 
secondary antibodies Alexa-568-, Alexa-555- and Alexa-647-conjugated secondary 
antibodies (1 : 600, Molecular Probes) and/or phalloidin-647 (1 : 200 - Molecular 
Probes, 1 : 2000 Sigma) for 2–4 hours at room temperature. The cells were then 
washed three times for 10 minutes in blocking buffer and were incubated with 
Hoechst in PBS for 3 minutes, followed by washing in PBS and mounting onto 
mowiol on a glass slide. 
ON COLLAGEN 
After fixation, cells on collagen were permeabilized in 0.5% Triton X-100/PBS for 
10 minutes. The cells were then washed once in PBS followed by three 10-minute 
washes in glycine wash buffer (7 mM Na2HPO4, 3.5 mM NaH2PO4, 130 mM NaCl and 
100 mM glycine). The cells were blocked for more than 2 hours in blocking buffer 
(7 mM Na2HPO4, 3.5 mM NaH2PO4, 130 mM NaCl, 0.2% Triton X-100, 0.05% Tween-
20, 10% FCS, 0.02% BSA and 7.7 mM NaN3), and incubated with primary antibodies 
for 16 hours at 4oC. This was followed by three 10-minute washes with gentle 
agitation in blocking buffer before incubation with Alexa-568-, Alexa-555- and 
Alexa-647-conjugated secondary antibodies (1:200, Molecular Probes) and/or 
phalloidin-647 (1:200 - Molecular Probes, 1:2000 - Sigma) for 2–4 hours at room 
temperature. Cells were then washed three times for 10 minutes in blocking 
buffer and were incubated with Hoechst/PBS for 3 minutes, followed by washing 
in PBS and mounting onto a glass slide with mowiol and an additional cover 
glass on top. 
2.2.12 PHASE CONTRAST MICROSCOPY 
Cells for the HGF assay were examined using a Bio-Rad Radiance 2100 MP system 
mounted on a Nikon 800 microscope using Lasersharp software (Biorad). 
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2.2.13 CONFOCAL MICROSCOPY 
Cells cultured on collagen gels were examined using a Leica TCS SPE, SPE2 or SPE3 
confocal microscope and Leica Application Suite (LAS) software. 
2.3 DATA ANALYSIS 
2.3.1 QUANTIFICATION OF IMMUNOFLUORESCENT IMAGES 
Images were analysed using Leica Application Suite (LAS) software while pixel 
intensity was quantified using Metamorph 6.0 digital analysis software (Universal 
Imaging). 
FLUORESCENCE INTENSITY 
A defined circular region was created in the cytoplasm of the indicated cells in xz 
confocal sections. For each cell, 10 regions were created. The total pixel intensity 
within each region was determined and the mean pixel intensity was calculated 
for each cell. 
ACTIN ACCUMULATION AT JUNCTIONS 
A defined circular region was created on along the phalloidin stained junction of 
the indicated cells in xz confocal sections. For each junction, 2-3 regions were 
created. The total pixel intensity within each region was determined and the 
mean pixel intensity was calculated for each type of junction. The value was then 
multiplied by the average length of particular types of junctions determined for 
the same cells with the LAS software. 
NUCLEAR LIFT 
Position of each nucleus in RasV12 cells was assessed in xz confocal sections 
through the middle of the cells. Depending on their proximity to the apical and 
basal membrane were classified into three groups:  
1) lifted – the upper edge of the nuclear envelope very close to the apical 
membrane, visible difference between position of the nucleus in RasV12 cells 
comparing to the position of nuclei in surrounding normal MDCK cells,  
2) moving – elongated shape, generally closer to apical membrane, visible 
difference between position of the nucleus in RasV12 cells comparing to the 
position of nuclei in surrounding normal MDCK cells,  
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3) at the same level as in normal cells – the lower edge of the nuclear 
envelope very close to the basal membrane, no visible difference between 
position of the nucleus in RasV12 cells comparing to the position of nuclei in 
surrounding normal MDCK cells. 
2.3.2 QUANTIFICATION OF IMMUNOBLOTS 
Immunoblots were quantified using ImageJ software. 
2.3.3 QUATIFICATION OF EXTRUSION RATES 
GFP-RasV12 cells that were apically extruded or formed basal protrusions were 
counted and expressed as a ratio relative to total cells. Cells were counted 
following 24 hours of tetracycline and inhibitor addition. 
2.3.4 QUANTIFICATION OF TIME-LAPSE MOVIES 
RasV12 cells visible throughout the movie were taken into consideration while 
quantifying time lapse images. Each RasV12 cell was followed for the duration of 
the movie and the time of its extrusion was recorded. Extrusion rates were 
quantified by dividing total number of cells at the end by total number of 
extruded cells. Proliferation rates were quantified by dividing total number of 
cells at the end by total number of cells at the beginning. Average group size at 
the end of the movie was also registered. 
2.3.5 STATISTICAL METHODS 
Two-tailed Student’s t tests were used to determine P values. All data were 
analysed in Microsoft Excel. 
2.4 SILAC SCREEN METHODS 
2.4.1 SILAC LABELLING 
MEDIUM PREPARATION 
Medium for SILAC labelling was prepared as follows: 13.26 g of arginine- and 
lysine-deficient DMEM powder (Caissons Lab) was mixed with 3.7 g of sodium 
bicarbonate and dissolved in 1 L ultrapure autoclaved water. pH was adjusted to 
7.1 and the medium was filtered. Before culturing MDCK cells the medium was 
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supplemented with dialysed FBS (30 MWCO) (Invitrogen), as well as 
penicillin/streptomycin and GlutaMax, as before. Labelled amino acids (Sigma 
Isotopes) were added at a final concentration of 50 µg/L: for a ‘light’ label lysine-0 
(unlabelled) and arginine-0 (unlabelled), for a ‘medium’ label lysine-4 (2H4-labelled) 
and arginine-6 (13C6-labelled), for a ‘heavy’ label lysine-8 (13C6, 15N4-labelled) and 
arginine-10 (13C6, 15N4-labelled). 
 LABELLING OF RASV12 AND MDCK CELLS 
MDCK and two sets of RasV12 cells were labelled for five generations in SILAC 
medium with ‘light’, ‘heavy’ and ‘medium’ amino acids, respectively. Cells were 
plated in 15 cm culture dishes and split accordingly: first split 1 to 5, second – 1 to 
4, third – 1 to 3, fourth – 1 to 2 (cells grew slower in medium with dialysed FBS). 
Labelling efficiency was calculated from MS analysis of labelled lysates. In short, 
cell lysates were mixed (‘heavy’ to ‘light’ in a 1 to 1 ratio or ‘medium’ to ‘light’ in a 
1 to 1 ratio), separated by SDS-PAGE, and two gel bands of high and low 
molecular weight were excised, digested and analysed by LC-MS. Relative 
quantification of ‘heavy’ to ‘light’ ratio and ‘medium’ to ‘light’ ratio in these 
proteins, revealed a labelling efficiency of 98% for both arginine and lysine within 
the proteins contained the isotopic labels. 
2.4.2 CELL CULTURE 
For an experiment, cells were trypsinised, counted and plated at 4 x 107 cells per a 
15 cm plate. In these confluent conditions, they formed a monolayer very quickly. 
Cells were grown in two conditions: ‘medium’ RasV12 cells were plated alone in two 
plates, while ‘heavy’ RasV12 cells were mixed in a 1 to 1 ratio with ‘light’ MDCK cells 
in four plates. All the cells were kept in ‘light’ medium, to minimise negative 
effects of label exchange during the experiment. After 2 hours, tetracycline was 
added (2 μg ml-1) to the medium. After 6 hours, cells were harvested. We 
confirmed that during an 8 hour incubation in ‘light’ medium, label exchange was 
not higher than 10-20%.  
2.4.3 CELL LYSIS 
After 6 hours from adding tetracycline, cells were washed with TBS and lysed in a 
total amount of 10 ml of 9 M Urea / 100 mM Tris/Cl pH 8 supplemented with 0.2 
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(three times for 15 seconds each until the lysate was clear). After spinning down 
for 10 minutes at 20,000 rcf, the supernatant was moved to a fresh tube. To reduce 
disulfide bonds DTT was added to the lysates at 5 mM final concentration and the 
tube was incubated in a water bath at 55oC for 15 minutes. After cooling down, 
alkylating agent iodoacetimide was added up to a final concentration of 10 mM, 
and the tube was incubated for a further 15 minutes in the dark. Finally, the 
lystates were topped up to 45 ml volume with 100 mM Tric/Cl pH 8.0 and 20 µg 
trypsin was added to digest isolated proteins into peptides. Digestion lasted 48 
hours, after which peptides were kept at 4oC until isolation (no longer than for 3 
days). 
2.4.4 PURIFICATION OF PEPTIDES 
Sep-Pak C18 Plus Short Cartridges (Waters) were used to purify peptides. Each 
column was firstly activated by application of 5 ml acetonitrile (MeCN), then 
washed twice with 7 ml 0.1% trifluoroacetic acid (TFA). TFA was added to the 
peptide solution at a final concentration of 1%. The lysate was then spun down 
for 5 minutes at 2000 rpm, room temperature, the supernatant was moved to a 
fresh tube and loaded onto the column. Pressure was applied and air bubbles 
were removed during extraction. The column with bound peptides was 
subsequently washed twice with 0.1% TFA 10ml. Peptides were eluted with 8 ml 
50% MeCN / 0.1% TFA. Eluates were aliquated into screw cap microcentrifuge 
tubes, frozen for at least 30 minutes on dry ice and finally dried in a Savant 
SC250EXP SpeedVac concentrator (Thermo Scienctific). Dried peptide pellets were 
store at -20oC. 
2.4.5 ISOLATION OF PHOSPHO-PEPTIDES 
For isolation of phosphopeptides, dried peptide pellets were resuspended in 
25%MeCN / 0.1% TFA to a concentration of 20 mg/ml. Phos-Select Iron Affinity gel 
(Sigma) was used for selective purification of phosphorylated peptides. 300 µl of 
the beads, were washed with 0.1% TFA, followed by two washes with 25% MeCN / 
0.1% TFA. 100 µl of the peptide solution (2 mg of peptides) was diluted to a 
concentration of 5 mg/ml in 150 µl 25% MeCN / 0.1% TFA and applied onto the 
gel for 2-hour long rotation at room temperature. The gel with bound 
phosphorylated peptides was then spun down for 30 seconds at 800 rcf and 
washed with following buffers: twice with 0.1% TFA, once with 0.1% TFA/ 50% 
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MeCN, twice with 1% TFA / 50% MeCN and finally once with ultrapure water. The 
elution was performed twice with 250 µl of 100 mM ammonium bicarbonate (ABC) 
pH 9.5 for 10 minutes at room temperature. Eluted fractions were combined, 
phosphorylated peptides were stabilised with 20 µl 20% TFA, frozen on dry ice for 
30 minutes and dried in a vacuum centrifuge. 
2.4.6 HYDROPHILIC INTERACTION CHROMATOGRAPHY (HILIC) 
Phosphorylated peptides isolated from 10 mg of total peptides were resuspended 
in 500 µl of 80 % ACN prior to injection and purified using HILIC chromatography 
(Ultimate 3000 HPLC system, Thermo) to fractionate the sample. The following 
solvents were used: A (0.005 % TFA), B (90 % ACN/0.005 % TFA) and C (0.04 % TFA). 
Samples were loaded in 90% solvent B. Phosphopeptides were fractionated on a 
2.1 x 150 mm TSKgel Amide column. Following gradient steps were performed: 
100% B for 3 min, to 90% B in 2 min, to 70% B in 20 min, up to 20% in 10 min 
while solvent C increased from 0 to 20%. Between 12 and 44 min 16 fractions of 
300 µl were colleted and lyophilized for LC-MS analyses. [Experiment was 
performed by John Sinclair, Jorgensen’s lab, ICR] 
2.4.7 LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC-MS/MS) 
Phosphorylated peptides were identified by Liquid Chromatography Tandem 
Mass Spectrometry (LC-MS/MS) using nanoflow capillary reversed-phase LC on an 
Eksigent NanoLC-Ultra 2D with a cHiPLC-nanoflex system (Eksigent, Dublin, 
California) coupled to an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific, Hemel Hempstead, UK). ‘Trap and elute’ configuration was chosen on 
the NanoFlex system, and two type of columns were used: a trap column (200 µm 
x 0.5 mm) and an analytical column (200 µm x 15 cm), both packed with ChromXP 
C18-CL 3 µm 120 Å. Samples dried after HILIC were resuspended in 10 µl of 0.1% 
FA and loaded at a flow rate of 5 µl/min for 5 min. Elution was performed at a 
flow rate of 300 nl/min in a linear gradient of 5 % to 30% of ACN, 0.1 % FA 
solution in 120 min. Data-dependent mode switching automatically between 
Orbitrap MS and MS/MS acquisition was used. Acquisition of survey full scan MS 
spectra (from m/z 400-2000) was performed in the Orbitrap Velos using a 
resolution of 30,000 at m/z 400. Isolation and fragmentation of top 10 most 
intense ions with charge states greater than 2 was performed to a value of 3e4 in 
a higher energy collision dissociation (HCD) cell. Normalized collision energy was 
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set at 42%. Fragments were detected in the Orbitrap with a resolution of 7,500. 
Ions were selected up to 2,000 counts while ion accumulation times reached a 
maximum of 500 ms for full scans and 400 ms for HCD. The dynamic exclusion 
parameters were: width of 5 ppm with 1 repeat lasting 8 seconds for a duration of 
60 seconds. [Experiment was performed by John Sinclair, Jorgensen’s lab, ICR] 
2.4.8 DATA ANALYSIS 
Peptide identification was performed using raw data obtained in Xcalibur 
software (Thermo) through processing in Proteome Discover v1.3 software 
(Thermo Scientific) with Mascot v2.2 search engine (Matrix Science) and Ensembl 
dog database. The following Mascot search parameters were used: precursor mass 
tolerance – 10 ppm; fragment mass tolerance – 0.6 Da; trypsin missed cleavage – 2; 
static modifications: carbamidomethylation (C); variable modifications: oxidation 
(M), deamidated (NQ), phosphophorylation (STY), arginine 13C6 (R6), arginine 
13C615N4 (R10), lysine 2HD4 (K4), and lysine 13C615N4 (K8). Filters applied to obtained 
peptide sequence matches (PSMs) were: a mascot significance threshold of at least 
0.05, peptide score of at least 20, peptide maximum rank of 1 and pRS 
phosphorylation site probabilities ≥ 85 % (PhosphoRS1.0). The false discovery rate 
(FDR) was set to a q-value ≤ 0.01 (Percolator) for peptides. 
Identified peptides with a ‘heavy’ to ‘medium’ ratio higher than 2 or lower than 
0.5 in any of the three performed experiments were chosen for preliminary search 
and the ratios were compared between experiments. For some peptides, the ratio 
was not quantified due to the stringent parameters of the search. In that case, 
spectra were analysed manually and the ratios assessed from the raw data. 
Phosphorylated peptides for which a ‘heavy’ to ‘medium’ ratio was reproduced in 
two biological repeats were chosen for further analysis. 
The identity of chosen peptides was confirmed by comparing them against the 
dog protein database with Basic Local Alignment Search Tool (BLAST, NCBI). 
Identified phosphorylation sites were aligned to sites in human, mouse and rat 
proteins. Current knowledge concerning characterisation of these sites 
(regulators, function) was obtained from the PhosphoSitePlus website. Other 
types of analysis were performed using databases such as STRING, SMART, Pfam, 
etc. 
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CHAPTER 3: HSP90 
3.1 INTRODUCTION 
 
 Apical extrusion of RasV12-transformed epithelial cells has been discovered 
and briefly characterised in the Fujita laboratory (the findings are summarised in 
section 1.5.4). Although some of the pathways downstream of Ras activation as 
well as a few proteins regulating cytoskeletal rearrangements have been both 
implicated or excluded from the process, answers to many questions remain 
unknown. Up to date, we cannot explain how normal and transformed cells 
recognise each other, what receptors mediate recognition, what signalling 
pathways are activated before and during extrusion, what is the mechanism and 
nature of this process and finally, what is the significance and fate of extruded 
transformed cells in an organism.  
Faced with so many questions, Dr Fujita resorted to unbiased biochemical 
screens, which would allow him to identify molecules regulated in normal or 
transformed cells only when they were interacting with each other. In the course 
of my PhD studies, I have contributed to several types of experiments that were 
performed in line with this train of thought. One of the screens, however, was 
undertaken before I joined the laboratory, and I was later asked to characterise 
the results. This experiment was a 2D gel screen, in which all the proteins isolated 
from MDCK and RasV12 cells plated alone were compared to all the proteins 
isolated from mixed cultures of these two cell types. Total cell lysates obtained 
after growing cells in these three conditions for 16 hours from inducing GFP-
RasV12 expression were firstly separated in non-denaturing conditions in which 
most of the proteins remain in the complexes that they form in vivo. A second 
round of separation was performed in denaturing conditions using standard 
SDS-PAGE in which proteins are separated according to their size. The final gels 
were subsequently stained with a SYPRO Ruby dye, and visualised patterns were 
analysed. Comparison of the dots in different conditions revealed that one of 
them was found repeatedly enhanced only in mixed cultures of MDCK and RasV12 
cells (Figure 5A). The protein was identified by mass spectrometry (MS) as heat 
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shock protein 90 beta (Hsp90β), and subsequently validated by immunoblotting 
(Figure 5B). 
 
Figure 5. Hsp90β  forms a different type of complex in mixed cultures compared to 
MDCK and RasV12 cells alone. (A) Total cell lysates from MDCK cells alone, RasV12 
cells alone and mixed cultures were separated on 2D gels according to the size of 
the complexes formed in the cells (native PAGE) and according to the size of 
denatured proteins (SDS PAGE). (B) Total cell lysates were separated on 2D gels 
and analysed by immunoblotting using anti-Hsp90β antibody. 
 
 
 Hsp90 is an evolutionarily conserved molecular chaperone, a protein that 
assists in folding as well as stabilization of other proteins, collectively known as 
its ‘clients’. According to the definition, a client is a molecule that without the help 
of a chaperone is degraded; in case of Hsp90, its clientele is estimated to 
encompass as much as 10% of the yeast proteome (Zhao and Houry, 2005). To 
facilitate this colossal task Hsp90 is very abundant in the cytosol, constituting 
about 1% of total protein mass in mammalian cells (Lai et al., 1984). Although 
the name of this protein suggests that it is expressed upon heat shock, this 
chaperone is in fact quite poorly induced above already high basal levels. Out of 
the two known vertebrate cytosolic isoforms, alpha and beta, only the former is 
 65 
upregulated in heat-inflicted stress conditions, while the latter is generally 
believed to be constitutively expressed, and just occasionally induced by growth 
factors (Meng et al., 1993; Zhang et al., 1999). Despite these differences, a lot of 
cellular roles are common for both Hsp90 isoforms (Millson et al., 2007). Among a 
few known exceptions are regulation of B-cell lymphoma 2 (Bcl-2) dependent 
stabilization of hypoxia-inducible factor 1 (HIF-1α), which is performed exclusively 
by Hsp90β (Trisciuoglio et al., 2010), or secretion of α, but not β, isoform to the cell 
surface as well as cell culture medium to facilitate maturation of matrix 
metalloproteinase 2 (MMP2) (Sims et al., 2011). 
 In vivo Hsp90 most commonly forms flexible homodimers, although the β 
isoform can also be found in monomers (Minami et al., 1991). Each unit within a 
dimer contains their own N-terminal ATP-binding domain, middle domain where 
co-chaperones and client proteins bind, as well as a C-terminal dimerisation 
domain (this part also contains a MEEVD motif which anchors co-chaperones with 
tetratricopeptide repeat, TRP) (reviewed in (Li et al., 2012)).  
To perform its chaperoning function, Hsp90 requires ATP. Interestingly, the 
ATP-binding pocket in this chaperone adopts a unique Bergerat fold geometry 
with a deep cavity characteristic only to few ATPases (e.g gyrase, histidine kinase). 
This unusual conformation explains high specificity of Hsp90 inhibitors 
interfering with the ATP-binding site (Bergerat et al., 1997; Travers et al., 2012). The 
nucleotide-binding domain preferentially binds ATP having over 100 times higher 
affinity to triphosphates comparing to diphosphates (Grenert et al., 1997). Upon 
binding of ATP, a “lid” closes over the molecule promoting N-terminal 
dimerisation of Hsp90, enforcing a conformational change from a V-shaped 
“open” state to a “closed” form. This in turn stimulates ATPase activity leading to 
ATP hydrolysis, opening of the lid, releasing ADP and returning to the initial V-
shaped state (reviewed in (Prodromou, 2012)). 
The ATPase cycle is coupled with sequential association and dissociation of 
different co-chaperones required for the Hsp90 function (reviewed in (Li et al., 
2012)). Over 20 of these regulatory proteins have been found to affect Hsp90 
function or deliver the clients. A prominent group mentioned earlier are TRP co-
chaperones binding the C-terminal domain of Hsp90. Among them are Hop and 
CHIP binding Hsp90 in a mutually exclusive manner. These two co-chaperones 
have the ability to direct the function of the complex to either promotion of 
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folding (Hop) or degradation (CHIP) of assisted clients, respectively (Kundrat and 
Regan, 2010). Another worth mentioning co-chaperone is Cdc37, known as a 
chaperone of kinases. It recognises these signalling proteins with its N-terminal 
domain to subsequently bind Hsp90 and deliver the clients to the machinery 
(reviewed in (MacLean and Picard, 2003)). 
Additionally Hsp90 activity is known to be regulated through not yet very 
well characterised posttranslational modifications, e.g. phosphorylation (Duval et 
al., 2007), acetylation (Kovacs et al., 2005) or S-nitrosylation (Retzlaff et al., 2009). 
Unknown up to date remains where exactly client proteins fit in the 
ATPase/co-chaperone cycle or even how most of them are recognized by the 
machinery. 
Since many of the over 200 confirmed client proteins assisted by Hsp90 
(current list can be found on http://www.picard.ch) are signalling molecules often 
required for cell proliferation and survival, the function of this chaperone is 
particularly crucial for cancer cells. Among the known Hsp90 clients implicated in 
carcinogenesis are ERBB2, C-RAF, CDK4, AKT/PKB, steroid hormone receptors, 
mutant p53, HIF-1α, survivin and telomerase. Hsp90, in particular isoform α, has 
been found upregulated in cancer cells (Kubota et al., 2010; Neckers, 2002) and, 
not surprisingly, inhibition of its function was shown to be especially toxic 
towards transformed cells (Price et al., 1977; Sasaki et al., 1979).  
Anti-tumour activity of geldanamycin (GA), a naturally occurring 
compound isolated in 1970s from a soil bacterium Streptomyces hygroscopicus 
(DeBoer et al., 1970), has been the first to be linked with inhibition of Hsp90 
(Whitesell et al., 1994). Multiple studies followed this discovery, leading to 
identification as well as synthesis of new Hsp90 inhibitors, over 20 of which 
entered clinical trials during the past two decades. Unfortunately, none of them 
has been approved for clinical use due to their toxicity, side effects, or insufficient 
data supporting their anti-tumour activity. Nonetheless, gaining insight into 
intrinsic properties of Hsp90 allows researchers to design ever better inhibitors 
giving hope for a forthcoming treatment (reviewed in (Neckers and Workman, 
2012)). 
Several reasons are often mentioned to explain unusual sensitivity of 
cancer cells to Hsp90 inhibition. According to some, but not all, biochemical 
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studies, Hsp90 present in transformed cells has higher affinity towards both ATP 
and ATP-mimicking inhibitors like GA (Kamal et al., 2003). Moreover, Hsp90 in 
these cells forms much bigger, more active ‘superchaperone’ complexes (Kamal et 
al., 2003) coordinating cancer-specific networks (Moulick et al., 2011). Another 
explanation for the essential role of Hsp90 in cancer can be inferred from the 
inherent characteristics of tumour cells themselves. By escaping the control of 
growth factors and cell cycle they become prone to different types of cellular 
stress: insufficient nutrients, proteotoxicity, hypoxia, genetic instability, or attacks 
from the immune system (reviewed in (Neckers and Workman, 2012)). According to 
the latter hypothesis, in transformed cells Hsp90 acts as a buffer helping to 
overcome cellular stress. Interestingly, a buffering role has also been suggested 
for Hsp90 in evolution, where is it believed to decrease a negative impact of 
mutations leading to higher variation between genotypes (Jarosz and Lindquist, 
2010). 
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3.2 RESULTS 
3.2.1 HSP90 IS INCREASED IN RAS CELLS WHEN THEY ARE SURROUNDED BY NORMAL 
CELLS  
 
 Due to the important role of Hsp90 in stress management, particularly in 
cancer cells, we decided to investigate the role of this protein in interactions 
between normal and transformed cells. From the data obtained in the 2D gel 
screen, we concluded that Hsp90 in mixed cultures either forms a different type of 
complex or undergoes altered posttranslational modifications comparing to 
RasV12 or MDCK cells alone. As a consequence of the nature of the screen, it could 
not be determined in which cell type from the mixed cultures Hsp90 was altered. 
Moreover, at this point it was not clear whether a biochemical screen in which 
transformed and normal cells were mixed in a ratio 1 to 1 could be utilised to 
gain insight into a situation studied up to date, where fewer transformed cells 
were plated within a monolayer of normal cells. 
Since imitating early stages of cancerogenesis was the original purpose of 
the study, RasV12 cells were now plated together with normal cells in a ratio 1 to 
100 on collagen type I matrix, as well as alone. In order to assess differences in 
Hsp90 amount and localization between mixed and single cell type cultures, 
immunostaining with an anti-Hsp90β antibody was performed at two different 
time points from inducing GFP-RasV12 expression. In experiments performed after 
7 hours from addition of tetracycline to the culture medium, a significant increase 
in Hsp90β staining was observed in RasV12 cells surrounded by normal cells, but 
not in RasV12 cells alone (Figure 6B, D). Hsp90β localized in these cells to their 
apical, enlarged during extrusion, part. A similar increase was also detected after 
24 hours from addition of tetracycline to the medium (Figure 6E), in RasV12 cells 
that had already undergone extrusion, suggesting that high levels of Hsp90β 
were maintained throughout the process. 
 As Hsp90 in vertebrates exists in two distinct cytosolic isoforms, α and β, of 
which function is often redundant towards client proteins, mixed and singe cell 
type cultures were immunostained with an anti-Hsp90α antibody. A comparable 
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enhancement in the staining intensity in RasV12 cells surrounded by normal cells 
was recorded (Figure 6A, C). 
Figure 6. Hsp90β  and Hsp90α  are both increased in RasV12 cells surrounded by 
normal cells, but not in RasV12 cells alone. (A, B) Confocal images of xz sections of 
RasV12 cells surrounded by normal cells and RasV12 cells alone on collagen. Cells 
were fixed after 7 hours of incubation with tetracycline (2 µg ml-1) and stained 
with anti-Hsp90α (A) and anti-Hsp90β (B) antibodies (red). (C, D, E) Quantification 
of accumulation of Hsp90α (C) and Hsp90β after 7 hours (D) and 24 hours (E) of 
incubation with tetracycline, in the cytoplasm of RasV12 cells surrounded by 
normal cells and RasV12 cells alone. In each experiment, approximately 24 (C), 15 
(D), 9 (E) RasV12-expressing cells were counted per condition. Data are mean of the 
means of four independent experiments ± s.d.;  *P < 0.05, ***P < 0.0001 (data in 
graph (E) represents two independent experiments). 
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 In order to assess whether upregulation of Hsp90 was a common 
phenomenon in transformed cells surrounded by normal cells, another system 
studied in the Fujita laboratory was examined by immunostaining with the anti-
Hsp90β antibody. Stable cell lines carrying a tetracycline-inducible construct with 
GFP-v-Src, analogous to RasV12 cells, created by Mihoko Kajita, were mixed with 
normal MDCK cells on collagen. GFP-v-Src expression was induced for 8 hours 
and immunostaining was performed. In contrast to RasV12 cells, in v-Src cells 
surrounded by normal cells reproducible enhancement of Hsp90β staining was 
not observed (Figure 7). 
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Figure 7. Hsp90β  is not reproducibly increased in v-Src cells surrounded by 
normal cells. Confocal images of xz sections of v-Src cells surrounded by normal 
cells and v-Src cells alone on collagen. Cells were fixed after 8 hours of incubation 
with tetracycline (2 µg ml-1) and stained with anti-Hsp90β antibody (red). 
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3.2.2 HSP90 INHIBITOR 17-AAG BLOCKS EXTRUSION 
 
 Knowing that both isoforms of cytosolic Hsp90 are upregulated in RasV12 
cells upon their interaction with normal cells prior to their extrusion, we took 
advantage of a variety of commercially available inhibitors of this chaperone to 
uncover its role in extrusion. 
 After a naturally existing Hsp90 inhibitor geldanamycin was found 
particularly toxic in cancer treatment, various modifications of this compound 
were synthesised in order to avoid this unwanted side effect. One of the 
derivatives was 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), a more 
successful, less toxic inhibitor which similarly to the original geldanamycin 
replaces ATP in the nucleotide binding pocket, interfering with the ATPase activity 
necessary for the function of this chaperone (Schulte and Neckers, 1998). 
 Firstly, to confirm that 17-AAG was active in MDCK cells, a hepatocyte 
growth factor (HGF) assay was performed. The idea behind the assay is an 
observation that treatment with geldanamycin as well as its derivatives prevent 
sparsely plated MDCK cells from scattering in response to HGF (Shen et al., 2005). 
Although the HGF response is mediated by the Met receptor, a client of Hsp90, it 
is not clear whether inhibition of this chaperone is responsible for the anti-
scattering effect. Upon addition of HGF alone to the cell culture medium, MDCK 
underwent visible epithelial to mesenchymal transition within 24 hours, however, 
treatment with as little as 50 nM 17-AAG, not only prevented them from 
scattering, but also visibly repressed their proliferation (Figure 8A). The decreased 
cell numbers can be explained by inhibition of Hsp90, a chaperone of many 
proteins involved in the cell cycle (eg. CDK1, CDK2, cyclin B etc.). Inhibition of 
Hsp90 chaperoning activity upon treatment with 17-AAG, was further confirmed 
by immunoblotting of total cell lysates of MDCK cells cultured in the presence of 
this inhibitor with an anti-ErbB2 antibody (Figure 8B). As 100 nM concentration of 
17-AAG was the most efficient in inducing degradation of ErbB2, an established 
client of Hsp90, it was chosen for further analysis. 
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Figure 8. Hsp90 inhibitor 17-AAG inhibits Hsp90 activity in MDCK cells. (A) Phase 
contrast images of MDCK cells cultured for 24 hours at low density with or 
without HGF (100 nM) and with Hsp90 inhibitor 17-AAG (50, 75, 100 nM). (B) Total 
cell lysates of MDCK cells cultured with an Hsp90 inhibitor and analysed by 
immunoblotting using anti-ErbB2 antibody. 
 
 
 Secondly, to assess the effect of Hsp90 inhibition on extrusion, RasV12 cells 
were mixed with normal cells in a ratio 1 to 100. After allowing them to form a 
monolayer for around 6 hours, cells were treated with tetracycline together with 
100 nM 17-AAG. Following a 24-hour treatment, cells were fixed and examined by 
immunofluorescence (Figure 9A). The effect observed after inhibition of Hsp90 
with 17-AAG was striking: extrusion of RasV12 cells from normal monolayers was 
nearly completely blocked by the treatment (Figure 9B). No signs of toxicity were 
detected for either of the cell types at that time point. 
 74 
Figure 9. Hsp90 inhibitor 17-AAG blocks extrusion of RasV12 cells from a 
monolayer of normal cells. (A) Confocal images of xz and xy sections of RasV12 cells 
surrounded by normal cells on collagen. Cells were fixed after a 24-hour 
incubation with tetracycline (2 µg ml-1) and the Hsp90 inhibitor 17-AAG (100 nM), 
and stained with phalloidin-647 (grey). (B) Quantification of frequency of apical 
extrusion and formation of basal protrusions of RasV12 cells in a monolayer of 
MDCK cells in the presence of Hsp90 inhibitor 17-AAG. In each experiment, 
approximately 13 groups of RasV12 cells were counted per condition. Data are 
mean ± s.d. of four independent experiments; **P < 0.005. 
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3.2.3 PHOSPHORYLATION OF ERK IS COMPROMISED BY HSP90 INHIBITOR 17-AAG 
 
 Apart from blocking extrusion, treatment with 17-AAG visibly affected the 
phenotype of transformed cells. Although RasV12 cells continued to increase their 
cell height comparing to their normal neighbours as reported by Hogan and 
colleagues (Hogan et al., 2009), they resembled normal cells to a much greater 
extent than RasV12 cells treated just with DMSO. Accumulation of both actin and E-
cadherin was visibly reduced on the junctions between RasV12 cells in a monolayer 
of normal cells (Figure 10A, B). In fact, a decrease in the intensity of junctional 
actin and E-cadherin staining, as well as in the signal from junctional GFP-RasV12 
itself, was also noticeable in RasV12 cells alone (Figure 10A, B), suggesting that 
under these conditions transformation itself might have been impaired. 
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Figure 10. Accumulation of junctional actin and E-cadherin in RasV12 cells is affected 
by treatment with Hsp90 inhibitor 17-AAG. (A, B) Confocal images of xy sections 
of RasV12 cells surrounded by normal cells and RasV12 cells alone on collagen. Cells 
were fixed after a 24-hour incubation with tetracycline (2 µg ml-1) and the Hsp90 
inhibitor 17-AAG (100 nM), and stained with either phalloidin-647 (A) or anti-E-
cadherin antibody (B) (purple). 
 
 
 Indeed, it has been reported previously that knock-down of Hsp90α 
compromised MAPK signalling (Bandyopadhyay et al., 2010). Given that MAPK 
activation downstream of RasV12 is required for extrusion to occur (Hogan et al., 
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2009), we decided to check whether levels of phosphorylated ERK were changed 
by addition of 17-AAG to the culture media of either MDCK or RasV12 cells.  
Firstly, characterisation of ERK activation upon tetracycline addition in 
RasV12 cells was performed. GFP cells, a stable cell line transfected with an original 
construct into which RasV12 encoding fragment was subsequently inserted, was 
used as a control. To cells plated at three different densities, tetracycline was 
added. Cells were lysed at three different time points from inducing GFP-RasV12 
expression, and lysates were analysed by immunoblotting with anti-phospho-
ERK, and anti-ERK antibodies. Activation of ERK was only noted at 7 hours from 
adding tetracycline (Figure 11 A), but not at any of the later time points (Figure 11 
B, C), suggesting that MAPK signalling downstream of RasV12 is only activated 
transiently in these cells (Figure 11 D). Additionally, higher activation of ERK was 
observed in cells plated in less confluent conditions. 
 
Figure 11. Upon induction of RasV12 expression ERK is activated transiently. (A, B, C) 
Total cell lysates of pTR-GFP cells and pTR-GFP-RasV12 cells analysed by Western 
blotting using anti-pERK, anti-ERK and anti-GAPDH antibody. Cells were grown in 
6-well plates at three different cell densities: 0.5 x 106 (an equivalent of ± 50% 
confluent cells), 0.75 x 106 (± 75% confluent cells), and 1 x 106 (cells forming a 
monolayer). Cells were lysed at different time points from adding tetracycline: 7 
hours (A), 18 hours (B), 24 hours (C). (D) Quantification of the data presented in (A, 
B, C). The ratios of pERK to ERK representing level of ERK activation at different 
time points were plotted. Each value represents pERK to ERK ratio in RasV12 cells 
normalised to pERK to ERK ratio in GFP cells plated at the same density and lysed 
at the same time. 
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 To investigate the impact of 17-AAG on activation of MAPK signalling 
upon RasV12 expression, lysates of both MDCK and RasV12 cells were analysed by 
immunoblotting with anti-phospho-ERK antibody 7 and 24 hours after addition 
of tetracycline to the media. In lysates treated for 7 hours with tetracycline and 
17-AAG of both MDCK as well as RasV12 cells, a remarkable reduction in the signal 
of phosphorylated ERK was recorded (Figure 12A). Consistently with previous 
findings concerning the time line of ERK activation in RasV12 cells, no difference 
was seen in the amount of phosphorylated ERK after 24 hours from addition of 
tetracycline between cells treated or non-treated with 17-AAG (Figure 12B). 
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Figure 12. Hsp90 inhibitor 17-AAG blocks ERK activation in MDCK and RasV12 cells. 
(A, B) Total cell lysates of MDCK cells and pTR-GFP-RasV12 cells treated with Hsp90 
inhibitor 17-AAG analysed by immunoblotting using anti-pERK and anti-GAPDH 
antibodies. Cells were lysed at different time points from adding tetracycline: 7 
hours (A) and 24 hours (B). 
 
 
 Taken together, these data indicate that treatment with 17-AAG affects 
activation of MAPK signalling downstream of RasV12, possibly though inhibiting 
chaperoning function of Hsp90 towards one of the proteins upstream of MAPK 
pathway, e.g. B-Raf. 
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3.2.4 PHOSPHORYLATION OF ERK IS NOT AFFECTED BY HSP90 INHIBITOR CELASTROL 
 
 Inhibition of ERK activation was previously found to prevent extrusion of 
RasV12 cells from a monolayer of normal cells (Hogan et al., 2009). As treatment 
with Hsp90 inhibitor 17-AAG resulted in hindering ERK phosphorylation in RasV12 
cells, we decided to use a compound impairing Hsp90 function via a different 
mechanism. 
Celastrol is a guinone methide triterpene isolated from a Chinese vine 
Tripterygium wilfordii, which has been used for thousands of years to treat fever, 
chills, edema and carbuncle. Only recently, celastrol was linked to inhibition of 
Hsp90 following a gene expression signature-based screen (Hieronymus et al., 
2006). Interestingly, celastrol, unlike most other Hsp90 inhibitors, including 17-
AAG, does not interfere with the ATP-binding site in this chaperone. Despite the 
fact that ATP can still be bound to the Hsp90-celastrol complex, ATPase activity is 
inhibited (Zhang et al., 2009). According to some reports, celastrol binds to C-
terminal domain of Hsp90, disrupting its interaction with a kinase co-chaperone 
Cdc37 (Sreeramulu et al., 2009; Zhang et al., 2008; Zhang et al., 2009). Importantly, 
treatment with celastrol does not preferentially affect kinase clients of Hsp90 
(Zhang et al., 2010) and therefore, according to some studies, the effect of this 
molecule on Hsp90 is in fact less specific (Chadli et al., 2010). 
We decided to test celastrol in extrusion, hoping that due to a different 
mechanism of inhibiting Hsp90, treatment with celastrol would result in altered 
client sensitivity, and possibly allow for ERK activation in our system. 
 Firstly, inhibition of Hsp90 in RasV12 cells was confirmed by 
immunoblotting of total cell lysates treated with celastrol for 18 hours. Both 
tested client proteins, Raf-1 as well as ErbB2 were degraded upon treatment with 
celastrol, but in line with previous findings, their individual sensitivity to the 
inhibitor differed from one client to the other (Figure 13A). In contrast to 
treatment with 17-AAG however, incubation with celastrol did not result in 
reduction of phosphorylated ERK after 7 hours from adding tetracycline (Figure 
13B). Furthermore, treatment with higher concentrations of celastrol had a 
stabilizing effect on phosphorylated ERK at later time points from induction of 
GFP-RasV12 expression (Figure 13C). 
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Figure 13. Hsp90 inhibitor celastrol blocks Hsp90 activity in RasV12 cells, but does 
not inhibit ERK activation. (A, B, C) Total cell lysates of RasV12 cells treated with 
different concentrations of Hsp90 inhibitor celastrol analysed by immunoblotting 
using anti-Raf, anti-ErbB2, anti-Ras, anti-GFP, anti-GAPDH (A), anti-pERK, anti-ERK 
(B, C) antibodies. Cells were lysed at different time points from adding 
tetracycline: 7 hours (B), 18 hours (A, C). 
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3.2.5 HSP90 INHIBITOR CELASTROL ENHANCES EXTRUSION ON COLLAGEN 
 
 Knowing that celastrol does not prevent ERK activation downstream of 
RasV12 expression, we decided to use this inhibitor to study the effect of Hsp90 
inhibition on extrusion.  
RasV12 cells were plated together with MDCK cells in a ratio 1 to 100 on 
collagen type I matrix. After 6 hours, tetracycline together with 1 µM celastol was 
added to the cell culture medium, followed by a 24-hour incubation. Cells were 
subsequently fixed with 4% PFA, and examined by immunoflourescence. 
Treatment with celastrol did not prevent extrusion of RasV12 cells from a 
monolayer of normal cells (Figure 14A). Instead transformed cells were extruded 
around 10% more efficiently at this time point (Figure 14B). 
RasV12 cells treated with celastrol both in mixed and single cell type 
cultures produced GFP positive intracellular vesicles, and generally appeared less 
fit than control cells (Figure 14A). In order to confirm that increase in extrusion of 
these cells did not occur following their cell death upon treatment with celastrol, 
we performed time lapse experiments. RasV12 cells were plated on collagen among 
normal cells in a ratio 1 to 50. After overnight incubation, tetracycline was added 
to the cultures together with 1 µM celastrol. Four hours later groups of RasV12 cells 
no larger than 4 neighbouring transformed cells were randomly chosen and 
followed using time lapse microscopy for further 48 hours. During that time both 
control and celastrol-treated RasV12 cells underwent extrusion from normal 
monolayers in a similar fashion (Figure 15A). In control conditions groups of 
extruded RasV12 cells after 48 hours of imaging formed a compact mass without 
visible in the bright field junctions, while cells incubated with celastrol appeared 
more separated (images 48:00-BF in Figure 15A). Nonetheless, in both conditions 
cells continued to proliferate after extrusion, indicating that even upon treatment 
with this Hsp90 inhibitor, they remained alive. Their viability was further 
confirmed by addition of ethidium homodimer-1 to the culture medium, a cell-
impermeant nucleic acid stain, which was not incorporated into extruded RasV12 
cells up to 48 hours from tetracycline addition (Figure 15B). 
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Figure 14. Hsp90 inhibitor celastrol enhances extrusion of RasV12 cells from a 
monolayer of normal cells. (A) Confocal images of xz and xy sections of RasV12 cells 
surrounded by normal cells and RasV12 cells alone on collagen. Cells were fixed 
after a 24-hour incubation with tetracycline (2 µg ml-1) and the Hsp90 inhibitor 
celastrol (1 µM), and stained with phalloidin-647 (magenta) and Hoechst (grey). (B) 
Quantification of frequency of apical extrusion of RasV12 cells from a monolayer of 
MDCK cells in the presence of Hsp90 inhibitor celastrol. In each experiment, 
approximately 11 groups of RasV12 cells were counted per condition. Data are 
mean ± s.d. of four independent experiments; *P < 0.05. 
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Figure 15. RasV12 cells treated with celastrol for 48 hours on collagen remain alive 
after extrusion. (A, B) RasV12 cells treated with 1 µM celastrol continued to 
proliferate after extrusion from a monolayer of normal cells (A), and did not 
incorporate ethidium dye after 48 hours from tetracycline addition (B). RasV12 cells 
were combined with normal MDCK cells at a ratio of 1 to 50 and cultured on type-
I collagen gels, followed by tetracycline and celastrol treatment. Images were 
extracted from a representative time-lapse analysis as an overlay of bright field 
(BF), green fluorescent channel (GC), and red fluorescent channel (RC), as indicated. 
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3.2.6 DOMINANT NEGATIVE FORM OF HSP90 ENHANCES EXTRUSION ON COLLAGEN 
 
Since treatment with Hsp90 inhibitors used in this study had contradicting 
effects on extrusion of RasV12 cells from normal monolayers, we decided to use a 
different approach to elucidate what role Hsp90 plays in this process.  
A dominant negative form of Hsp90β created by site directed mutagenesis 
within the ATP-binding pocket was previously shown to inhibit VEGF-induced 
phsphorylation of Akt, eNOS and dependent on them NO release in endothelial 
cells (Miao et al., 2008). In order to clarify whether inhibition of Hsp90 indeed 
resulted in higher extrusion rates of RasV12 cells surrounded by normal 
neighbours, we purchased commercially available constructs encoding the 
dominant negative form of this chaperone as well as a wild type form tagged 
with an HA tag in mammalian expression vectors (Addgene). Unfortunately, an 
attempt to create a stable cell line expressing the dominant negative form of 
Hsp90 failed, possibly due to toxicity of long term inhibition of this protein in 
RasV12 cells. As a result, both constructs were instead transiently transfected into 
MDCK cells together with original GFP-RasV12 and GFP constructs in six possible 
combinations (Figure 16B). 24 hours from transfection cells were fixed and 
immunostained with an anti-HA antibody, Hoechst and phalloidin (Figure 16A). 
Cells positive for both GFP signal and anti-HA staining with non-fragmented 
nuclei were chosen for quantification of extrusion. 
While over 15% of cells transfected with a GFP-RasV12 construct alone 
underwent extrusion at this time point, and over 45% had a tall phenotype 
characteristic for cells immediately before extrusion, cotransfection with 
constructs encoding either of the Hsp90 forms, increased these numbers. 30% of 
cells transiently expressing wild type of Hsp90β and over 45% of cells expressing 
the dominant negative form of this chaperone (DNHsp90β) underwent extrusion 
by 24 hours from transfection (Figure 16B). Importantly, cells cotransfected with 
control GFP plasmid and either of Hsp90 constructs, remained within normal 
monolayers. 
In order to exclude higher expression levels of the dominant negative 
form of Hps90β as the cause for higher extrusion rates, we immunoblotted total 
lysates of transfected MDCK cells with anti-Hsp90β, anti-HA, anti-GFP and anti-Ras 
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antibodies. After 24 hours from transfection, detected levels of DNHsp90 form 
were in fact lower than of the wild type form (Figure 16C). In lysates obtained 
from cells cotransfected with GFP-RasV12, the amount of DNHsp90 further deceased 
comparing to cotransfection with GFP-plasmid alone, possibly due to loose 
attachment to the monolayer of some of the extruded groups, which 
subsequently might have been lost before the lysis. ERK activation was not 
affected in RasV12 cells expressing DNHsp90 comparing to RasV12 cells expressing 
Hsp90β (Figure 16D). 
From the presented above data we concluded that inhibition of Hsp90 
leads to higher extrusion rates of transformed cells from normal monolayers, a 
result confirmed with Hsp90 inhibitor celastrol as well as DNHps90β. 
 
Figure 16. MDCK cells transiently transfected with RasV12 and a dominant negative 
form of Hsp90β  are more efficiently extruded from a monolayer of normal cells 
than MDCK cells co-transfected with RasV12 and wild-type Hsp90β . (A) Confocal 
images of xz sections of MDCK cells transiently transfected with constructs 
driving expression of GFP, GFP-RasV12, Hsp90β-HA, DNHsp90β-HA in indicated 
combinations, plated on collagen. Cells were fixed after 24 hours since 
transfection, and stained with anti-HA antibody (red), phalloidin-647 (magenta) 
and Hoechst (grey). (B) Quantification of frequency of apical extrusion of cells co-
transfected with GFP or RasV12 with either wild-type Hsp90β or DNHsp90β  from a 
normal monolayer. In each experiment, approximately 20 cells were counted per 
condition. Data are mean ± s.d. of five independent experiments; *P < 0.05, **P < 
0.005, ***P < 0.0001. (C) Total cell lysates of MDCK cells co-transfected 24 hours (C) 
earlier with GFP or RasV12 with either wild-type Hsp90β or DNHsp90β analysed by 
immunoblotting using anti-Hsp90β, anti-HA, anti-Ras, anti-GFP and anti-GAPDH 
antibodies. (D) Confocal images of xy sections of RasV12 cells transiently 
transfected with constructs driving expression of Hsp90β-HA, DNHsp90β-HA and 
subsequently plated with MDCK cells in a 1 to 1 ratio on collagen. Cells were fixed 
after 32 hours from transfection with an 8-hour incubation with tetracycline (2 µg 
ml-1), and stained with anti-pERK (red) and anti-HA-tag antibodies (magenta). 
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3.9 DISCUSSION 
 
 In this study, I benefited from a 2D gel screen previously done in the Fujita 
laboratory, in which Hsp90 was identified as a protein altered in mixed cultures of 
normal and transformed cells, compared to these two cell types grown separately. 
Using Hsp90 antibodies and a system imitating early stages of cancerogenesis 
established by Catherine Hogan (Hogan et al., 2009), I found that both cytosolic 
isoforms of Hsp90, alpha and beta, present in mammalian cells were upregulated 
and localized apically in RasV12 cells surrounded by normal cells early after 
inducing oncogene expression. Conversely, a similar level of upregulation was 
not reproduced in Src cells plated within normal monolayers, indicating that 
Hsp90 overexpression or stabilization is not a common phenomenon in all types 
of extruding transformed cells. Interestingly, although Hsp90α has been 
previously found upregulated in stress as well as in some types of cancers cells, 
Hsp90β is believed to remain at a constant level. According to one study, 
Hsp90β expression might be regulated by PKC epsilon (Wu et al., 2003); however, 
none of the available PKC inhibitors affected Hsp90 upregulation in our system 
(data not shown). 
 To study the role of Hsp90 in extrusion, we took advantage of two 
commercially available inhibitors, each hindering the chaperoning activity of this 
protein via a different mechanism. 17-AAG, a derivative of the better known 
geldanamycin, nearly completely blocked extrusion, possibly due to inhibition of 
ERK activation detected at 8 hours from adding tetracycline. Treatment with MAPK 
inhibitors was previously shown to prevent extrusion (Hogan et al., 2009); hence, 
it is likely that by affecting this pathway, 17-AAG interfered with Ras-dependent 
transformation itself. This hypothesis is further supported by the results of 
treatment with the second Hsp90 inhibitor, celastrol. Upon addition of this 
compound to mixed cultures of RasV12 and MDCK cells, both extrusion and ERK 
activation not only still occurred, but were enhanced. In the case of ERK, its 
phosphorylated form was stabilised. It remains unclear why treatment with two 
inhibitors of the same protein, resulted in opposite effects on MAPK activation. 
One possible explanation is that by acting on Hsp90 via different mechanisms, 
these inhibitors target slightly different pools of client proteins. Variable 
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sensitivity of client proteins to inhibition of Hsp90 has been reported before, 
although a theory behind this phenomenon is yet to be proposed. If Raf proteins 
stabilised by interaction with Hsp90 were more sensitive to inhibition with 17-
AAG, ERK activation could be affected by treatment with this compound. Celastrol, 
on the other hand, as a less specific inhibitor targeting a few other cellular 
pathways, could promote ERK activation via a Hsp90-independent mechanism. 
 To resolve the riddle of what role Hsp90 plays in extrusion, we decided to 
use a different approach. A dominant negative form of this chaperone 
cotransfected with RasV12 into MDCK cells, enhanced their extrusion from normal 
monolayers comparing to either RasV12 transfected alone or together with a wild 
type form of Hsp90β. Importantly, the latter also resulted in higher extrusion rates 
comparing to cells expressing only RasV12. This finding opens a possibility that 
increased extrusion could be an effect of lower fitness of doubly transfected cells, 
further amplified by partial inhibition of an important cellular chaperone. 
 Since Hsp90 was identified as a protein forming an altered molecular 
complex or differentially modified in mixed cultures of RasV12 and MDCK cells, one 
of the aims of my project was clarifying what the change was. The first attempt to 
immunoprecipitate interactors of Hsp90 from single cell type and mixed cultures 
of normal and transformed cells, failed. Neither of three commercially available 
antibodies, some of which were previously used for immunoprecipitation of this 
protein in mammalian cells, efficiently bound the endogenous form of this 
chaperone in our system. The reason for our failure could have been a large size 
of the Hsp90 complex, and multiple binding partners possibly preventing the 
antibodies from accessing particular epitopes within this molecule. In a second 
attempt, a stable cell line of RasV12 cells expressing wild type form of Hsp90β with 
an HA tag was established. These cells were subsequently mixed with normal cells 
and an efficient anti-HA antibody was used to immunoprecipitate their Hsp90 
complexes. RasV12 cells stably expressing Hsp90β mixed with RasV12 cells were used 
as a control. Unfortunately, despite identification of a few proteins that were 
immunoprecipitated to a greater extend with Hsp90β-HA from RasV12 cells in 
mixed cultures with normal cells, neither result was validated using specific 
antibodies. 
The combined results from the study with the dominant negative Hsp90 
and the lack of success in immunoprecipitation of different interactors of Hsp90 
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in mixed cultures point towards a more general role of this chaperone in 
maintaining fitness of tumour cells in their battle against normal epithelium. In 
this scenario, Hsp90 could be overexpressed as an element of a non-specific stress 
response in about-to-be-extruded RasV12 cells, possibly playing a similar 
protective part to another chaperone, Sparc, known from cell competition in 
Drosophila, but also found upregulated in some cancer cells (section 1.3.5). 
Although attractive, this theory does not account for the results of the 2D gel 
screen and further studies are required to elucidate what changes occur in 
Hsp90β from RasV12 cells grown in the presence of normal cells. 
 In the view of Hsp90 as a target for cancer treatment, it is important to 
address the question of the fate of RasV12 cells after extrusion upon exposure to 
the inhibitors of this chaperone. Although RasV12 cells treated with celastrol died 
in both mixed and single cell type cultures on glass (data not shown), neither of 
the two compounds we used for Hsp90 inhibition resulted in apoptosis or even 
cytostasis of RasV12 cells on collagen type I matrix up to 48 hours from inducing 
oncogene expression. These findings highlight the importance of further studies 
on the effect of Hsp90 inhibition in living organisms. It is possible that higher 
concentrations of celastrol should be used on collagen or in vivo to kill cancer 
cells; however, the anti-tumour effect of Hsp90 could well be more complex than 
our current understanding of this problem. Perhaps inhibition of Hsp90 leaves 
cancer cells more prone not only to attacks of the immune system (Annamalai et 
al., 2009), but also to recognition by the epithelium itself. Whether extrusion is a 
part of this epithelial immune response and if it, at least partially, underlies the 
sensitivity of tumours to Hsp90 inhibition in vivo, remains to be elucidated. 
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CHAPTER 4: SCREEN FOR TYROSINE-PHOSPHORYLATED 
PROTEINS 
4.1 INTRODUCTION 
 
 During my PhD I performed a number of biochemical screens in order to 
identify molecules selectively regulated by interactions between normal and 
transformed cells. Many signalling pathways controlling cellular behaviour (e.g. 
changes of cell shape, migration, response to growth factors, etc.) are activated via 
alterations in phosphorylation status of participating proteins. Therefore I 
decided to focus on identification of differences in the level of phosphoryalation 
of isolated proteins. In a first attempt, I concentrated on tyrosine 
phosphorylation, as proteins carrying this modification can specifically and easily 
be isolated and analysed. 
 
4.2 RESULTS 
 
Firstly, MDCK and RasV12 cells were plated separately or in a coculture with 
a mixing ratio of 1 to 1 (Figure 17). After an incubation of 6 to 8 hours allowing 
the cells to attach and form a monolayer, tetracycline (2 µg ml-1) was added to the 
medium. Following an overnight incubation, cells were lysed and phosphorylated 
proteins were immunoprecipitated using a mixture of two different antibodies 
against phosphorylated tyrosine residues conjugated to either agarose or 
sepharose beads. Immunoprecipitated fractions were subsequently separated by 
SDS-polyacrylamide gel electrophoresis and bands were visualized by staining 
with SYPRO Ruby dye. 
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Figure 17. Schematic representation of an immunoprecipitation experiment of 
tyrosine-phosphorylated proteins. Phosphorylated proteins were isolated using a 
cocktail of anti-phospho-tyrosine antibodies from lysates of homotypic cultures 
of RasV12 and MDCK cells as well as both of these cell types mixed in a 1 to 1 ratio. 
Immunoprecipitated fractions were then separated using SDS-polyacrylamide 
gels followed by protein staining and analysis. 
 
 
Banding patterns from several independent experiments were examined. 
Bands that were visibly enhanced in immunoprecipitated fractions from mixed 
cultures comparing to fractions from MDCK and RasV12 cells alone, were chosen 
for further analysis. Bands of two proteins that were found to be reproducibly 
enriched in at least three independent experiments were cut out from the gels 
and identified by mass spectrometry (Figure 18). 
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Figure 18. Immunoprecipitation of tyrosine-phosphorylated proteins using anti-
phospho-tyrosine antibodies from single cell type cultures of RasV12 and MDCK 
cells and both cell types mixed in a 1 to 1 ratio. (A, B, C) Comparison of 
immunoprecipitated fractions from normal MDCK cells alone (MM), RasV12 cells 
alone (RR) and a mixed in a 1 to 1 ratio population (RM). Fractions were separated 
on SDS-polyacrylamide gels and stained with SYPRO Ruby dye. Data from three 
independent experiments are shown (A, B, C). In red – proteins enriched in mixed 
population and isolated for mass spectrometry anaysis. (a, b, c) Enlargement of 
boxed areas in (A, B, C). 
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 The higher molecular weight band (considerably higher than 220 kDa) was 
identified as plectin (actual size: 500 kDa), whereas the smaller one (± 130 kDa), as 
myosin IE (actual size: 127 kDa). 
In order to validate the results of the screen we have purchased several 
commercially available antibodies as well as two custom antibodies against 
plectin, neither of which recognised this protein in lysates of MDCK cells by 
immunoblotting. Eventually, we confirmed the result of our screen using an anti-
plectin antibody from Santa Cruz Biotechnology (Figure 19). Although the last 
antibody recognised canine plectin in immunoblotting, there was still quite a lot 
of non-specific background staining present. This antibody was also suitable for 
immunofluorescence after methanol fixation; however, initially promising results 
suggesting that plectin localized in a perinuclear region in RasV12 cells just before 
their extrusion were unfortunately difficult to reproduce. 
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Figure 19. Plectin is enriched in fraction immunoprecipitated on anti-phospho-
tyrosine beads from mixed cultures of normal and transformed cells. 
Immunoprecipitated fractions from experiment (B) in figure 18 were separated on 
SDS-polyacrylamide gels and analysed by immunoblotting using anti-plectin 
antibody. 
 
  
The other molecule identified in the screen, myosin IE, had not been 
extensively studied before, hence not much was known about its function and 
very few antibodies against this protein were commercially available. The 
antibody we bought was unfortunately not specific in immunoblotting. 
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4.4 DISCUSSION 
 
As a result of the screen two proteins were identified, both preferentially 
phosphorylated (or interacting with preferentially phosphorylated proteins) upon 
interaction of normal and transformed cells. One of them, plectin, is a widely 
expressed, large protein scaffold mediating interactions of major cytoskeletal 
components: microfilaments, microtubules and intermediate filaments (reviewed 
in (Allen and Shah, 1999)). Particularly important for organisation of intermediate 
filaments, pectin anchors them to junctional complexes, the nuclear envelope and 
cytoplasmic organelles (reviewed in (Wiche and Winter, 2011)). Lately plectin was 
implicated in proliferation and migration of cancer cells (McInroy and Maatta, 
2011); consequently, high levels of this protein were found to correlate with poor 
prognosis for patients with head and neck squamous carcinoma (Katada et al., 
2012).  
Interestingly, plectin was found enriched in the phosphorylated fraction in 
a corresponding screen performed in the Src system, as well as later on in the 
Scribble system (unpublished data from the Fujita laboratory), pointing towards a 
more universal role of this protein in interactions of normal and transformed 
cells. Although plectin was a potentially interesting target to study, due to 
problems with validation and immunostaining, we decided not to continue 
research on this protein during my PhD. 
The other proteins identified in the screen, myosin IE, is a single-headed 
fast motor protein, participating in the phagocytic uptake of solid particles and 
cells in Dictyostelium discoideum (Durrwang et al., 2006). Since nearly all studies on 
myosin IE up to date were performed in this organism, we lacked resources to 
validate the result of the screen or to examine the role of this protein in 
extrusion. 
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CHAPTER 5: SILAC SCREEN 
5.1 INTRODUCTION 
 
 In all proteomic screens described so far, aiming to identify changes in 
RasV12 and normal MDCK cells upon their interaction, we were unable to 
distinguish between proteins isolated from these two cell types in lysates or 
immunoprecipitated fractions of the mixed cultures. Moreover, an important issue 
was the inability to quantitatively assess the identified changes. Additionally, in 
visual comparisons of banding patterns in SYPRO Ruby stained gels, proteins 
modified or upregulated in one cell type, while downregulated in the other, could 
have been easily missed.  
In order to avoid the problems listed above, we established a collaboration 
with Dr Claus Jørgensen’s laboratory at the Institute of Cancer Research to use a 
phosphoproteomic approach developed by Dr Jørgensen (Jorgensen et al., 2009). 
This strategy was based on a cell type-specific labelling technique with stable 
isotopomeric versions of amino acids (SILAC), combined with mass spectrometric 
identification and relative quantification of phosphorylated peptides. Once again 
we chose to analyse signalling pathways employing phosphorylation to transmit 
information and evoke cellular responses. This time, however, we decided to 
focus on changes in RasV12 cells that occur only upon their interaction with 
normal cells. Moreover, we expanded our search of modifications to three most 
common types of naturally occurring eukaryotic phosphorylations: serine, 
threonine and tyrosine phosphorylation, bearing in mind that the latter, although 
extensively studied, is quite rare compared to the others (from: www.uniprot.org). 
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5.2 SETUP OF THE SCREEN 
 
 In order to differentially label proteins with stable isotopomeric arginine 
and lysine, RasV12 and MDCK cells were grown for five generations in the SILAC 
medium. Three different labels were used: ‘heavy’ and ‘medium’ for RasV12 cells, 
and ‘light’ for normal MDCK cells (details in section 2.4.1). A gradual decline in 
growth and proliferation rates of both cell types was observed along with the 
incorporation of the label, as a consequence of prolonged incubation in media 
supplemented with dialysed FCS. Thus, conditions of labelling required 
optimisation, as cells could not be plated too sparsely, particularly at later stages 
of the labelling process. Incorporation of isotopomeric amino acids into cellular 
proteins was confirmed by mass spectrometry and reached 98% for each type of 
label after five generations of labelling. 
 Taking into account that the planned experiment required incubation of 
differentially labelled MDCK and RasV12 cells in mixed cultures, which can 
eventually lead to an exchange of isotopomeric amino acids, we were compelled 
to shorten the standard seeding protocol. Preliminary tests revealed that MDCK 
cells plated in highly confluent conditions formed a monolayer nearly instantly 
after attaching to the dish. Moreover, when GFP-RasV12 expression was induced 
only 2 hours after plating the cells, 8 hours later RasV12 cells surrounded by normal 
cells became taller than their neighbours and began to accumulate actin on the 
junctions between each other. Importantly, in line with our previous observations, 
Hsp90β was upregulated in these cells and localized to their apical domain (Figure 
20). Eventually RasV12 cells underwent extrusion from normal monolayers 
indicating that this experimental setup could be used to study extrusion. 
 
 102 
Figure 20. Hsp90β  is increased in RasV12 cells surrounded by normal cells, but not 
in RasV12 cells alone 8 hours from addition of tetracycline and 10 hours from 
plating. Confocal images of xz sections of RasV12 cells surrounded by normal cells 
and RasV12 cells alone on collagen. Cells were plated in confluent conditions (2 x 
106 cells / well in a 6-well plate), left for 2 hours to attach, fixed after 8 hours of 
incubation with tetracycline (2 µg ml-1) and stained with anti-Hsp90β antibody 
(red) and phalloidin (purple). 
 
 
 For the main experiment, fully labelled cells were plated confluently in 15-
cm plates in two conditions: ‘heavy’-labelled RasV12 cells mixed with ‘light’-labelled 
MDCK cells (in four plates) and ‘medium’-labelled RasV12 cells alone (in two plates) 
(Figure 21). After seeding, all types of cultures were incubated in ‘light’ medium to 
minimise the effects of the exchange of isotopomeric amino acids on subsequent 
quantification of ‘heavy’- and ‘medium’-labelled peptides (in the experiment we 
focused on changes in RasV12 cells). Two hours after plating, tetracycline was 
added to the culture medium. At this point, highly confluent cells appeared to 
form monolayers and reestablished cell contacts. Following a further 6 hour-
incubation, lysis buffer was added to the plates, cells were collected and 
sonicated. Only the soluble fraction obtained after sonication underwent further 
biochemical analyses. After trypsinisation of isolated proteins, obtained peptides 
were purified. Precipitation of phosphorylated peptides was achieved using an 
immobilized metal ion affinity chromatography (IMAC) approach. Eventually, 
fractionation with hydrophilic interaction liquid chromatography (HILIC) was 
performed, and phosphorylated peptides were identified by mass spectrometry 
and quantified. 
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Figure 21. Schematic representation of the SILAC screen for phosphorylated 
peptides. Proteins in RasV12 and MDCK cells were labelled for 5 generations and 
plated at confluence in two conditions: RasV12 cells alone or in a coculture with 
MDCK cells. After 2 hours, tetracycline (2 µg ml-1) was added. Following a 
subsequent incubation for further 6 hours, cells were lysed, lysates were 
combined, and indicated biochemical steps were performed leading to isolation 
and identification of phosphorylated peptides (for details check section 2.4). 
 
 104 
5.3 RESULTS 
 
 Three successful experiments were performed: the first (referred to as ‘Exp 
1’ in Tables 5, 6, 7; coloured in yellow) was done without the HILIC fractionation 
step; the second (referred to as ‘Exp 2’ in Table 5, 6, 7; coloured in orange) included 
HILIC and was performed on the same biological samples as the first experiment; 
the third (referred to as ‘ Exp3’ in Tables 5, 6, 7; coloured in pink) was performed 
on newly obtained biological samples according to the same protocol as Exp 2. 
For each peptide, a ratio of labels ‘heavy’ to ‘medium’ was calculated (hereafter 
called H/M ratio). In biological terms this ratio reflected a change in 
phosphorylation levels occurring in RasV12 cells upon their interaction with normal 
cells (‘heavy’ label) compared to RasV12 cells grown alone (‘medium’ label). Peptides 
with the H/M ratio higher than 2 or lower than 0.5 in either attempt were 
compared among different experiments. Peptides for which the identified ratio 
was reproduced biologically (in Exp 1 or Exp 2, and in Exp 3) were chosen for 
further analysis. Importantly, in each attempt the H/M ratio for most of the 
peptides identified was close to 1 (Table 5). 
 
Table 5. Combined statistical analysis of three successful SILAC experiments. 
Presented numbers apply to already filtered results (for details check section 2.4.8). 
 Exp 1 Exp 2  Exp 3 Combined 
results 
All identified 
peptides 4,432 12,913 11,570 28,915 
Different 
peptides 1,285 3,087 2,504 4,285 
Peptides with 
H/M score 512 892 677  
Peptides with 
H/M x > 2 20 45 12 
         18  
(17 proteins) 
Peptides with 
H/M 2 > x > 0.5 481 821 631  
Peptides with 
H/M x < 0.5 11 26 34 
         16  
(15 proteins) 
All identified 
proteins 460 882 784 1084 
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Of note, in Exp 3 the identified H/M ratios were shifted towards lower 
values (over twice as many downregulated than upregulated phosphopeptides 
were identified), suggesting that more ‘medium’- than ‘heavy’-labelled RasV12 cells 
were used in this experiment. Therefore, H/M values for upregulated peptides in 
this experiment (Table 6) are generally lower; this was taken into account in the 
analysis of these results. 
Due to stringent parameters applied in the search concerning the quality 
of the analysed spectra, H/M ratios were not quantified for all identified peptides 
by the Proteome Discover v1.3 software (details of the search in section 2.4.8). For 
some of these peptides, it was possible to analyse their spectra manually and 
assess H/M ratios from the raw data (described as not quantified, N/Q, in Tables 6, 
7). A few peptides were not repeatedly identified between experiments (described 
as N/I in Tables 6, 7). 
 Altogether, among 4,285 different phosphorylated peptides identified in 
all three experiments, we found 18 of them reproducibly upregulated (Table 6), 
and 16 of them reproducibly downregulated (Table 7) in RasV12 cells upon their 
interaction with normal cells. A comparison against Ensembl dog database as well 
as further confirmation using Basic Local Alignment Search Tool (BLAST from 
NCBI website) revealed that these peptides were obtained from triptic digestion 
of 17 and 15 different proteins, respectively. In total, 31 proteins of very diverse 
functions, potentially important for interactions between normal and 
transformed cells, were identified in this screen (Tables 8, 9 list the most 
prominent known cellular functions performed by these proteins according to 
combined data from Gene NCBI, UniProt and PhosphoSitePlus databases; Figure 
22 is a graphical representation of these functional data). 
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Table 6. Modified peptides found reproducibly upregulated in RasV12 cells from 
mixed cultures in the SILAC screen. Exp – experiment. Exp 1 and 2 were performed 
on the same biological samples, but with an independent repeat of peptide 
isolation and MS identification. Exp 3 was a full biological repeat. H/M ratio – a 
ratio of a number of ‘heavy’-labelled peptides to a number of ‘medium’-labelled 
peptides identified. N/I – peptide was not identified in this experiment. N/Q – 
peptide was identified, but H/M ratio was not quantified, in brackets values of 
estimated H/M ratio from the raw data. Abbreviations of protein names are in 
agreement with the Gene NCBI database and are explained in table 8. 
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Table 7. Modified peptides found reproducibly downregulated in RasV12 cells from 
mixed cultures in the SILAC screen. Exp – experiment. Exp 1 and 2 were performed 
on the same biological samples, but with an independent repeat of peptide 
isolation and MS identification. Exp 3 is a full biological repeat. H/M ratio – a ratio 
of a number of ‘heavy’ labelled peptides to a number of ‘medium’ labelled 
peptides identified. N/I – peptide was not identified in this experiment. N/Q – 
peptide was identified, but H/M ratio was not quantified, in brackets values of 
estimated H/M ratio from the raw data. Abbreviations of protein names are in 
agreement with the Gene NCBI database and are explained in table 9. 
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Table 8. Well-established functions of proteins found phosphorylated in RasV12 
cells upon interaction with normal cells in the SILAC screen. Full names of proteins 
as well as their functional role in cellular processes based on Gene (NCBI), UniProt 
and PhosphoSitePlus databases. 
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Table 9. Well established functions of proteins found dephosphorylated in RasV12 
cells upon interaction with normal cells in the SILAC screen. Full names of proteins 
as well as their functional role in cellular processes based on Gene (NCBI), UniProt 
and PhosphoSitePlus databases. 
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Figure 22. Known key functions and most common cellular localization of proteins 
identified in the SILAC screen. Pathways and processes that particular proteins 
regulate are specified in colour-coded frames within the figure. Phosphorylation 
status of regulated sites is indicated with a red star, if upregulated, and a blue 
star, if downregulated. PM – plasma membrane, NE – nuclear envelope. 
Abbreviations of proteins are in agreement with the Gene NCBI database and are 
explained in tables 8 and 9. 
 
 
 
Identified peptides were subsequently aligned with homologous human 
proteins and equivalent phosphorylation sites of interest were localized using the 
PhosphoSitePlus database (Table 6, 7). All but one modifications had a 
corresponding phosphorylation site within human proteins. Moreover, all of 
them had been identified before, most commonly exclusively in mass 
spectrometric studies (PhosphoSitePlus database). Five of the sites had been 
extensively studied before and have a known cellular function. 
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5.4 DISCUSSION 
The proteins regulated in RasV12 cells upon their interaction with normal 
cells identified in the SILAC screen belong to a number of different groups and 
participate in multiple cellular processes. Several modified molecules regulate 
cytoskeletal rearrangements (for example, VASP, plectin, vimentin), modify cell-cell 
interactions and cell attachment (for expample, ZO-1, COL17A1) or play a role in 
cell motility (for example, MRCKβ, TNS1). Other identified proteins control vesicular 
trafficking (for example, TXLNA, SRP14), cell growth (for example, JUNB), protein 
translation (for example, EF-2) or cell cycle progression (for example, CDK1, 
MCM2). 
Among the modifications with a previously identified cellular function 
were phosphorylations within two cell cycle proteins, CDK1 and MCM2, cell cycle-
regulated SQSTM1, actin-binding cytoskeletal VASP, and the regulator of 
translation EF-1. 
Phosphorylation of threonine 14 and tyrosine 15 in CDK1 inhibits 
enzymatic activity of this kinase leading to cell cycle arrest between phases G2 
and M (Krek and Nigg, 1991; Norbury et al., 1991). Inhibited CDK1 is not able to 
phosphorylate its etablished target protein SQSTM1 on serine 272, a site found 
downregulated in our screen. As a result of phosphorylation by CDK1, SQSTM1 is 
believed to stabilize cyclin B1 and active CDK1 ensuring correct entry and exit 
from mitosis (Linares et al., 2011). It is unclear, however, how lack of this 
phosphorylation along with inhibited CDK1 would affect proliferation of 
transformed cells. It is possible that this mechanism is transiently activated to 
prevent proliferation during extrusion, as complex morphological processes and 
cell migration are not normally compatible with mitosis and usually require cell 
cycle arrest. 
Another cell cycle protein with upregulated phosphorylation on a serine 
site is MCM2. This phosphorylation was shown in mammalian cells to be 
necessary for activation of MCM2, permitting its interaction with DNA and 
initiation of DNA replication. Taken together with data on other proteins 
identified in the screen known to have a role in the cell cycle, these results 
suggest that upon interaction with normal cells proliferation of RasV12 cells is 
affected. In order to verify this hypothesis, we performed BrdU labelling of RasV12 
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cells interacting with normal cells (different mixing ratios were used) and RasV12 
cells alone. Since proliferation is tightly linked to contact inhibition, which is still 
observed in RasV12-transformed cells, incorporation of BrdU into dividing nuclei 
was normalized to cell density. Unfortunately, after normalisation we could not 
see any differences between proliferation of RasV12 cells in mixed cultures and 
RasV12 cells alone (data not shown). We noticed however, that RasV12 cells plated 
alone were repeatedly less confluent despite counting the cells prior to each 
experiment. It is possible that migratory phenotypes of RasV12 cells after oncogene 
induction allows them to spread and, providing that they are grown alone, to 
balance cell density on the plates. In contrast, RasV12 cells mixed with normal 
MDCK cells are trapped between immobile neighbours and locally experience 
greater contact inhibition, possibly leading to phosphorylation and inhibition of 
CDK1 in these conditions. 
Nevertheless, dismissing the cell cycle related results of the SILAC screen 
could be a mistake. Inhibition of proliferation of transformed cells within a 
monolayer of normal cells was reported in the 1960s (Borek and Sachs, 1966; 
Stoker, 1964) as well as more recently (Alexander et al., 2004; Leung and Brugge, 
2012). It is likely then that within an established epithelium, where divisions occur 
mainly to replace dying or extruded cells, RasV12 cells experience inhibitory signals, 
which overcome their transformed phenotype. In this scenario extrusion would 
be a way to release this epithelial block and allow uncontrolled divisions (a 
similar hypothesis was suggested in (Leung and Brugge, 2012); however, no 
quantitative data were presented to support the existence of this block). 
Apart from proteins implicated in the cell cycle, we identified modifications 
within many other types of proteins, including molecules regulating cytoskeletal 
rearrangements and cell motility. Knowing that modifications affecting 
cytoskeletal organisation and cellular shape are often relatively simple to follow 
by immunofluorescence or time-lapse imaging, we decided to choose two 
proteins from this functional group for validation. Our first candidate was VASP, 
an actin-binding member of Ena/VASP family, which drew our attention due to 
the known inhibitory role of the identified phosphorylated site on VASP-
dependent actin polymerisation. The other protein was a serine-threonine protein 
kinase MRCKβ, a protein studied by other members of the Matter laboratory, for 
which many required reagents were already available. 
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In the SILAC screen, plectin was also identified as a protein with several 
different sites modified in RasV12 cells upon their interaction with normal cells. As 
mentioned previously, plectin was independently found in the screen for 
tyrosine-phosphorylated proteins (Chapter 4). Although neither of the 
modifications sequenced in the SILAC approach was on a tyrosine residue, this 
protein appears to play a role in extrusion and should be studied in greater 
details with appropriate resources in the future. 
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CHAPTER 6: VALIDATION OF THE SILAC SCREEN – VASP 
6.1 INTRODUCTION 
 
 The vasodilator-stimulated phosphoprotein (VASP) was originally purified 
from platelets in 1989 as a molecule phosphorylated by protein kinases 
dependent on both cAMP and cGMP (Halbrugge and Walter, 1989). Only three 
years later, VASP was found to interact with actin and localize along microfilament 
bundles (stress fibres and junctional actin) as well as to focal adhesions (Reinhard 
et al., 1992). During the past 20 years of extensive studies on VASP, this protein 
was shown to be implicated in many processes, including regulation of platelet 
activation (Aszodi et al., 1999; Massberg et al., 2004), maintenance of endothelial 
barrier (Furman et al., 2007; Rentsendorj et al., 2008), phagocytosis (Coppolino et 
al., 2001), lamellipodia formation and cell motility (Bear et al., 2002; Lindsay et al., 
2007), metastasis and invasion of cancer cells (Zuzga et al., 2011), and even cellular 
growth and proliferation (Chen et al., 2004). A common denominator for all these 
functions is the interaction of VASP with actin and, in particular, promoting 
elongation and bundling of growing microfilaments (reviewed in (Bear and 
Gertler, 2009; Trichet et al., 2008)). Despite controversy surrounding VASP since its 
discovery (reviewed in (Trichet et al., 2008)), there is general agreement in the field 
that through association with barbed ends of microfilaments, VASP acts as an 
anti-capping protein (reviewed in (Bear and Gertler, 2009)). 
Apart from direct interactions with actin, VASP facilitates cytoskeletal 
remodelling by binding to other molecules, e.g. components of focal adhesions, 
vinculin and zyxin (Brindle et al., 1996; Reinhard et al., 1995). Three different 
domains within VASP mediate formation of all these complexes: (1) an N-terminal 
Ena/VASP homology 1 domain (EVH1) that binds specific poly-proline motifs in, 
for example, vinculin and zyxin; (2) a central proline-rich region (PRR) with affinity 
to proteins containing SH3 and WW domains as well as to profilin, which 
complexes with G-actin; (3) a C-terminal Ena/VASP homology 2 domain (EVH2) 
interacting with G- and F-actin and mediating VASP oligomerisation (Figure 23) 
(reviewed in (Bear and Gertler, 2009; Chesarone and Goode, 2009)). 
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There are three well characterised phosphorylation sites within human 
VASP that are known to regulate its activity: serine 157 (S157), serine 239 (S239) 
and threonine 278 (T278). In vivo they are targeted by three different nucleotide-
dependent kinases: (1) cAMP-dependent proteins kinase A (PKA), which 
phosphorylates S157 and with lower affinity S239, (2) cGMP-dependent protein 
kinase G (PKG) with preference for S239 over S157 (Butt et al., 1994), and (3) AMP-
activated protein kinase (AMPK) known to target T278 (Blume et al., 2007). Recently 
protein kinase C (PKC) was also implicated in phosphorylation of VASP (Chitaley et 
al., 2004).  
 
Figure 23. Structure, binding partners and major regulators of VASP. 
 
 
Detailed functional characterization of these three major phosphorylation 
sites in VASP using phosphomimetic substitutions, revealed that while 
modification of S157 abrogates interaction of this protein with several SH3 
domain-containing partners, e.g. Abl (Lambrechts et al., 2000), and, to some extent, 
affects its localization (Benz et al., 2008; Benz et al., 2009), it has no effect on actin 
polymerisation. Conversely, phosphorylation of either S239 or T278 within the 
EVH2 domain results in inhibition of the anti-capping and filament-bundling 
activities towards actin (Benz et al., 2009), and consequently affects formation of 
membrane protrusions (Lindsay et al., 2007; Zuzga et al., 2011). In platelets, 
modification of S239 occurs downstream of nitric oxide (NO) release from the 
endothelium, which in turn activates PKG and ultimately leads to inhibition of 
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platelet activation by promoting their round phenotype (Becker et al., 2000). 
Phosphorylation of S239 has a similar effect on invasion of cancer cells, 
preventing them from forming invadopodia and again resulting in a round 
cellular shape (Benz et al., 2009). 
In the SILAC screen, modification on S239 in VASP was found upregulated 
6 hours after inducing GFP-RasV12 expression. If the effect of this phosphorylation 
in our cells is similar to what was previously reported for fibroblasts, platelets or 
colon carcinoma cell lines, RasV12 cells should round up at this point. Indeed, prior 
to their extrusion from normal monolayers RasV12 cells become taller, and adopt a 
more roundish cellular shape. This observation further encouraged us to study 
modification of VASP on S239, which could be a necessary step in extrusion, 
leading to detachment and release of a transformed cell. 
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6.2 RESULTS 
6.2.1 VASP DEPLETION ENHANCES EXTRUSION OF RAS CELLS FROM A MONOLAYER OF 
NORMAL EPITHELIAL CELLS 
 
 To study if VASP is important for extrusion and what role it plays, we used 
an siRNA-based technique to deplete this protein in RasV12 cells prior to mixing 
them with normal cells. Since phosphorylation on the site identified in the SILAC 
screen inhibits VASP activity towards actin, we hoped that depletion of the whole 
protein would mimic this phosphorylation in our system and give us some 
indication of its contribution to extrusion. 
 Firstly, the conditions for depleting VASP in normal MDCK cells using an 
Interferin-based transfection system were optimised. While the protein content of 
VASP was reduced in MDCK cells after treatment with each of the three 
oligonucleotides (in fact, treatment with O3 resulted in increased toxicity 
indicated by the lower tubulin content), a similar effect was not observed in RasV12 
cells (Figure 24 A). To deplete VASP in transformed cells, we decided to use a 
modified protocol, in which instead of allowing the cells to attach over night 
before treating them with the transfection reagents, we added oligonucleotides 
immediately after plating. Under these conditions, more cellular membrane was 
supposed to be exposed to Interferin and siRNA complexes, resulting in a better 
uptake of the siRNA and depletion of the targeted protein. In fact, depletion of 
VASP in RasV12 cells was so efficient that cells treated with nucleotides O2 and O3 
died and detached from the plates within 2 days of transfection. Hence, in all 
subsequent experiments we decided to use oligonucleotide O1 only (Figure 24 B). 
 Downregulation of VASP in RasV12 cells cocultured with normal cells was 
further confirmed by immunofluorescence on glass (Figure 24 C), as well as on 
collagen (Figure 24 D, E). Interestingly, while on glass VASP localized to cell-cell 
junctions and the cytoplasm (Figure 24 C), on collagen the signal was mostly 
cytoplasmic, and only rarely seen at the junctions (Figure 24 D, E). Even so, the 
differences between intensity or localization of VASP in RasV12 cells cocultured 
with normal cells in comparison to RasV12 cells alone were negligible.  
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Figure 24. Treatment with siRNA reagents targeting VASP mRNA results in 
efficient depletion of VASP proteins in MDCK as well as RasV12 cells. (A, B) Total cell 
lysates of MDCK cells and RasV12 cells transfected with siRNA reagents, cultured for 
4 days from transfection and analysed by immunoblotting using anti-VASP 
antibody. Transfection conditions were optimized for MDCK cells (A) and RasV12 
cells (B) by shortening the time between plating and transfection for RasV12 cells. 
(C, D, E) Confocal images of xy (C, D) and xz (E) sections of RasV12 cells with 
depleted VASP surrounded by normal cells on glass (C) and on collagen (D, E). 
Cells were fixed after 8 hours of incubation with tetracycline (2 µg ml-1) and 
stained with anti-VASP antibody (red in C, E and purple in D) as well as phalloidin 
(purple in C). Ctrl – control siRNA, O1, O2, O3 – three different oligonucleotides 
designed and used to deplete VASP in MDCK cells. O1 – O3 – a pool of all three 
oligonucleotides mixed in a ratio 1:1:1. 
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Since an antibody against VASP phosphorylated on S239 was commercially 
available (Cell Signaling), we tested it for immunofluorescence. Unfortunately, the 
signal obtained by immunostaining with this antibody was non-specific as no 
differences were seen in staining of VASP-depleted cells compared to the control 
cells (data not shown). 
Having established conditions for depletion of VASP in RasV12 cells, we 
examined the effect of the VASP knockdown on extrusion. RasV12 cells were 
treated with the transfection reagents, and, after a 2 day-incubation, plated on 
collagen together with normal MDCK cells in a ratio 1 to 50. Following an 
overnight incubation, GFP-RasV12 expression was induced. Four hours later, small 
groups of RasV12 cells (size 1 to 4 cells) were randomly chosen and followed for 21 
hours (25 hours from addition of tetracycline) by time-lapse microscopy (Figure 25 
A). 
While the average time at which single RasV12 cells underwent extrusion 
during the imaging did not significantly differ between VASP-depleted and 
control cells (Table 10), over twice as many VASP-depleted cells escaped from the 
monolayer throughout the experiment (Figure 25 B, Table 10). 
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Figure 25. Depletion of VASP in RasV12 cells enhances their extrusion from a 
monolayer of normal cells. (A) RasV12 cells depleted in VASP (VASP KD) were 
extruded more efficiently than RasV12 cells transfected with control siRNA (CTRL 
KD). RasV12 cells were combined with normal cells at a ratio of 1 to 50 and cultured 
on type-I collagen gels, followed by tetracycline treatment. Images were extracted 
from representative time-lapse analysis. (B) Quantification of time-lapse analysis 
of RasV12 cells extruded from a monolayer of MDCK cells 25 hours after 
tetracycline addition (21 hours from the beginning of the recording). Data are 
mean ± s.d. of two independent experiments (n = 174 CTRL KD cells, n = 163 VASP 
KD cells); *P < 0.05. Arrows indicate extruded RasV12 cells. 
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Table 10. Depletion of VASP in RasV12 cells enhances their extrusion from a 
monolayer of normal cells. Details of quantification of time-lapse analysis from 
figure 25. Proliferation rate was assessed by dividing total cell number at 21 hours 
by total cell number at 0 hours. Extrusion rate was assessed by dividing the 
number of all extruded cells up to 21 hours by total cell number at 21 hours. 
 
Proliferation 
rate 
Average 
group size at 
21 hours 
Extrusion rate 
Average 
extrusion time 
[hours] 
CTRL KD 2.5 ± 0.5 5.1 ± 0.1 30% ± 5% 14 ± 2 
VASP KD 2.2 ± 0.0 6.5 ± 0.1 71% ± 2% 13 ± 0 
 
 
Importantly, depletion of VASP in non-transformed GFP cells (stable cells 
lines created by transfection of the original construct into which RasV12 was 
cloned) did not result in extrusion of these cells from a normal monolayer even 
after 24 hours from tetracycline addition (Figure 26). 
 
Figure 26. Depletion of VASP in GFP cells does not result in their extrusion from a 
monolayer of normal cells. Confocal images of xz and xy sections of GFP cells with 
depleted VASP surrounded by normal cells. Cells were fixed after 24-hour 
incubation with tetracycline (2 µg ml-1), and stained with Hoechst (grey) and 
phalloidin (purple). 
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6.2.2 VASP DEPLETION DOES NOT AFFECT ACTIN ACCUMULATION AT THE RAS-RAS 
JUNCTIONS IN NORMAL MONOLAYERS 
 
 Searching for differences in phenotype that would account for more 
efficient extrusion of RasV12 cells depleted in VASP comparing to the control RasV12 
cells, we firstly looked at junctional actin accumulation. According to the previous 
studies carried out in the Fujita laboratory, RasV12 cells accumulate F-actin on the 
junctions between each other when they are plated among normal cells, 
comparing to a situation in which they are grown alone (Hogan et al., 2009). 
Knowing of the actin anti-capping activity attributed to VASP, leading to 
microfilament polymerisation, as well as of its junctional localization in MDCK 
cells, we examined whether depletion in VASP affected accumulation of F-actin in 
RasV12 cells surrounded by normal cells. RasV12 cells transfected earlier with 
oligonucleotides targeting VASP mRNA were plated together with normal cells on 
collagen. Following an 8 hour-long incubation with tetracycline, cells were fixed, 
stained with phalloidin and examined by confocal microscopy. Junctional actin 
accumulation was quantified as an average pixel intensity of phalloidin staining 
along the junction multiplied by the junctional length. To avoid deviation coming 
from differences in immunostaining, we normalised the intensity of junctional 
staining in RasV12 cells to an average pixel intensity along the junctions between 
normal MDCK cells (M-M).  
No significant differences were observed in accumulation of actin on 
junctions between RasV12 cells themselves (R-R) surrounded by normal cells or 
junctions between RasV12 cells and normal cells (R-M) upon deletion of VASP 
comparing to the control (Figure 27 A, B). Moreover, upon examination of actin 
content in cocultures incubated with tetracycline for 24 hours, no visible 
differences between actin accumulated at junctions in RasV12 cells depleted in 
VASP to the control were observed (data not shown). 
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Figure 27. Depletion of VASP in RasV12 cells does not affect junctional actin 
accumulation between RasV12 cells in a monolayer of normal cells. (A) Confocal 
images of xz sections of RasV12 cells with depleted VASP surrounded by normal 
cells. Cells were fixed after 8 hours of incubation with tetracycline (2 µg ml-1) and 
stained with phalloidin (purple). (B) Quantification of accumulation of actin at 
junctions between neighbouring RasV12 cells (R-R) and between RasV12 cells and 
MDCK cells (R-M) after 8 hours of incubation with tetracycline. The final actin 
accumulation values were obtained by multiplying average intensity of 
phalloidin staining at the junctions (normalised to average junctional intensity of 
phalloidin staining between MDCK cells) by the average junctional length. Data 
are average of three independent experiments ± s.d. Altogether, 84, 92, 68 (in 
control RasV12 cells) and 49, 91, 59 (in VASP depleted RasV12 cells) R-R, R-M, and M-M 
junctions, respectively, were analysed. JA – junctional actin accumulation. 
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6.2.3 VASP DEPLETION MILDLY DECEASES NUCLEAR LIFT IN RAS CELLS TO THE APICAL 
DOMAIN DURING EXTRUSION 
 
 During extrusion RasV12 cells become taller than the rest of the epithelium 
and adopt a “mushroom-like” shape with the nucleus close to the apical 
membrane (Hogan et al., 2009). At 8 hours from inducing GFP-RasV12 expression, 
approximately 50% of the nuclei are relocated apically in RasV12 cells, while in 
MDCK cells surrounding them as well as in transformed cells plated alone, this 
change is not observed. The nuclear relocation is inhibited by treatment with 
blebbistatin (Figure 28) suggesting that this process, similarly to extrusion itself, is 
dependent on myosin activity and actomyosin contractility. 
 
Figure 28. Inhibition of myosin II with blebbistatin compromises nuclear 
movement to the apical domain in RasV12 cells during their extrusion from a 
monolayer of normal cells. Quantification of the number of RasV12 cells with nuclei 
lifted to the apical domain after 8 hours of incubation with tetracycline and 60 
µM blebbistatin. The values are percentage of lifted nuclei to total quantified 
nuclei in RasV12 cells. Data are mean of two independent experiments ± s.d. (n = 62 
cells per condition per experiment); *P < 0.05. 
 
 
 To determine whether the lift of the nucleus in a transformed epithelial 
cell during its extrusion was dependent on actin polymerisation downstream of 
VASP, we examined how VASP depletion affected nuclear positioning at 8 hours 
after tetracycline induction. Indeed, in VASP-depleted RasV12 cells, apical relocation 
of the nuclei was suppressed by approximately 10% comparing to the control 
RasV12 cells (Figure 29 A, B). As mentioned earlier, in contrast to treatment with 
blebbistatin, this moderate inhibition or delay of nuclear positioning did not 
 126 
result in preventing extrusion. We concluded that although VASP might be 
partially responsible for actin polymerisation leading to the nuclear lift during 
extrusion, it is not essential for the escape to occur. 
 
Figure 29. Depletion of VASP in RasV12 cells compromises nuclear movement to the 
apical domain in RasV12 cells during their extrusion from a monolayer of normal 
cells. (A) Confocal images of xz sections of RasV12 cells with depleted VASP 
surrounded by normal cells and RasV12 cells alone on collagen. Cells were fixed 
after 8 hours of incubation with tetracycline (2 µg ml-1) and stained with Hoechst 
(grey), anti-VASP antibody (red) and phalloidin (purple). (B) Quantification of the 
number of RasV12 cells with lifted to the apical domain nuclei after 8 hours of 
incubation with tetracycline. The values are percentage of lifted nuclei to total 
quantified nuclei in RasV12 cells. Data are mean of three independent experiments 
± s.d. (n = 125 CTRL KD cells, n = 112 VASP KD cells); *P < 0.05. 
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6.2.4 VASP DEPLETION AFFECTS APPREARENCE OF STRESS FIBERS AND LOCALIZATION OF 
VINCULIN TO FOCAL ADHESIONS IN RAS CELLS 
 
 Since neither of the processes involving actin in RasV12 cells we examined 
thus far was profoundly affected by depletion of VASP, we turned towards focal 
adhesions, the basal structures at which VASP is known to localize. To look at 
focal adhesions, we plated cocultures of RasV12 and normal cells on glass, knowing 
that these cellular components are not well defined (or visible) in epithelial cells 
grown on softer types of matrix, e.g. collagen or matrigel. Consistent with our 
previous data obtained for cells plated on collagen type I, on glass RasV12 cells 
depleted in VASP underwent extrusion within 24 hours from inducing GFP-RasV12  
expression in far greater numbers comparing to the control RasV12 cells (data not 
shown). 
 Firstly, we checked whether VASP localized to the basal part of the cells in 
our system. Indeed, immunostaining with anti-VASP antibody on glass revealed 
the presence of a signal specific for VASP in this area (Figure 30). 
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Figure 30. A pool of VASP localizes basally in RasV12 cells surrounded by normal 
cells. Confocal images of xy basal sections of RasV12 cells with depleted VASP 
surrounded by normal cells on glass. Cells were fixed after 8 hours of incubation 
with tetracycline (2 µg ml-1) and stained with anti-VASP antibody (purple). (a, b) 
Enlargement of boxed areas in the main figure. 
 
 
 Next, we examined the appearance of focal adhesions and stress fibres in 
RasV12 cells with depleted VASP compared to the control by staining for vinculin 
and F-actin. Cells treated with siRNA reagents were plated on glass coverslips and 
grown in cocultures with normal MDCK cells for 8 hours after inducing GFP-RasV12 
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expression. Immunostaining with an anti-vinculin antibody revealed that 
localization of this protein to the basal part of RasV12 cells was suppressed 
compared to vinculin in the surrounding normal neighbours (Figure 31 A). This 
effect was further enhanced by depletion of VASP in RasV12 cells from mixed 
cultures (Figure 31 A). Likewise, far fewer stress fibres were observed in RasV12 cells 
compared to normal cells and, in particular, in VASP-depleted RasV12 cells (Figure 
31 B). 
 
Figure 31. Stress fibres formation and localization of vinculin to focal adhesions 
are affected by depletion of VASP in RasV12 cells surrounded by normal cells. (A, B) 
Confocal images of xy basal sections of RasV12 cells with depleted VASP 
surrounded by normal cells on glass. Cells were fixed after 8 hours of incubation 
with tetracycline (2 µg ml-1) and stained with anti-VASP antibody (red in A), anti-
vinculin antibody (purple in A), and phalloidin (red in B). (a, b) Enlargement of 
boxed areas in A. 
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Considering the possibility that depletion of VASP might affect stability of 
focal contacts and stress fibres leading to compromised attachment and quicker 
extrusion of RasV12 cells from normal monolayers, we examined the effect of VASP 
depletion on these structures in RasV12 cells plated alone. In RasV12 cells treated 
with siRNA targeting VASP transcripts after 8 hours of GFP-RasV12 induction, both 
localization of vinculin to focal adhesions as well as formation of stress fibres 
along the cell base were heavily impaired compared to control RasV12 cells (Figure 
32 A, B). This finding is consistent with our hypothesis of compromised 
attachment resulting in enhanced extrusion of RasV12 cells upon depletion of 
VASP. Moreover, in many VASP-depleted cells F-actin formed large globular 
structures along the cell base, suggesting an imbalance between actin branching 
and actin elongation factors in these cells (Figure 32 B). 
Intrigued by the particularly striking appearance of vinculin in basal 
confocal sections of RasV12 cells surrounded by normal MDCK cells, we examined 
localization of this protein to the focal contacts formed by transformed cells 
grown in cocultures compared to these cells grown alone. Indeed, 8 hours after 
GFP-RasV12 induction, vinculin was not adopting the normal basal dashed pattern 
in RasV12 cells plated with normal neighbours, but remained occasionally present 
at their cell periphery (Figure 33). Importantly, in tranformed cells plated alone, 
this phenomenon was not observed, and vinculin formed a clear dashed basal 
pattern (Figure 33). 
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Figure 32. Stress fibre formation and localization of vinculin to focal adhesions are 
affected by depletion of VASP in RasV12 cells plated alone. (A, B) Confocal images of 
xy basal sections of RasV12 cells with depleted VASP on glass. Cells were fixed after 
8 hours of incubation with tetracycline (2 µg ml-1) and stained with anti-VASP 
antibody (red in A), anti-vinculin antibody (purple in A, red in B), and phalloidin 
(purple in B). 
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Figure 33. Vinculin localization to focal adhesions is reduced in RasV12 cells 
surrounded by normal cells compared to RasV12 cells alone. Confocal images of xy 
basal sections of RasV12 cells surrounded by normal cells and RasV12 cells alone on 
glass. Cells were fixed after 8 hours of incubation with tetracycline (2 µg ml-1) and 
stained with anti-vinculin antibody (red) and anti-VASP antibody (purple). (a, b, c) 
Enlargement of boxed areas in the main figure. 
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6.3 DISCUSSION 
 
 For validation of the SILAC screen performed earlier, we chose a protein 
previously implicated in remodelling of the cytoskeleton. Having an anti-capping 
activity towards actin inhibited by the very phosphorylation on S239 that we 
found upregulated in RasV12 cells surrounded by normal cells, VASP was an 
attractive candidate for our study. 
 We began with depletion of VASP in RasV12 cells, which was expected to 
mimic the phosphorylation on S239 in our system, at least in respect to its 
regulation of actin polymerisation. The depletion of VASP in transformed cells 
resulted in more efficient extrusion of these cells from a monolayer of normal 
cells. Importantly, these cells remained viable after extrusion and proliferated on 
the top of the monolayer similarly to control RasV12 cells. This observation 
indicates that it was not induction of cell death that stimulated enhanced 
extrusion. Importantly, constitutive Ras signalling was required for the VASP 
depletion effect, as control GFP cells were not extruded upon depletion. 
Searching for the role that VASP plays in extrusion, we examined several 
possible cellular locations and processes related to actin polymerisation in VASP-
depleted cells. While downregulation of VASP in RasV12 cells did not affect 
accumulation of junctional actin in these cells plated within a normal monolayer, 
it mildly impaired the process of nuclear relocation to the apical membrane 
occurring in transformed cells during their extrusion. Therefore, VASP-dependent 
actin polymerisation contributes, but is not essential for the nuclear lift to occur. 
Knowing that VASP is often localized to focal contacts where it interacts 
with zyxin and vinculin, we examined these structures in transformed cells with 
endogenous and lower levels of VASP. Indeed, depletion of VASP resulted in 
apparently less vinculin localized to focal adhesions and less prominent stress 
fibres in RasV12 cells grown in cocultures with normal cells as well as in RasV12 cells 
grown alone. In conclusion, the depletion of VASP in RasV12 cells, having an 
autonomous effect on stability of focal contacts and stress fibres, resulted in 
more efficient extrusion of these cells when grown within normal monolayers. 
Although the role of VASP in maintenance and elongation of stress fibres is still 
debated (reviewed in (Ciobanasu et al., 2012)) and conflicting functions were 
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assigned to this protein in different cell types (Bear et al., 2002; Schlegel and 
Waschke, 2009), our data from RasV12-transformed epithelial cells feed into this 
discussion and suggest that, at least in our system, VASP is important for cell 
attachment. Reassuringly, our findings are in agreement with some previous 
studies on endothelial cells and mouse fibroblasts, in which downregulation of 
VASP and vinculin, respectively, was shown to promote cell migration often linked 
to instability and increased dynamics of focal adhesions (Bear et al., 2002; 
Saunders et al., 2006). 
Another burning question is why depletion of VASP resulted in 
mislocalisation or instability of vinculin at focal contacts? There are two possible 
explanations: the lack of direct interaction of vinculin with VASP or lower tension 
at focal sites due to compromised actin polymerisation rates, either of which 
could potentially result in quicker turnover of vinculin. Indeed, the latter option is 
supported by a study in which a mechanosensor inserted into vinculin proved 
that high tension across this protein was associated with maturation of focal 
adhesions, whereas less force applied on vinculin led to their disassembly 
(Grashoff et al., 2010). 
During the study of focal contacts in transformed cells, we noticed that the 
basal localization of vinculin in control RasV12 cells was already quite low relative 
to either surrounding normal cells or transformed cells grown on their own. Quite 
likely, at 8 hours from addition of tetracycline, focal contacts started to undergo 
disassembly, which is necessary for transformed cells to escape from the 
epithelium. At this time point, the talin content in focal adhesions was unaffected 
in the control cells (data not shown), suggesting that disassembly of these 
structures during extrusion occurs gradually (talin interacts with integrins directly 
and is recruited relatively early to nascent adhesions (Zaidel-Bar et al., 2003)). A 
close assessment of stress fibres at 8 hours from inducing GFP-RasV12 expression 
in transformed cells surrounded by normal neighbours was not conclusive. 
Although in many of these cells far fewer stress fibres were observed; in others 
these structures were still quite prominent. Perhaps a more striking effect on 
stress fibres could be seen at a later time point after addition of tetracycline. 
 Of course, a crucial question to our study remains unanswered. In order to 
fully validate the screen as well as understand how reducing cell attachment is 
executed in RasV12 cells during their extrusion, we need to examine the effect of 
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phosphorylation of VASP on S239 in this process. According to our current 
hypothesis, this modification is a necessary step in disassembly of focal contacts 
in transformed cells. This theory is supported by previous observations in 
fibroblasts, endothelial cells, platelets as well as cancer cells, all of which were 
demonstrated to retract their lamellipodia and round up upon phosphorylation 
of VASP on S239 (details in section 6.1). Encouraging data were obtained in a 
study showing changes in actin cytoskeleton in the presence of phosphomimetic 
mutants of VASP. The presence of VASP in which S239 was replaced with aspartic 
acid (D) in microvascular endothelial cells resulted in formation of large actin 
aggregates at the basal membrane of these cells (Figure 3 G in (Benz et al., 2009)), 
resembling structures observed in VASP-depleted RasV12 cells (Figure 33 B).  
To confirm our hypothesis, we will perform rescue experiments with 
transiently expressed wild type and mutants of VASP carrying mutations 
mimicking permanent phosphorylation (S239 replaced with D) as well as lack of 
phosporylation (S239 replaced with A) in VASP-depleted RasV12 cells. We will 
examine the effect of the rescue on extrusion as well as the appearance of focal 
adhesions and stress fibres. 
 Since a conserved pathway downstream of NO release and PKG activation 
was frequently shown to regulate phosphorylation of VASP on S239 in various 
cell types, including MDCK cells (Jaeger et al., 2010), we will investigate its role in 
extrusion. If PKG activated by NO indeed phosphorylates S239 of VASP in RasV12 
cells before their extrusion, it would be interesting to know what the source of 
NO is in our system. Is it produced by RasV12 cells themselves in order to escape 
from the monolayer of normal cells or is it a part of an intrinsic epithelial defence 
mechanism leading to elimination of a transformed cell through apical extrusion? 
Further studies beyond the scope of this thesis are required to address all the 
issues listed above. 
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CHAPTER 7: VALIDATION OF THE SILAC SCREEN – MRCK 
BETA 
7.1 INTRODUCTION 
 
 In the SILAC screen we have found that phosphorylation on two sites 
within myotonic dystrophy kinase-related Cdc42-binding kinase β (MRCKβ) are 
non-cell-autonomously downregulated in RasV12 cells interacting with normal 
MDCK cells. Modification of these sites has been reported before (in the 
PosphoSitePlus database), but not studied in depth. Knowing that MRCK can be 
activated by Cdc42, a Rho GTPase which was previously implicated in extrusion 
(Hogan et al., 2009), we became interested in this molecule. 
 Cdc42 is a member of the Rho family of small GTPases conserved from 
yeast to mammals. In cells it exists in two states: GTP-bound active form or GDP-
bound inactive form. Transitions between these two states are facilitated by a 
large group of GEFs, GAPs and GDIs. Upon activation by a variety of surface 
receptors, Cdc42 binds and stimulates multiple proteins, including kinases such as 
p21-activated kinases (PAKs), mixed-lineage kinases (MLKs), MRCKs as well as 
scaffolding proteins such as Par6, WASP, and IQGAP (reviewed in (Stengel and 
Zheng, 2011)). Through modulation of its effectors Cdc42 is implicated in a 
number of cellular processes primarily related to reorganisation of actin 
cytoskeleton, e.g. formation of actin-rich membrane protrusions called filopodia, 
establishment of cell polarity, and migration (reviewed in (Etienne-Manneville and 
Hall, 2002)).  
Downstream of Cdc42, its effect on migration is mediated in part by MRCK 
kinases. The two conserved isoforms of MRCKs, α and β, alongside ROCK, belong 
to the AGC kinase family (reviewed in (Pearce et al., 2010)). MRCKs are large 190 
kDa proteins with kinase domains highly homologous to that of ROCK. 
Consequently, they also share a similar set of substrates, among them myosin 
light chain (MLC) and a myosin binding subunit of the myosin light chain 
phosphatase complex, MYPT1 (Tan et al., 2001). In contrast to ROCK, which was 
demonstrated to phosphorylate MLC on both serine 19 (S19) and threonine 18 
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(T18), MRCKs appear to regulate this molecule only on S19 (Tan et al., 2011). At a 
cellular level, activation of the Cdc42-MRCK pathway can complement Rho-ROCK 
signalling in migration. While MRCKs regulate actomyosin contractility necessarily 
for invasion of cells with elongated mesenchymal morphology, ROCK is important 
for migration in three-dimensional environments characterised by rounded 
blebbing morphology (Wilkinson et al., 2005). Rho- and Cdc42-dependent 
pathways were also found to collaborate in collective cell migration in which 
leading fibroblasts rely on signalling downstream of Rho, whereas the movement 
of the following carcinoma cells is dependent on MRCK (Gaggioli et al., 2007). 
Additionally, MRCK was implicated in the maintenance of focal adhesions (Dong 
et al., 2002) as well as nuclear positioning and reorientation of the microtubule 
organising centre (MTOC) in migrating fibroblasts through activation of actin 
retrograde flow (Gomes et al., 2005). 
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7.2 RESULTS 
7.2.1 MRCK DEPLETION ENHANCES EXTRUSION OF RAS CELLS FROM A MONOLAYER OF 
NORMAL EPITHELIAL CELLS 
 
 To study the role of MRCKβ in extrusion of RasV12 cells from normal 
monolayers we depleted this protein using the Interferin-based siRNA method. 
Similarly to our previous observations concerning depletion of VASP, MRCK could 
only be downregulated in RasV12 cells, if the transfection reagents were added 
immediately after plating the cells. Since MRCKβ depletion using an isoform-
specific oligonucleotide was relatively inefficient, we decided to target both MRCK 
isoforms using the pool of all three siRNA molecules tested (Figure 34). MRCKα 
isoform is less abundant in MDCK cells and, in our hands, could not be detected 
by immunoblotting. 
 Unfortunately, we were unable to obtain specific immunostaining of 
MRCKβ in MDCK cells with several tested commercially available antibodies; 
hence, each depletion experiment was confirmed by immunoblotting. 
 
Figure 34. Treatment with siRNA reagents targeting MRCK mRNA results in 
efficient depletion of MRCKβ  protein in RasV12 cells. Total cell lysates of RasV12 cells 
transfected with siRNA reagents, cultured for 4 days from transfection and 
analysed by immunoblotting using anti-MRCKβ antibody. Ctrl – control siRNA,  
Pan – siRNA designed to deplete both isoforms of MRCK, α – MRCKα, β – MRCKβ, 
Pool – the three oligonucleotides mixed in a ratio 1 : 1 : 1. 
 
 
 To determine whether MRCK was important for extrusion, we cocultured 
MRCK-depleted RasV12 cells with normal cells in a ratio 1 to 50 on collagen and 
followed their fate using time-lapse imaging. Twenty five hours after inducing 
GFP-RasV12 expression (21 hours from the beginning of imaging), 74% of MRCK-
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depleted RasV12 cells had left the monolayer, comparing to only 30% of control 
RasV12 cells (Figure 35 A, B; Table 11). This result corresponded to data obtained for 
cells cocultured on glass coverslips instead of the collagen matrix (data not 
shown). 
 
Figure 35. Depletion of MRCK in RasV12 cells enhances their extrusion from a 
monolayer of normal cells. (A) RasV12 cells depleted in MRCK (MRCK KD cells) were 
extruded from a monolayer of normal cells more efficiently than RasV12 cells 
transfected with control siRNA (CTRL KD cells). RasV12 cells were combined with 
normal MDCK cells at a ratio of 1 to 50 and cultured on type-I collagen gels, 
followed by tetracycline treatment. Images were extracted from a representative 
time-lapse analysis. (B) Quantification of time-lapse analyses of RasV12 cells 
extruded from a monolayer of MDCK cells 25 hours after tetracycline addition (21 
hours after the beginning of the recording). Data are mean ± s.d. of two 
independent experiments (n = 174 CTRL KD cells, n = 159 MRCK KD cells); *P < 0.05. 
Arrows indicate extruded RasV12 cells. 
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Table 11. Depletion of MRCK in RasV12 cells enhances their extrusion from a 
monolayer of normal cells. Details of quantification of time-lapse analyses from 
figure 35. Proliferation rates were assessed by dividing total cell number at 21 
hours (25 hours of incubation with tetracycline) by total cell number at 0 hours (4 
hours of incubation with tetracycline). Extrusion rate was assessed by dividing the 
number of all extruded cells up to 21 hours by total cell number at 21 hours. 
 
 
Proliferation 
rate 
Average 
group size at 
21 h 
Extrusion rate 
Average 
extrusion time 
[hours] 
CTRL KD 2.5 ± 0.5 5.1 ± 0.1 30% ± 5% 14 ± 2 
MRCK KD 2.3 ± 0.6 5.3 ± 0.3 74% ± 6% 13 ± 1 
 
 
 Importantly, when MRCK was depleted in GFP cells (a cell line stably 
expressing the original GFP construct into which RasV12 was cloned) plated among 
normal neighbours, these cells did not undergo extrusion or present any 
apparent phenotypical changes up to 24 hours from inducing GFP expression 
(Figure 36). 
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Figure 36. Depletion of MRCK in GFP cells does not result in their extrusion from a 
monolayer of normal cells. Confocal images of xz and xy sections of GFP cells with 
depleted MRCK surrounded by normal cells. Cells were fixed after 24-hour 
incubation with tetracycline (2 µg ml-1), and stained with Hoechst (grey) and 
phalloidin (purple). 
 
 
 
7.2.2 MRCK DEPLETION DOES NOT AFFECT ACTIN ACCUMULATION AT RAS-RAS 
JUNCTIONS IN NORMAL MONOLAYERS 
 
 Next, we decided to assess whether downregulation of MRCK, an 
important regulator of myosin II activity, had any effect on F-actin in transformed 
cells during their extrusion. Considering the possibility that high extrusion rates 
of MRCK-depleted RasV12 cells could be correlated with actin localization, we 
determined accumulation of F-actin at junctions between transformed and 
normal cells (R-M) as well as transformed cells themselves (R-R) plated among 
normal neighbours. 
After 8 hours of induction of oncogenic Ras, cocultures of MRCK-depleted 
RasV12 cells and normal cells were fixed with 4% PFA and immunostained with 
phalloidin (Figure 37 A). F-actin present at cellular junctions was quantified in the 
same manner as described previously for VASP-depleted cells (section 6.2.2). No 
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significant changes in accumulation of junctional F-actin were observed at this 
time point in RasV12 cells upon depletion of MRCK (Figure 37 B). 
 
Figure 37. Depletion of MRCK in RasV12 cells does not affect junctional F-actin 
accumulation between neighbouring RasV12 cells in a monolayer of normal cells. (A) 
Confocal images of xz sections of RasV12 cells with depleted MRCK surrounded by 
normal cells and RasV12 cells alone on collagen. Cells were fixed after 8 hours of 
incubation with tetracycline (2 µg ml-1) and stained with phalloidin (purple). (B) 
Quantification of accumulation of actin at junctions between neighbouring RasV12 
cells (R-R) and between RasV12 cells and MDCK cells (R-M) after 8 hours of 
incubation with tetracycline. The final F-actin accumulation values were obtained 
by multiplying average intensity of phalloidin staining at the junctions 
(normalised to average junctional intensity of phalloidin staining between MDCK 
cells) by the average junctional length. Data are mean of two independent 
experiments ± s.d. Altogether, 67, 67, 43 (in control RasV12 cells) and 44, 45, 47 (in 
MRCK depleted RasV12 cells) R-R, R-M, and M-M junctions, respectively, were 
analysed. 
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7.2.3 MRCK DEPLETION PROMOTES NUCLEAR LIFT IN RAS CELLS TO THE APICAL DOMAIN 
DURING EXTRUSION 
 
 Since blebbistain, an inhibitor of myosin II activity, was shown to prevent 
relocation of the nuclei in RasV12 cells prior to their extrusion (Figure 28), we 
examined whether depletion of MRCK had any effect on this process. At 8 hours 
from tetracycline addition over 60% of nuclei in MRCK-depleted RasV12 cells plated 
among normal neighbours were localized apically, comparing to 45% relocated 
nuclei in the control RasV12 cells (Figure 38 A, B). This significant promotion of the 
nuclear lift indicates that MRCK activity is not required for this process in RasV12 
cells prior to their extrusion. On the contrary, downregulation of this kinase 
appears to enhance both extrusion and the accompanying apical translocation of 
the nucleus. In other words, MRCK promotes the differentiated phenotype with 
the nucleus positioned close to the basal membrane. 
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Figure 38. Depletion of MRCK in RasV12 cells promotes apical nuclear movement in 
RasV12 cells during their extrusion from a monolayer of normal cells. (A) Confocal 
images of xz sections of RasV12 cells with depleted MRCK surrounded by normal 
cells and RasV12 cells alone on collagen. Cells were fixed after 8 hours of 
incubation with tetracycline (2 µg ml-1) and stained with Hoechst (grey), and 
phalloidin (purple). (B) Quantification of RasV12 cells with apically located nuclei 
after 8 hours of incubation with tetracycline. The values are a percentage of 
apically lifted nuclei to total quantified nuclei in RasV12 cells. Data are mean of 
three independent experiments ± s.d. (n = 134 CTRL KD cells, n = 90 MRCK KD 
cells); *P < 0.05. 
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7.3 DISCUSSION 
 
 Knowing that Cdc42 activity in RasV12 cells is necessary for their extrusion 
from normal monolayers (Hogan et al.), we became interested in MRCK, a kinase 
activated downstream of Cdc42. Since MRCK is a known regulator of myosin II, 
which is essential for extrusion, we hoped that this kinase found modified in the 
SILAC screen could be the missing link between Cdc42 and myosin II in our 
system. To our surprise, however, depletion of MRCK in RasV12 cells resulted in 
enhanced extrusion. Extruded MRCK-depleted transformed cells, similarly to the 
control cells, remained loosely attached to the monolayer and proliferated at least 
for 50 hours after induction of GFP-RasV12 expression. 
 In the SILAC screen phosphorylation of two sites within the tail domain of 
MRCK was decreased. Since depletion of the whole protein results in enhanced 
extrusion of transformed cells, it is likely that decreased phosphorylation of these 
sites inhibits MRCK activity, but this has not been tested yet. We can speculate 
that downstream of Cdc42 other targets are required for extrusion, while 
activation of MRCK needs to be suppressed. In this scenario, inhibition of MRCK 
may act as a switch between two different states of MLC phosphorylation: from 
single phsophorylated MLC (pMLC; regulated by MRCK) to double 
phosphorylated MLC (ppMLC; regulated by ROCK). Previous data from the Fujita 
laboratory support this hypothesis. Active ROCK was indeed shown to be 
necessary for extrusion and to regulate double phosphorylation of MLC in our 
system (Hogan et al., 2009). Unfortunately, due to problems with immunostaining 
for pMLC, we are currently unable to confirm our predictions. In fact, according to 
our latest preliminary data, there is some basal accumulation of pMLC in RasV12 
cells prior to their extrusion, and this seems to be reduced in MRCK-depleted cells. 
It is possible that active myosin II located basally promotes cell attachment to the 
matrix; hence, inactivation of MRCK leads to more efficient extrusion. Indeed, 
MRCK has been previously implicated in the maintenance of focal adhesions 
(Dong et al., 2002). Moreover, myosin contractility is an established functional 
switch between accumulation of maturation factors at focal contacts and their 
disassembly (Kuo et al., 2011). 
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To verify our theory of MRCK modulating the attachment of RasV12 cells 
and contributing to their extrusion, we will assess the appearance of focal 
adhesions and stress fibres in MRCK depleted cells and optimise pMLC 
immunostaining. Finally, we will construct phosphomimetic mutant versions of 
MRCKβ in which the sites of interest are replaced with D (to mimic permanent 
phosporylation) or A (to mimic the lack of phosphorylation). We will transfect 
these constructs into MRCK-depeted RasV12 cells to assess the involvement of 
identified phosphorylation sites in regulation of the kinase activity as well as 
their role in extrusion. 
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CHAPTER 8: 
FINAL DISCUSSION 
 149 
CHAPTER 8: FINAL DISCUSSION 
8.1 SUMMARY OF DATA PRESENTED 
 
 In this thesis, I present data that contribute to a better understanding of 
interactions between normal and transformed cells at early stages of extrusion. 
By performing different unbiased biochemical screens, I identified many 
molecules that may be important for these interactions. I also confirmed that 
three of the identified proteins have a role in extrusion and that inhibiting their 
functions results in changing the dynamics this process. 
 
8.2 IS EXTRUSION STRESSFUL? 
 
 The first important finding described in this thesis is the upregulation of 
the molecular chaperone Hsp90 in transformed cells surrounded by normal 
neighbours. Decreasing Hsp90 activity either by treatment with the inhibitor 
celastrol or using a dominant negative form of this protein in our system resulted 
in enhanced extrusion of RasV12 cells. Since the change in the amount of Hsp90 
was non-cell-autonomous, it appears that transformed cells undergo some form 
of stress during extrusion possibly caused by the necessary changes in the 
protein expression programme, in an analogous manner to upregulation of 
certain heat shock proteins in cells entering the cell cycle. The mechanism that 
leads to upregulation of this chaperone is not known. Alternatively, Hsp90 could 
also be overexpressed in order to perform a more specific function and serve as a 
chaperone for a particular client. The results from the 2D gel screen indeed 
indicated that Hsp90 forms an altered complex, suggesting that interaction 
between normal and transformed cells changes its client(s). During this study, 
however, we were unable to identify a specific binding partner of Hsp90 in 
cocultures. 
 Involvement of another chaperone was demonstrated in cell competition 
in Drosophila. dSparc, also known as osteonectin, is upregulated in ‘loser’ cells at 
early stages of several different types of cell competition (details in section 1.3.5). 
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The role attributed to dSparc is to transiently protect these cells from activation of 
caspases and to delay their apoptosis (Portela et al., 2010). Moreover, human 
SPARC was found to be overexpressed at the boundaries between tumour mass 
and surrounding normal tissues, suggesting that its expression is also affected by 
contacts between normal and altered cells (Petrova et al., 2011). Similarly, Hsp90α 
was found upregulated in different types of cancer (Kang et al., ; Ogata et al., 
2000). High expression levels of both chaperones were correlated with poor 
prognosis for patients, and often with increased metastasis (Chen et al., 2011; 
Derosa et al., 2012; Pick et al., 2007; Zhao et al., 2010). Our data suggest that during 
Ras-mediated extrusion Hsp90 could play a corresponding protective role as 
dSparc in cell competition. Taken a step further, the analogy with dSparc places 
RasV12 cells in the position of ‘losers’. Following the hypothesis of an intrinsic 
epithelial immune response leading to clearance of transformed ‘intruders’, 
perhaps the theory behind the role of Hsp90 in cancer should be revisited. Apart 
from managing proteolytic stress triggered by transformation itself, this central 
cellular chaperone could also buffer competition-related signalling from normal 
epithelium to tumours. 
 
8.3 ATTACHMENT MUST BE MODIFIED DURING EXTRUSION 
 
 The results of the SILAC screen performed in this study brought to our 
attention a large group of proteins modified in transformed cells upon 
interaction with normal cells. While most of the proteins will be left for future 
analyses due to the limited time available, here we concentrated on molecules 
previously implicated in cytoskeleton rearrangements: VASP and MRCKβ. 
Depletion of either VASP or MRCKβ in RasV12 cells led to increased extrusion rates 
of these cells from normal monolayers. My data show that VASP is important for 
formation of stress fibres and maturation of focal adhesions in RasV12 cells. The 
lack of well-defined basal adhesion structures in VASP-depleted transformed cells 
is most likely the cause for their loosened attachment and more efficient 
extrusion from normal monolayers. In the near future, we will aim to confirm that 
phosphorylation of VASP, which we found upregulated in the screen, has a 
corresponding effect on attachment of RasV12 cells to VASP depletion, and is an 
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actual step in extrusion. Preliminary data we obtained suggest that MRCKβ could 
also be involved in altering attachment of transformed cells.  
Identification of proteins regulating mechanical aspects of extrusion is an 
important progress in understanding this process. Until now, we have been 
unable to pinpoint pathways involved in disassembly of focal contacts. Our 
current findings can be related to the recent analysis of clonal outgrowth of 
single transformed cells carried out in acinar structures (Leung and Brugge, 2012). 
In this study, sole depletion of talin led to luminal translocation of otherwise 
normal epithelial cells. Although in our system loosening attachment is not 
sufficient for extrusion to occur and the presence of an active oncoprotein is 
necessary, we began to dissect the complex process of extrusion into separate 
stages, which eventually will lead us to a full understanding of this phenomenon. 
 
8.4 OTHER CYTOSKELETAL ISSUES – HOW DOES THE NUCLEUS TRAVEL? 
 
 During extrusion not only attachment is modified in RasV12 cells. Their 
whole cellular shape is changed from columnar into droplet-like with the nucleus 
localized apically. It does not come as a surprise that apart from VASP and MRCKβ 
other cytoskeletal proteins were identified in the SILAC screen, e.g. tensin, 
vimentin and plectin. In particular, plectin drew our attention since it had 
previously been identified in an independent screen for tyrosine-phosphorylated 
proteins as increased in cocultures of RasV12 and MDCK cells (chapter 4) as well as 
in mixed populations of Src- and Scribble-transformed cells with normal 
neighbours (unpublished data from the Fujita laboratory). This enormous scaffold 
protein ties the three major types of filaments together: microfilaments, 
microtubules and intermediate filaments. Therefore, it seems very plausible that 
plectin function is regulated during a process that requires major alterations of 
cell shape as does extrusion. 
 The nuclear lift occurring during extrusion is one of the likely candidate 
events dependent on the interplay between vimentin filaments, plectin and actin 
cytoskeleton. Intriguingly, although blebbistatin was shown to inhibit the nuclear 
relocation, no actin accumulation around the nucleus was ever observed. It is 
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possible that this process is mediated by intermediate filaments present in the 
cytoplasm of RasV12 transformed cells. Both plectin and vimentin appear to form 
nuclear rings in RasV12 cells (data not shown), and in case of vimentin, we found it 
accumulated in already extruded RasV12 cells (data not shown). Perhaps similarly to 
a process of actin-dependent positioning of the nucleus in migrating as well as 
immobile astrocytes, intermediate filaments are the missing link that transmits 
the tension from peripheral actin to the nucleus (Dupin et al., 2011). Further 
studies are necessary to shed some light on the process of nuclear relocation and 
its consequences for extrusion. 
 
8.5 IMPLICATIONS OF THE NITRIC OXIDE HYPOTHESIS 
 
 The finding of upregulated phosphorylation of S239 in VASP in RasV12 cells 
cocultured with normal cells brought up an entirely new question. PKG, a kinase 
that is nearly exclusively responsible for phosphorylation of S239 in vivo across 
different cell types, is often regulated by NO. If this pathway participates in 
modification of VASP in our system, it would be crucial to know which cells 
produce NO. Synthesis of this molecule could well be a part of the hypothesised 
epithelial immune response leading to the removal of transformed cells from a 
monolayer. Additionally, NO present in RasV12 cells would also affect metabolism 
of these cells. Incidentally, during this study a non-cell-autonomous decrease of 
mitochondrial membrane potential in RasV12 cells surrounded by normal cells was 
discovered (data not shown), supporting the notion of disturbed metabolism. 
 Interestingly, activation of p38 MAPK, which drives apoptosis of 
outcompeted Scribble cells (Norman et al., 2012), has not only often been shown 
to correlate with increases in NO levels in endothelial cells (Sanchez et al., 2012), 
but also to mediate NO-induced apoptosis in mouse embryonic stem cells (mES) 
(Lee et al., 2012). It would be exciting to know if p38 is activated during extrusion 
of RasV12 cells and whether NO could be a common denominator between the 
Scribble and the Ras systems.  
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8.6 ARE TRANSFORMED CELLS ACTIVE OR PASSIVE IN EXTRUSION? 
 
 Another intriguing question arises with the appealing hypothesis of an 
innate immune response of the epithelium against transformed cells: why are 
RasV12 cells not killed in a similar fashion to Scribble cells? Perhaps extrusion of 
this particular type of transformed cells is not passive. They might be using 
collective migration to escape from aggressive neighbours before the threshold 
of the proapoptotic epithelial signals is achieved. There are several lines of 
evidence supporting the hypothesis of active rather than passive extrusion. 
Firstly, before extrusion RasV12 cells repolarise: the nucleus is translocated 
from a basal to an apical position, while the Golgi apparatus (GA) as well as the 
endoplasmic reticulum (ER) are moved in the opposite direction and in tall cells 
localize below the nucleus (data not shown). This change in polarisation is 
accompanied by the disassembly of focal adhesions (vinculin is nearly completely 
lost from these structures once cells become taller) as well as by relocation of 
basolateral polarity marker, Scribble, from the predominantly lateral to the basal 
area (data not shown). At this point, however, adherence junctions are preserved. 
In fact, both E-cadherin as well as F-actin accumulate gradually between the 
neighbouring RasV12 cells within normal monolayers prior to and after extrusion. 
This accumulation might contribute to creating tension between transformed 
cells, which allows them later to collectively push themselves out of the 
monolayer. According to our unquantified observation, if a single transformed 
cell surrounded only by normal neighbours undergoes extrusion, it does not 
proliferate but remains in a cytostatic state on the top of the monolayer without 
incorporating ethidium dye for at least 50 hours. Hence, it is possible that for 
evading apoptotic/cytostatic signals, RasV12 cells need to emigrate in groups. 
Secondly, vimentin, a marker of epithelial to mesenchymal transition (EMT) 
is upregulated in RasV12 cells prior to their extrusion and further accumulates in 
already extruded cells (data not shown). 
 Finally, active Rho and Cdc42 present in RasV12 cells are required for 
extrusion to occur (Hogan et al., 2009). As mentioned earlier, these two major 
small GTP-ases are well known regulators of cytoskeletal rearrangements 
implicated in cell migration. Since depletion of MRCK in our system results in 
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quicker extrusion, it is possible that a switch from Cdc42-MRCK-dependent 
mesenchymal movement to Rho-ROCK-mediated migration is required for 
extrusion. 
 Active involvement of normal cells in extrusion was also studied in the 
Fujita laboratory, particularly in the Src system. Vimentin and filamin were found 
to accumulate in MDCK cells in contact with transformed cells and to form a ring 
or a ‘hugging’ protrusion. Furthermore, depletion of filamin prevented extrusion 
of Src cells [under submission]. These findings clearly show that normal cells 
dynamically pursue elimination of their neighbours either by squeezing them out 
of the monolayer or transducing signals in a filamin-dependent manner to their 
transformed neighbours. 
 From all the gathered data and observations, it appears that both sides, 
normal and transformed, could play an active role during extrusion and the final 
result most likely depends on an interplay between these two cell types. 
 
8.7 QUESTIONS FOR THE FUTURE 
 
 Currently a lot of questions as to extrusion and its significance lack 
answers. Most importantly, we have still not determined how normal and 
transformed cells recognise each other. Although this thesis marks out a few new 
directions that could be taken to shed more light on the pathways activated 
upon recognition, we cannot be sure, what the actual role of extrusion is. It might 
be a part of an immune response: extruded cells could be eliminated directly by 
the immune system or through exposure to harsh conditions in the lumen of 
urinal tacks, intestines, etc. Alternatively, extrusion could play a role in tumour 
formation, for example in growth of glandular tumours (breat, pancrease, etc) that 
often fill the apical lumen of an organ. On the other hand, extrusion could be a 
prelude to early metastasis. Perhaps extruded cells migrate to a more supportive 
environment to develop into tumours. It is also possible that the directionality of 
extrusion is biased in vitro. Perhaps, in vivo in vertebrates transformed cells at this 
early stage of cancerogenesis migrate underneath the epithelium to metastasise 
in a previously described for advanced tumours fashion. 
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Considerable amount of support could come from the latest research in 
Drosophila, which prove that cell competition, similar in many aspects to the 
phenomena studied in mammalian systems, is not only a developmental process. 
Competition has recently been observed also in epithelia of adult flies (de 
Navascues et al., 2012). It is likely that parallels drawn between the two models 
will lead to a better understanding of extrusion and its role in tumuorigenesis. 
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